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Supervisors: Robert O. Williams, III, and Jason T. McConville 
 
Our goal was to develop a mucoadhesive, oral vaccination delivery platform 
designed to target Peyer’s patches at ileum. In order to achieve this, we prepared poly 
(methyl methacrylate) (PMMA) particles of various sizes using W/O/W emulsification 
solvent evaporation and surface polymerization methods. We then coated and employed 
mucoadhesive polymers into the carrier system to enhance the residence time in the 
targeted site. Also we developed our own in vitro mucoadhesion testing ramp as an 
evaluation tool. Finally, nano- and micro-structured particles were manufactured as two 
different oral vaccine delivery systems (Solid Lipid Nanoparticles, SLNs; and Protein 
Coated Microcrystals, PCMC). After the model antigen, bovine serum albumin (BSA) 
was loaded into the SLNs or PCMC; mucoadhesive polymers were then incorporated and 
formulated the mixture into pellets. The pellets were then layered with an enteric coating, 
which was composed of a mixture of Eudragit® FS 30 D/Eudragit® L 30 D-55 for ileum 
targeted delivery. The in vitro mucoadhesion test ramp was capable of investigating the 
mucoadhesive properties of tablets and pellets, providing a rank order for study. Most 
important of all, it was anticipated that this might reduce the burden of testing animals for 
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future proposed mucoadhesive studies. Microcapsules/beads of specific size were 
manufactured reproducibly by solvent evaporation and surface polymerization. Although 
we could not specify the cut-off size at the pyloric sphincter in mice, we concluded that 
the cut-off size at the pyloric sphincter in rats was approximately 2.5-3 mm, which was 
supported by both the biodistribution data and the direct image results from scintigraphy 
scanning. Moreover, we found that the particle size significantly alters the gastric 
emptying time in both rodent models. The small microcapsules/beads were hindered in 
the folds of the stomach (size 50-100μm for mice and size 0.5-1 mm for rats) and 
emptied the slowest, followed by the large particles, then the medium particles. Finally, 
PCMC and SLNs we manufactured were suitable carriers for protein API, such as BSA. 
These particles were of fitting size for M cell uptake, which would possibly induce 
mucosal immune responses. Therefore, an antigen containing PCMC and SLNs might be 
suitable platforms for oral vaccination. 
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Chapter 1: Introduction 
1.1 Background and Significances 
Immunization against microbial infections has been regarded as one of the most 
cost effective methods. Currently, the parenteral route is the most prevalent route of 
vaccine delivery. This route is effective against pathogens invading via the systemic 
route, but less efficient against mucosal infections. The antibodies elicited by systemic 
immunity do not extend to mucosal or serosal sites, which are also the major entry sites 
for invading pathogens. Mucosal vaccination has been shown to generate both mucosal 
and systemic immune responses in both animal and human models, and therefore could 
be considered to demonstrate a more effective protection. Oral vaccination is potentially 
cost efficient, with good patient compliance, and have much more physicochemical 
stability (compared to injection vaccines) during storage and transportation. However, the 
oral route for mucosal vaccination has not reportedly been successful in presenting 
antigens to the body, mainly due to the environmental issues of the GI tract before 
presentation to the immune-responsive M-cells (at Peyer's patches). Recent research has 
suggested that targeted microparticle and/or nanoparticle-based vaccines could 
potentially be used to negate some of the issues associated with mucosal delivery. These 
particles (e.g. PLGA, PLA, enteric-coating polymers, alginates, and chitosans) have been 
shown to improve cell uptake, and act as adjuvants to promote a stronger immune 
response while being targeted to the appropriate tissues. This review covers a wide range 
of multiparticulate-based drug delivery systems that have recently been investigated for 
oral vaccination use. 
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1.2 Current vaccination solutions 
Presently, most vaccines are attenuated vaccines administrated via systemic routes 
(the parenteral route) [1]. However, there are several drawbacks, including patient 
compliance, side effects, storage/transportation issues (refrigeration required) and 
sterilization [2]. Although vaccination via injection can induce effective systemic 
immune responses against infective virus and bacteria, parenterally administered vaccines 
are not generally effective for induction of a mucosal immune response [3]. Table 1.1 
comparatively summarizes some general advantages and disadvantages of parenteral, 
nasal, and oral vaccination [4] routes. 
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Table 1.1: Comparison of oral vaccines versus parenteral/nasal vaccines 
	   Parental Nasal Oral 





Direct	  ingestion,	  most	  
patient	  compliance	  
Adminstration site Cells	  and	  tissues	  in	  circulation	   Mucosal	  surface	   Mucosal	  surface	  
Delivery risk Possible	  infection	  at	  the	  








Adjuvent Various	  adjuvant	  (aluminum,	  











High	  (Digestion	  and	  
insufficient	  uptake	  in	  
the	  gastrointestinal	  















IgG	  and	  IgA))	  
Mucosal	  and	  systemic	  
antibody/T	  cell,	  may	  
induces	  oral	  tolerance	  
(both	  IgG	  and	  IgA))	  
Current clinical use Extensive	   Limited	  number	  
of	  clinical	  trials	  
Extensive	  use	  for	  live-­‐
attenuated	  vaccines	  
and	  limited	  number	  of	  
clinical	  trials	  of	  subunit	  
oral	  vaccines	  
Cost High	  (due	  to	  sterile	  
equipment/storage	  and	  medical	  
personnel	  required)	  
Medium	   Low	  
 
In some cases, antibodies induced via parenteral routes are not accessible to 
mucosal surfaces, which are the primary sites for most infectious pathogens. Among the 
induced antibodies, those produced by humoral immune responses at the mucosal 
surfaces are of importance in fighting against pathogens [5]. Intranasal (IN) vaccination 
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has recently been widely studied for its advantages of generating both local and systemic 
immunity. IN administration is needle-free, non-invasive, painless, and most importantly, 
does not require sterile preparation and can be self-administered. Moreover, the large 
surface area of the nasal cavity and the presence of microvilli have been suggested to 
further enhance the possible therapeutic effect of vaccines [6]. However, despite these 
potential advantages, a high mucosal clearance rate in the nasal cavity is a key issue. 
Therefore, mucoadhesive polymers have been investigated in many studies to improve 
the residence time of the vaccine and increase efficacy. Among these polymers, chitosan 
is the most widely studied, while other polymers include Carbopol®, hyaluronic acid, and 
N-trimethyl chitosan chloride (TMC) [7].  
Oral vaccination, potentially an ideal vaccination route since both mucosal and 
systemic immune responses can be provoked via the stimulation of mucosally-situated 
IgA and IgG plasmacyte precursors [8]. The oral route is attractive for vaccination 
because the GI tract of a human has over 300 m2 of mucosal surface containing immune 
inductive tissue, such as the intraepithelial lymphocytes and lymphoid follicles at the 
laminar propria and Peyer’s patches, known as the gut associated lymphoid tissues 
(GALT). Live-attenuated oral poliovirus vaccine (OPV) was developed and licensed in 
1961, and due to its ease of administration OPV is widely used in the world for 
elimination of wild-type poliovirus transmission [9].  As most pathogens invade their 
host through their digestive tract, immunization with live-attenuated vaccines actually 
mimics natural infections of the antigen. In fact, these result in the induction of local 
secretory immunoglobulin A (sIgA) and the reduction of virus shedding of from the 
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intestine; while an intramuscular or intravenous injection vaccine can only induce serum 
antibodies, rather than inducing secretory IgA. sIgA derives from monomeric IgA and 
becomes dimerized by complexing with secretory component (SC, an epithelial 
glycoprotein) associated with the epithelial cell [10]. At least 80% of the antibodies are 
produced locally in the gut lamina propria (mainly IgA) [11]. Nearly 3 grams of dimeric 
IgA is produced and translocated to the gut lumen everyday as sIgA, which is more than 
the total daily production amount of IgG in an average human subject [12]. sIgA 
highlights the importance of the defense of mucosal infections by the fact that most 
pathogens/antigens are encountered by the mucous membrane. It was well known that 
sIgA in breast milk showed promising protection for the neonates against cholera, 
enterotoxic Escherichia coli and Campylobacter infections, especially in third-world 
countries [13]. However, efficacy of orally administered vaccines is generally low due to 
degradation of the delivered antigen in the gastrointestinal (GI) tract, and low antigen 
uptake by the gut associated lymphoid tissue (GALT, part of the mucosal-associated 
lymphoid tissues (MALT)) [14]. In order to reach immune component cells located in the 
epithelium, lamina propria, or beneath the basal membrane, penetration of the intestinal 
epithelial barrier is required of an oral vaccine. To achieve that, a suitable carrier system 
is necessary for an oral vaccine. These carriers can be microspheres of synthetic polymers 
(such as, PLGA, and polyacryl starch) [15], natural polymers (such as chitosan, and 
alginate) [16], or liposomes [5]. It is proven that particles with sizes below 10μm can be 
taken up by the M-cells in the Peyer’s patches and transported through the intestinal 
epithelial barrier [17]. The uptake antigens are then transported to the regional lymphoid 
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tissues, processed, and stimulate antigen specific B lymphocytes in the germinal centres 
of follicles located beneath domes (Figure 1.1) [18]. In spite of the significant barriers to 
protein/peptide-based vaccine delivery in the gastrointestinal tract, oral delivery 
continues to be the most intensively studied for these macromolecules delivery. The 
advantages of oral vaccination over traditional vaccine injection are obvious, these 
include: (a) Ease of administration without sterile needles/syringe, as well as well-trained 
professionals, (b) ease of transportation and storage, since oral vaccines are relatively 
more stable than injection vaccine and are less susceptible to contaminations, (c) mass 
immunization can be achieved, (d) large patient acceptability (good patient compliance), 
(e) reduction in the risk of infection at the injected site, compared to parental vaccines 
(i.e. Human immunodeficiency Virus and Hepatitis B infections in developing countries) 
[19], and (f) induction in both mucosal and systemic immune responses. While most 
vaccines are administered through parental route, there are several vaccines that have 
been developed for oral administration. These include cholera vaccine (bacterial vaccine), 
typhoid vaccine (bacterial vaccine), polio vaccine (viral vaccine), and rotavirus vaccine 
(viral vaccine). These vaccines are based on killed/inactivated or live-attenuated 
pathogens and are able to generate both cellular and humoral immune responses. 
However, vaccines based on killed/inactivated whole organisms can only induce a 
weaker immunity and therefore, a large dose, or a multiple dosing regiment, is required 
[20]. Lately, research has focused on using purified sub-units of bacteria or virus as a 
vaccine. Due to the nature of these new vaccines (mostly protein, peptide, or DNA-based 
macromolecules), these macromolecules are highly susceptible to gastric acid and are of 
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low permeability to the mucus membrane in the GI tract [21]. Therefore, a combination 
of using biopharmaceutical macromolecules and polymeric carrier has been widely 
investigated in recent years [22-24]. On one hand, these polymeric particles act as 
adjuvants to the immune response by themselves, and are able to enhance the induction 
of immunity [25]. On the other hand, polymeric particles/carriers provide protection to 
the biopharmaceutical macromolecules against degradation and inactivation in the GI 
tract. Several researchers have also pointed out the enhanced transmucosal transport of 
biopharmaceutical macromolecules in the presence of polymeric particles/carriers [23]. 
Figure 1.1: Illustration of pathogens/antigens sampling by M-cells. (1) M cell uptake 
antigens via phagocytosis and translocate the antigens to the lumen side of 
intestine. (2) Invaded antigens or bacteria. (3) An antigen being delivered to 
antigen presenting cells. (4) Dendritic cell. (5) Enterocytes. 
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1.3 Mucosal immune system  
The increased availability of new protein and peptide-based drugs and antigens 
offers new approaches for treatment against diseases. However, protein/peptide-based 
drugs are macromolecules that are inherently susceptible to loss of both their native 
structure (enzymatic digestion and/or hydrolysis induced by gastric acid) and 
conformation. Additionally, these macromolecules have a short half-life (normally in a 
few hours) and are prone to rapid clearance in the liver and other body tissues. Due to the 
large molecular weight (normally > 3,000 Da) and the hydrophilic nature of 
protein/peptide-based drugs, these macromolecules generally have low bioavailability 
(<1%) and short a half-life (<30 minutes). Therefore, a carrier-mediate drug delivery 
system with high drug encapsulation efficiency and high biocompatibility is required to 
improve the bioavailability of these protein/peptide-based drugs and provide possible 
administration via alternative routes (e.g., oral, nasal, and pulmonary).  
As indicated, the major reason for using a mucosal route of vaccination is that most 
infections affect or start at a mucosal surface. Mucosal infection is the major cause of 
death for those aged of 5 years, with approximately 10 million child mortalities annually 
[10]. By provoking both mucosal and systemic immunity, a more pronounced and long-
term effect can be achieved by mucosal vaccination. In fact, the mucosal immune system 
provides two layers of adaptive anti-inflammatory defensive mechanisms: (1) the 
immune exclusion, and (2) and oral tolerance. The first mechanism is majorly provided 
by sIgA antibodies to restrict the epithelial contact and penetration of invaded pathogens 
and other potentially defective antigens (Figure 1.2), while the latter strategy is to prevent 
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overreaction against innocuous luminal antigens (i.e. various food proteins), which is 
dependent mainly on the development of regulatory T cells (Treg) [10]. 
Figure 1.2: Mechanism of Peyer’s patches mediated mucosal immune responses at gut 
associated lymphoid tissue (GALT). (1) Invaded pathogens (i.e. antigens 
and bacteria). (2) An antigen being uptake by M cell and presented to a 
dendritic cell. (3) Activation of B-lymphocytes. (4) Activation of T cells in 
the mesenteric lymph nodes (induced by the dendritic cells) (5) Matured B 
cell with pathogen-specific sIgA. (6) Pathogen-specific sIgA and T cells 
entered the bloodstream and sent back to the infected mucosal membrane. 
(7) Interaction of pathogen-specific sIgA against pathogens. 
 
Table 1.2 lists currently available vaccines against mucosal infections [26]. About 
70% of the body's immune system is found in the digestive tract. GALT is made up of 
several types of lymphoid tissue that store immune cells (such as T and B lymphocytes), 
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with Peyer’s patches as the major sites of GALT. Therefore, Peyer’s patches, which are 
present mainly in the lower ileum, become the primary target for oral vaccines. 
Physiologically, the intestinal epithelium overlying the Peyer’s patches is specialized to 
allow the transport of pathogens by M-cells into the lymphoid tissue [27]. Vaccination 
via GALT differs from the injection route as it has a higher capacity and can provide a 
diversified immune response, including both cellular and humoral components, as well as 
a local and systemic response [15]. Attenuated vaccines are themselves not an ideal 
vaccination method; however, there are several issues, such as adverse effect (e.g. fever, 
fatigue), and the requirement for refrigerated storage and transportation. Consequently, 
subunit vaccines, which are manufactured from antigenic components of infectious 
organisms, have gained popularity. Unfortunately, when administered orally, these 
subunit vaccines show poor immunogenicity, low GI tract absorption and low GALT 
uptake. Moreover, the amount of antigens required for oral immunization is far more than 
those for parenteral administration (via systemic immunity) [28]. To increase 
immunogenicity of oral subunit vaccines, some adjuvant systems are proposed, including 
bacterial toxins and their derivatives (e.g. Cholera toxin, bacterial pili protein and 
lectins), CPG containing DNA (bacterial DNA contains unmethylated-CpG dinucleotide), 
cytokines and chemokines, DNA vaccines, micro- and nano-particulates (e.g. PLA, 
PLGA, polystyrene and polymethyl methacrylate), liposomes and lipopeptides 
(attachment of synthetic or bacterial lipids to peptide antigens) [29, 30]. Among these 
methods, the multiparticulate systems (micro- or nanoparticles) are able to protect the 
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loaded antigens from gastric damage and are able to control the release of loaded antigen 
as well. 
Table 1.2: Internationally licensed vaccines against mucosal infections 
Vaccine Delivery route Trade name 
Polio (live-attenuated polio virus) Oral Various 
Cholera (Cholera toxin B subunit/inactivated V. cholera 
whole cells) Oral 
Dukoral (SBL 
Vaccine) 
Typhoid (Vi polysaccharide) Subcutaneous/ intramuscular 
TyphimVi 
(Aventis) 




Rotavirus (live-attenuated monovalent human rotavirus 
strain) Oral RotaRix 
Influenza (live-attenuated cold-adapted influenza virus 
reassortant strains) Nasal 
FluMist 
(MedImmune) 
Diarrhea (live-attenuated vaccine, ACE527) Oral Phase Ⅲ 
Dysentery (live-attenuated vaccine, Shigella infection, 
CVD 1208S) Oral Phase Ⅱa 
Anthrax (live-attenuated Anthrax vaccine and subunit 
vaccine) Oral Pre-clinical 
Peptic ulcer, gastric cancer (Killed/inactivated) Oral Phase Ⅰ 
1.4 Peyer’s patches 
     In most cases, mucosal immunity is expressed in the gut region [31] (about 80% of 
the body’s activated B cells present in the intestinal mucosa). The organized mucosa-
associated lymphoid tissues (O-MALT) occur throughout the gastrointestinal tract and 
consist of lymphoid follicles are arranged as solitary follicles or as clusters forming 
distinct structures such as the Peyer’s patches (PP), the major inductive site for both 
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humoral and cell-mediated immunity [19] and appendix. Gut-associated lymphoid tissues 
(GALT) are responsible for the production of secretory immunoglobins. The epithelium 
over-lying the lymphoid follicles is termed the follicle associated epithelium (FAE) and is 
distinguished from the intestinal epithelium at other sites by the presence of the 
specialized antigen sampling membranous epithelial cells (also called microfold cells and 
M cells). In the intestine, induction and regulation of mucosal immune responses are 
taken place primarily in Peyer’s patches. Peyer’s patches are the inductive sites for 
immune surveillance (regulation of antigen (Ag)-specific IgA Ab responses following 
oral immunization) [32], and are optimal sites of uptake for those drugs that need to be 
delivered to the intestinal lymph (drugs that undergo extensive first pass metabolism) 
[33]. Peyer’s patches have high transcytotic capability and are able to transport a broad 
range of substances, including bacteria, viruses, antigens and particles from the intestinal 
lumen to the underlying lymphoid tissues. The number and location of PP varies between 
species, however, the basic physiological pattern is similar [34]. In humans, PP tend to 
increase in size and number with increasing age. Generally, the ileum contains more PP 
than the jejunum, while the duodenum contains very few PP [35]. Pathogens enter GI 
tract are wither taken up by M cells or dendritic cells (DCs). M cells sample these 
antigens and forward them to the antigen presenting cells (APCs), including macrophages 
and antigen carrying dendritic cells. M cells of the PP non-selectively transport 
macromolecules, particles and microorganisms [36]. Neutra and co-workers pointed out 
that lectins and polycations that adhere to glycoconjugates on the luminal membranes of 
M cells are endocytosed via deep, clathrin-coated pits from the inter-microfold domains 
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of M cell surface. M-cells uptake and transport particles from the lumen site of the GI 
tract and subsequently present them to underlying follicles [30]. The basement membrane 
beneath the M cells contains pores approximately 3μm in diameter. The unique pore 
structure, reportedly key in facilitating antigen-cell interactions during the immune 
response [35]. Moreover, M cells represent the most efficient cell type for intestinal 
absorption of biologically active agents administered in particulate form. Particle 
interaction with M cells is greatly influenced by the surface properties of both the cells 
(which exhibit species associated variations) and the particles. The level of targeting to M 
cells of particles can be modified by, types of polymer used, size of the particles, ligand-
modification of the particle surface, hydrophobicity, and surface charge [37]. The 
immune response to Staphylococcus enterotoxin B was studied in mice using PLGA 
microspheres. Particles less than 5μm were effectively taken up by the PPs and 
dissembled to the mesenteric lymph nodes as well as the spleen, which corresponded to 
induction of enterotoxin-specific IgM and IgG antibodies (humoral immune response). In 
contrast, particles between 5-10 μm have been shown to remain in the PP for 35 days, 
while particles above 10 μm were shown to be taken up by the PP [38]. In addition, 
hydrophobic polymeric microparticles (polystyrene, polymethylmethacrylate and 
polyhydroxybutrate) showed more efficiency for uptake than hydrophilic particles [33].  
In order to illustrate particle sampling by M cells, Beier and co-workers investigated the 
kinetics of particle uptake in the domes of Peyer’s patches. A suspension of 
Saccharomyces cerevisiae was injected into the gut lumen of anesthetized mini-pigs; the 
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position of yeast cells in the tissue was determined after 1, 2.5, 4, and 24 hours using 
fluorescence light and thin-section electron microscopy. 30% of the yeast cells were 
found to be trafficking at the intercellular space of the epithelium during the first hour 
post-administration. After 4 hours, 70% of the yeast cells were completely translocated 
through the basal membrane and taken up by the phagocytes surrounding the PP [39]. 
1.5 Oral Vaccination Delivery Platforms  
          Using micro- or nanoparticles as drug delivery carriers has been widely 
studied in the past 20-30 years. Recently, research has focused on utilizing these micro- 
or nanoparticles for mucosal vaccination (i.e. nasal and oral vaccination) due to the 
following advantages: (1) Micro- or nanoparticulate vaccines can be delivered and 
distributed more efficiently at the targeted site, (2) due to the nature of their nano-
structured size, nanoparticles can be more efficiently sampled by the M cells, as well as 
dendritic cells by endocytosis/phagocytosis, (3) the particles can act as adjuvant by 
themselves and help induce enhanced immune responses. One of the major challenges of 
oral vaccination is avoidance of an immune tolerance. This issue could be avoided by 
encapsulating vaccine antigen into small particles. Efficient and enhanced uptake of 
particulate antigen by M cells in the Peyer’s patches by phagocytosis has been observed, 
while only minimal antigen uptake (through pinocytosis) was found in the solution form. 
Nonetheless, protein antigens taken up as particles are more potent in activating antigen 
presenting cells (APCs) than soluble antigens. Orally delivered particulate vaccines were 
found to be uptake by M-cells in the Peyer’s patches of the intestine. After being 
processed by APCs (i.e. dendritic cells and macrophages that reside in the Peyer’s 
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patches) and elicit both T cell and B cell-mediated immune response. Table 1.3 lists 
recently developed multiparticulates-based oral vaccination delivery systems. 
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Table 1.3: Recent multiparticulates-based delivery systems developed for oral 
vaccination  
*Active Pharmaceutical Ingredient 



































































































Homogenization 50-250 nm - ~50% 
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Table 1.3 (continued) 
























cholera toxin B 
subunit (rCTB) 
Polymerization - - - 





BSA Lipid cast film 
method 
100-120 nm - ~20% 
 
1.5.1 PLGA and PLA-based micro- and nanoparticles 
          In the past few decades, biodegradable polymers (i.e. poly (lactic-co-glycolic 
acid and polylactic acid) have been widely invested in various dosage forms, such as oral, 
nasal, and pulmonary drug delivery systems. Biodegradable polymers provide sustained 
release of entrapped antigen/drugs and could be degraded in the body and then are 
eliminated from the body [40]. Biodegradable polymer-based particles can be sampled by 
M cells and dendritic cells via phagocytosis. in addition, researchers have demonstrated 
that phagocytosis can become more efficient with increasing polymer hydrophobicity 
[41]. Therefore, biodegradable polymers, such as poly (lactic-co-glycolic acid) and 
polylactic acid, have been utilized for mucosal vaccination research for the past two 
decades. PLGA is a copolymer synthesized by random ring-opening co-polymerization of 
two different monomers, glycolic acid and lactic acid. Based on its biodegradability and 
high biocompatibility [42], PLGA is approved by FDA and commonly used in 
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pharmaceutical industry, especially being uses in microencapsulation [43, 44]. PLA is 
another widely used biodegradable copolymers manufactured by ring-opening 
polymerization of lactide lactic acid and lactide. Delivery of PLGA, PLA has been 
investigated in numerous dosage forms, including nasal [45], pulmonary [46] and oral 
[47] drug/antigen delivery. Nayak et al. prepared rotavirus (strain SA11) encapsulated 
with polylactide (PLA) and polylactide-co-glycolide (PLGA) microspheres using a 
W/O/W solvent evaporation technique. Microspheres sized 2-8μm were obtained by 
sonication during the primary emulsion and homogenization during the secondary 
emulsion process, whereas nanoparticles sized 250-500 nm were formed when sonication 
was used during both primary and secondary emulsion processes. The encapsulation 
efficiency of the PLA and PLGA particles was seen to vary between 25-55% depended 
on the composition of the formulations. With BSA as a stabilizer (to prevent antigen 
degradation in the emulsification process), PLA microspheres in a size range between 1-3 
μm showed approximately 45% encapsulation efficiency. Only about 30–35% burst 
release of antigen was shown in this particular PLA formulation, followed by a sustained 
release of antigen in subsequent weeks. Furthermore, a single dose oral inoculation (20 
μg) of antigen encapsulated PLA microparticles to Swiss Webster mice elicited 
significantly higher (p < 0.05) IgA (>5 fold rise in IgA titer) and IgG (>4 fold rise in IgG 
titer) antibody titer, compared to the control group. In addition, while antibody titers in 
mice inoculated with soluble antigen were increased after immunization, a declining of 
antibody titers was observed shorty after initial elevation. However, mice inoculation 
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with antigen loaded PLA microspheres showed significantly improved (p < 0.05) long-
lasting IgA and IgG antibody titer. Therefore, the results from Nayak and co-workers 
illustrated that PLA microspheres could be a useful polymeric microparticulated oral 
vaccine delivery platform for rotavirus, since the PLA microspheres were of ideal particle 
size (less than 5 μm) for mucosal vaccination and most importantly, both systemic and 
mucosal immune responses could be elicited and sustained for up to 3 months [48]. 
          Although not fully described in vivo, a study has pointed out that the 
degraded products (lactic acid and glycolic acid) of PLA and PLGA form a local acidic 
environment, which might result in acidic hydrolysis of the carrying antigen (or 
protein/peptide-based drug) [49]. Therefore, copolymerization of hydrophilic 
polyethylene glycol (PEG) with PLA and/or PLGA has been developed for micro- or 
nanoparticle-based drug delivery systems [46, 50]. Ren and coworkers synthesized 
triblock copolymers (PELA) by incorporated PEG into PLA (PLA : PEG w/w ratio = 
95:5). Helicobacter pylori (HP) lysate was encapsulated into PELA microspheres using a 
W/O/W double emulsification solvent evaporation method. The final products were 
seized between 3.20-4.05μm in diameter and the loading capacity and encapsulation 
efficiency of HP was approximately 5% and 80%, respectively. Adding hydrophilic PEG 
into the PLEA copolymer enhanced the entrapment of water-soluble bacteria lysates and 
led to the high encapsulation efficiency. In order to evaluate particle distribution in the GI 
tract, the microspheres were first orally administered to miniature pig (sus scorfa 
domestica). After three days, most of the particles were found in the gastric region of the 
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animal, while the majority of the microspheres were shown at the intestine by CT scan 
after 15 days. When HP loaded microspheres were orally inoculated into BALB/c mice 
(at three immunization doses of 0, 1, and 2 weeks, followed by a booster immunization at 
week 7), a significantly elevated (p < 0.05) sIgA was in the saliva, compared to the mice 
immunized with soluble antigens. Furthermore, one week after the booster immunization, 
the specific sIgA-ASCs (Antibody secretory cells), IgG-ASCs, and gut sIgA in oral 
microspheres inoculated mice were also significantly increased (p<0.05), compared to 
both mice immunized with soluble antigen and the control group [51]. Therefore, PELA 
microparticles could be another useful platform for protein/peptide-based API and are 
capable of delivering antigens to the intestine and elicit both mucosal and systemic 
immunity. 
1.5.2 pH-sensitive enteric coating polymer-based microparticles  
Recently, adenoviral vectors (AdV) have been widely used for as a vector for gene 
delivery and expression of foreign proteins for vaccination. The reason why AdV are 
attractive for vaccine delivery to mucosal surfaces is that most of AdV serotypes invade 
through these surfaces, followed by replication of themselves in mucosal sites of the 
digestive tracts [52]. Unfortunately, the strong mucosal immune responses elicited by 
AdV could actually degrade the vaccine and reduce the efficacy of the AdV vaccines 
[53]. Therefore, polymeric particles micro- or nanoparticles have been introduced to 
enhance mucosal immunity.  
Eudragits®, pH-sensitive acrylic co-polymers manufactured by Evonik Industries 
AG, are commonly used in varies oral dosage forms as enteric coating material against 
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gastric degradation [54]. These acrylic co-polymer products pH-sensitive and various 
grades of Eudragit® dissolve at certain pH range. Therefore, targeted delivery of oral 
dosage forms to specific pH region along GI tract could be achieved by utilizing an 
appropriate grade of Eudragit®. Hypromellose acetate succinate (HPMCAS, also known 
as hydroxypropyl methylcellulose acetate succinate) is a cellulose ester, which is also 
typically used as an enteric coating agent for solid dosage forms in the pharmaceutical 
industry [55]. Tawde and co-workers incorporated whole cell lysate of murine ovarian 
cancer cell line (ID8, a source antigen that correlates closely to human ovarian cancer 
cell) into Eudragit® FS 30D and HPMCAS-based microparticles using a Buchi B-191 
Mini Spray Drier. In order to target the microparticles to M cells at the Peyer’s patches, 
an M cell-specific ligand, Aleuria aurantia lectin (AAL) was used in the formulation. The 
obtained microparticles made of Eudragit® FS 30D were approximately 1.6 µm in 
diameter with an encapsulation efficiency of about 92%. Microparticles were 
administered to C57BL/c mice via oral gavage to evaluate the vaccine efficacy using a 
challenge with live tumor cells (back injection of tumor cells). Three weeks after the 
tumor challenge, the vaccinated mice showed significant (p < 0.05) retardation of tumor 
volume compared to non-vaccinated animals. A significantly elevated (p < 0.05) serum 
IgG level was observed in vaccinated mice, in comparison to non-vaccinated animals. 
Additionally, CD8+ T-cells, CD4+ T-cells and B-cells in various lymphatic organs were 
increased in vaccinated mice. Therefore, orally delivered, whole cell lysate entrapped 
microparticles made of enteric polymers are of potential in triggering humoral as well as 
cellular immune response in the mice model [56]. Such vaccine could be a potential 
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treatment for patients with residual tumor in the future, although further studies are 
required to test the stability of the vaccine. 
1.5.3 Chitosan-based micro- and nanoparticles 
Chitosan, a natural hydrophilic polysaccharide is generally obtained by partial 
deacetylation of chitin from the hard exoskeleton of crustacean (i.e. crab, lobster, and 
shrimp). Chitosan is regarded as biocompatible and biodegradable by lysozymes and 
chitinases produced by macrophages in human bodies [57]. Chitosan can enhance tight 
junction permeability [58] and shows strong mucoadhesive properties in numerous 
studies [59, 60]. Additionally, chitosan is able to interact with negatively charged mucus 
membrane of gastrointestinal tract due to its positive net charge [61]. Lameiro et al. 
encapsulated adenoviral vectors by the method of ionotropic complexation of chitosan 
chains with bile salts. The encapsulation efficiency was over 80%, while using sodium 
deoxycholate as counter-anion and poloxamer 188 (Pluronic F68) as surfactant. The 
obtained microparticles were then inoculated directly into 293 and Caco-2 cells. 24 hours 
after viral inoculation, the microparticles were detected to be spread up to 30–40% of the 
total cells in the monolayer. Furthermore, encapsulation in chitosan-bile salt containing 
microparticles was capable of protecting the adenovirus from low pH medium (used in 
the in vitro dissolution test), and delaying adenovirus release after cell contact (due to the 
mucoadhesive property of chitosan) [53]. Overall, chitosan-bile salts microparticles 
showed protection for the encapsulated AdV in a cell model; however, further in vivo 
studies are required to verify whether these formulations are of good properties for future 
mucosal adenovirus delivery. However, it has been pointed out that chitosan loses its 
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mucoadhesive, as well as penetration enhancing property under acidic conditions due to 
deprotonation [62]. N-trimethyl chitosan (TMC) has drawn attention in recent research 
due to its solubility in water over a wide pH range. In addition, this modified chitosan is 
of absorption enhancing property even in neutral or basic pH environment [63]. Chen et 
al. manufactured TMC nanoparticles by ionic gelation using fluorescein isothiocyanate 
labeled BSA (FITC-BSA) and Urase as a model protein vaccine. The TMC nanoparticles 
obtained were sized between 300-500 nm with approximately 80% (FITC-BSA)-95% 
(Urease) encapsulation efficiency and 10% (FITC-BSA)-45% (Urease) loading capacity. 
From the permeability test in Caco-2 cell monolayer, significantly (p < 0.05) higher 
permeation efficiency was observed in TMC nanoparticles, compared to the control 
group (about 1.4 fold increase). Furthermore, after oral inoculation of TMC 
nanoparticles, both serum IgG and gut sIgA were significantly elevated (p < 0.05) in the 
mice, compared to the antibodies amount in Urease solution administered animals and the 
control group. On the other hand, mice subcutaneously injected with TMC nanoparticles 
showed only significantly increase (p < 0.05) serum IgG, but not secretory IgA. This 
indicated that TMC nanoparticles are of potential in eliciting both systemic and mucosal 
immunity, and could be a better vesicle as an oral vaccine, compared to subcutaneously 
injection vaccine [64]. 
1.5.4 Alginates-based micro- and nanoparticles 
Although chitosan is generally regarded as of mucoadhesive (due to its innate 
positive charge) and permeation enhancing (though tight junction) properties as 
previously described, it is only soluble in acidic conditions (pKa 5.6). Therefore, chitosan 
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may be deprotonated in physiological fluid and lose its mucoadhesive and permeation 
enhancing capability [65]. Therefore, one solution for this issue is to use a negatively 
charged material, such as sodium alginate, to coat/protect the acid-sensitive chitosan by 
electrostatic interactions. Alginates are anionic polysaccharides obtained from the cell 
wall of brown algae. In the pharmaceutical industry, alginates are used in a wide variety 
of applications as thickeners, stabilizers, and gelling agents. Alginates have 
mucoadhesive properties and have been investigated in various oral delivery formulations 
[66, 67]. Li et al. first manufactured chitosan microparticles via ionic gelation. The 
prepared colloidal chitosan solution was then incubated with BSA solution to form 
protein loaded microparticles. Sodium alginates were then coated onto the chitosan 
microparticles in a layer-by-layer manner. The particle size of manufactured 
microparticles with and without alginate coating was approximately 1300 nm and 400 
nm, respectively. BSA encapsulation efficiency was dependent on the initial protein 
concentration. The highest encapsulation efficiency (EE) was achieved (60%) at a BSA 
concentration of 2 mg/mL, while EE dropped greatly to less than 30% when BSA 
concentration was over 2 mg/mL. In addition, due to the competitive absorption between 
BSA and alginate onto the surface of the chitosan microparticles, BSA loading capacity 
was the highest (about 90%) at 1:1 alginates/chitosan (w/w) ratio, and was less than 40% 
at 4:1 alginates/chitosan ratio. However, microparticles prepared at 4:1 alginates/chitosan 
ratio showed the best stability due to the inversed positive zeta potential obtained from 
alginates coating (from -28mv to +27 mv) [68]. From Li’s results, alginate-coated 
chitosan microparticles appeared to be a suitable vehicle for oral protein delivery, the 
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alginates were able to protect the entrapped BSA from acid degradation, as well as 
provide control over the release of BSA. However, a further investigation in an animal 
model would be required to evaluate the performance of this formulation in a in vivo. In 
another study, Borges and co-workers prepared alginate-coated chitosan nanoparticles by 
a similar method, while recombinant hepatitis B surface antigen (HBsAg) was loaded as 
the model antigen, with or without a potent adjuvant, oligodeoxynucleotides containing 
immunostimulatory CpG motifs (CpG-ODN). The size of coated nanoparticles was in a 
range between 300-600 nm, with encapsulation efficiency and loading capacity of 
approximately 2.5% and 85%, respectively. From their results, the loaded HBsAg 
maintained their integrity after the manufacturing process (evaluated by SDS-PAGE), as 
well as after an in vitro dissolution test (in pH7.4 phosphate buffer solution). After 
coating, nanoparticles containing both HBsAg and CpG-ODN or only HBsAg were 
administered into BALB/c mice via oral gavage. Both formulations showed significantly 
elevated (p < 0.05) percentage of CD4+ T-lymphocytes expressing CD69 (a cell 
membrane receptor expressed on B and T lymphocytes, and was commonly used as a 
parameter in vaccination studies) in the mice spleen, which suggested these formulations 
were able to elicit cellular immune responses. Furthermore, both formulations induced a 
significantly proliferated IL-2 and IFN-γ production, which resulted in the presence of 
serum IgG and sIgA in the gut of the mice [69]. Alginate-coated chitosan particles have 
been demonstrated as a possible platform for future oral vaccine delivery. However, a 
burst release of encapsulated antigen from alginate-coated chitosan nanoparticles was 
found in simulated gastric fluid (pH 1.2), therefore, further protection is certainly 
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necessary to control the release of entrapped antigen and prevent its release in the gastric 
region. 
Nograles and co-workers produced alginate microspheres using water-in-oil (W/O) 
emulsification technique. The average particle size of alginate microspheres was about 45 
μm. Plasmid DNA (pDNA) with fluorescent protein reporter gene (GFP), pVAX-GFP, 
was encapsulated into the alginate microspheres at encapsulation efficiency of 
approximately 72%. The pVAX-GFP loaded alginate microparticles showed a 
significantly increased (p < 0.05) release under basic conditions, compared to acidic 
conditions. This was due to the shrinkage of alginate microspheres in acidic environment 
while the swelling of these microparticles in basic conditions. The pVAX-GFP loaded-
microspheres were inoculated into BALB/c mice via oral gavage to monitor the 
biodistribusion of GFP in the intestine. After inoculation, GFP protein was detected in the 
mice intestinal cells within 24 to 48 hours [70].  Therefore, alginate microparticles were 
able to protect and deliver DNA to the intestine for gene expression, which implied 
alginate microparticles of potential for future oral vaccination using recombinant DNA. 
1.6 Lipid based micro- and nanoparticles 
1.6.1 Liposomes based micro- and nanoparticles 
 
DNA vaccines have recently been conducted as a potential new generation of 
vaccine for humans. DNA vaccines are generally considered as being potentially safer 
and more stable at room temperature (compared to live-attenuated vaccines), cheaper to 
produce, and easy to manufacture [71]. Manipulating DNA into a particulate delivery 
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system potentially renders DNA useful for mucosal immunization, by which it is possible 
to stimulate both humoral and cell-mediated responses. Additionally, increasing evidence 
has shown that DNA vaccination at the mucosal site is of better performance to that at 
peripheral sites in generating immune response against a number of infectious agents, 
including viruses and bacteria [72, 73]. This is partially explained by the observation that 
memory T and B cells induced upon mucosal vaccination acquire mucosa-homing 
receptors and preferentially accumulated at the mucosal site of induction. However, 
mechanisms that lead to elicit activation of memory T and B cells are still to be 
determined. Liposomes have been widely investigated for antigens and genes delivery via 
different routes [74, 75] due to their properties of high biocompatibility and 
biodegradability. Cationic liposomes can also act as adjuvants and improve the 
expression of the plasmid DNA or recombinant DNA encapsulated inside. Liposomes can 
be uptake by endocytosis absorption sites. In addition, several studies in the past decade 
have suggested that liposomes fused with the plasma membrane and mediated the entry 
of DNA into the cell compartment [76]. Wang et al. encapsulated recombinant Ag85A 
(coded for mycobacterium antigen 85A, one of the protein ingredients secreted by 
Mycobacterium tuberculosis bovis) in liposomes, followed by oral inoculation of the 
liposomes to C57BL/c mice (three does in at a bi-weekly interval). Immunofluorescent 
staining was performed to detect Ag85A antigen in intestine cells, M cells and dendritic 
cells in the mice intestine. For mice inoculated with recombinant DNA-loaded liposomes, 
Ag85A antigen was expressed and detectable at both M cells and dendritic cells in the 
mice intestine (especially in M cells), compared to no Ag85A expression in the control 
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group. This suggests that M cells indeed, take a crucial role in sampling antigen 
continuing vesicles and translocate these vesicles to the dendritic cells afterward. In 
addition, from the results of an in vivo Mycobacterium tuberculosis challenge test (in a 
BALB/c mice model), sIgA level was significantly (p < 0.05) elevated after 
immunization, compared to the control group. This provides proof that oral vaccination 
of recombinant DNA-loaded liposomes is able to elicit mucosal immunity in the mice 
model. Additionally, Ag85A antigen was intensively expressed in the basolateral 
compartment of epithelium, rather than expressed in the apical membrane of intestinal 
epithelial cells. This implied that the basolateral compartment of intestine epithelium 
plays an important role in initiating Ag85A-specific immune response, while the full 
mechanism is still unknown [77]. 
Nevertheless, plasmid DNA is susceptible to gastric pH and enzymatic 
degradation. Therefore, a chitosan –plasmid polyplex, namely polyplex, was introduced 
for that it is regarded as of the capability in providing protection of the DNA from 
nuclease degradation and a mucoadhesive property that permits a sustained interaction 
between the encapsulated materials and the membrane epithelia [78]. Channarong et al. 
prepared chitosan coated plasmid DNA (pRc/CMV-HBs) loaded liposomes and polyplex 
(chitosan-plasmid DNA complex) loaded liposomes (PPLs) using 
phosphatidylcholine/cholesterol as the main lipid component (w/w ratio: 5:4) for oral 
DNA vaccination. The main size of all pRc/CMV-HBs loaded liposomes were between 
60 to 500 nm in diameter; while the size of polyplex ranged between 350 to 550 nm, 
dependent on the chitosan content. The loading efficiency of pRc/CMV-HBs was over 
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80%. After the manufacturing process, plasmid DNA was found stable in both SGF (1 
hour at 37 °C) and SIF (2 hour at 37 °C), which implied protection imparted by the 
liposome/polyplex. To further evaluate whether the chitosan-coated liposomes and PLLs 
were of potential as oral gene delivery systems, each formulation that carrying pEGFP-
C2 was investigated in BALB/c mice via intragastric inoculation (single dose 
inoculation). After 24 hours, both chitosan-coated liposomes and PLLs were detected at 
the upper part of duodenum and the signal of PPLs was found throughout the intestine. 
This higher potential for oral DNA delivery of chitosan-coated PLL was due to the 
increase in permanent positive surface charges that enhanced the internalization of the 
DNA, as well as the prevention of enzymatic degradation [79]. 
1.6.2 Bilosomes-based micro- nanoparticles 
Although lipid-based carrier platforms have been recently investigated for oral 
vaccination, it has been pointed out that these lipid-based vehicles (such as liposomes) 
are susceptible to bile salts and enzymatic degradation in the GI tract [80]. Therefore, a 
relatively stable (in the GI tract) lipid-based carrier is required for future oral 
drug/vaccination delivery. A colloidal delivery system consisting of bilosomes, similar to 
niosomes (nonionic surfactant base vesicles), but with have incorporated bile salts into 
the vesicular lipid bilayer membrane. Bilosomes are made of naturally occurring lipids, 
which makes them highly biocompatible. In addition, the bilosomes components have 
also been shown to possess inherent adjuvant properties when associated with antigen 
[81]. Singh et al. prepared BSA loaded bilosomes by lipid cast film method. The 
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manufactured bilosomes were then chemically conjugated with Cholera toxin B sub-unit 
(CTB) to enhance the affinity of the formulation toward M cells at Peyer’s patches. In 
their study, bilosomes manufactured were stable at 5 and 20 mM bile salt concentration 
(average bile salt concentration in health humans), as well as in simulated gastric fluid 
and in simulated intestinal fluid. The average particle size of bilosomes was between 100 
to 120 nm in diameter, with BSA encapsulation efficiency (%) of about 30%. CTB 
anchored bilosomes (BSA loaded) was orally administered to BALB/c mice as a single 
primary inoculation and a three-primary inoculation (in three consecutive days) and 
compared to a single subcutaneous (SC) immunization. A single dose of oral CTB 
conjugated bilosomes was able to generate almost equivalent immune response (serum 
IgG), compared to subcutaneous immunization of the same antigen (along with Freund’s 
adjuvant). Additionally, CTB anchored bilosomes was able to elicit an mucosal immune 
system response, since significantly increased (compared to SC BSA and non-CTB 
conjugated BSA loaded bilosomes) (p < 0.05) fractions of specific IgA against BSA to 
total IgA levels in intestinal, salivary and vaginal secretions of the inoculated mice was 
found. In another study, haemagglutinin antigen (HA) was entrapped into a bilosome 
vesicle (BV) system and inoculated to BALB/c mice as a lipid based oral delivery system 
by Mann and co-workers. The mean particle size of these bilosomes was about 50 to 250 
nm in diameter and of an antigen loading of approximately 50%. Three BV systems were 
prepared using homogenization methods: (1) Unilamella (BV1), (2) Double lipid group 
(BV2), (3) Double protein group (BV3). Three weeks after treatment, both BV1 and BV3 
showed significantly (p = 0.012 and p = 0.009, respectively) higher IgG1 titer, compared 
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to the control group. On the other hand, IgA titer was significantly higher after three 
weeks for BV1 (p = 0.05), and after four weeks for BV2 (p = 0.03) and after 2, 3 and 4 
weeks for BV3 (p = 0.05, 0.05 and 0.05 respectively), compared to the untreated controls. 
Therefore, only BV3 (comprised of a double protein to lipid ratio) was able to induce 
both mucosal and systemic responses and could be possible applied for future oral 
vaccine development [82]. From previous studies, small lipid vesicle formulations ( < 
100 nm) induce Th2 responses while large vesicles ( > 200 nm) induce Th1 biased 
responses to entrapped antigen following subcutaneous administration [83]. Although the 
exact mechanism underlying this immune response is not yet fully understood, Mann and 
co-workers also demonstrated that it is possible to polarize the immune response to 
entrapped antigen via oral vaccination with different sized vesicles (bilosomes). While 
small vesicles (Z-average diameter 250 nm) induce a Th2 response, a mixed population of 
small and larger vesicles (Z-average diameter 980 nm) promotes a significant Th1 bias as 
measured by IgG2a and IFN-γproduction (using influenza A entrapped bilosomes in a 
ferret model). These results implied that an oral vaccine formulation could be modified 
physically to adapt resultant Th biased immune responses after inoculation [84]. 
1.6.3 Niosomes-based micro- and nanoparticles 
 
Liposomes were widely investigated as a vehicle for oral vaccine delivery in the 
past few decades. However, liposomes are found susceptible to gastrointestinal 
environment (i.e. stability issues in gastric or intestinal fluid, bile salt caused dissolution) 
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and enzymatic degradation. Therefore, modified lipid-based vesicles niosomes were 
developed to provide a greater stability over traditional liposomes. A niosome is a non-
ionic surfactant-based liposome. Niosomes are closed bilayer vesicles formed by non-
ionic amphiphiles. It has been stated that niosomes are of strong adjuvant property and 
have good penetrating capability. Furthermore, since niosomes were composed of non-
ionic surfactant, they are generally regarded to have better stability and can be easily 
stored, compared to liposomes. Jain and co-workers developed an oral vaccination 
delivery niosomes made of cholesterol, stearylamine and sorbitan monstearate [85]. 
Plasmid DNA, pRc/CMV-HBs (coded for the small proteins of the hepatitis B virus, 
HBsAg) was encapsulated into the niosomes by using a reverse phase evaporation 
method. The manufactured niosomes were further coated with a modified polysaccharide 
o-palmitoyl mannan (OPM) in order to protect the niosomes against bile salt caused 
dissolution in the GI tract, as well as targeting the mannose receptors expressed on 
macrophages and dendritic cells present in the vicinity of Peyer’s patches. In the 
immunization experiment, OPM-coated niosomes were orally administered to BALB/c 
mice and compared to mice administered with equivalent amount of naked plasmid DNA 
or recombinant HBsAg via intramuscular injection (a 2-time inoculation in two weeks). 
The size of plain niosomes and OPM-coated niosomes were approximately 2.3 µm and 
2.5 µm, respectively, while the encapsulation efficiency of plasmid-DNA was found to be 
about 63% and 61%, respectively for plain and OPM coated niosomes, respectively. 
However, the stability of plain niosomes showed 45–50% DNA loss after 1 hour in both 
SGF SIF, while about 25–30% DNA loss was found in OPM-coated niosomes under the 
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same condition. This suggested that OPM coating was able to prevent the disruption of 
niosomes and reduce the degradation of encapsulated DNA. Nevertheless, all mice 
inoculated with oral niosomes were seropositive (>1 mIU/ml) in 2 weeks. It was 
suggested that antibody levels in the vaccinated mice were more than sufficient (>10 
mIU/ml) to get seroprotection against hepatitis B. Additionally, OPM coated niosomes 
generated a significantly higher anti-HBsAg IgG (p < 0.05), compared to plain niosomes. 
On the other hand, OPM-coated niosomes elicited mucosal immune response, while 
negligible IgA amount was found on intramuscular administration of naked plasmid 
DNA or recombinant protein vaccine. This is in concordance to the general agreement 
that parenterally administered vaccines lack the ability to elicit mucosal immune system, 
while oral vaccination could stimulate both mucosal and systemic immunity. 
Furthermore, a strong cell mediated immune response (significantly higher level of both 
IL-2 and IFN-γelicited) was observed in mice administered with intramuscular naked 
DNA and oral OPM-coated niosomes. Therefore, OPM coated niosomes could be another 
lipid-based vehicle as DNA vaccine carrier and adjuvant for future oral vaccination 
delivery [85]. 
1.7 Polyacryl starch-based microparticles 
 
Polyacryl starch microparticles are able to be taken up by follicle-associated 
epithelium (FAE) in the Peyer’s patches and elicit both local and systemic immunity [86]. 
Stertman et al. prepared polyacryl starch microparticles by polymerization. Two model 
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antigens, human serum albumin (HAS) and recombinant cholera toxin B subunit (rCTB) 
were encapsulated into the microparticles. The final formulations were orally 
administered into BALB/c mice via oral gavage. When rCTB was conjugated to 
polyacryl starch, they were taken up over both the FAE and the villus epithelium, while 
HAS conjugated microparticles were only taken up over FAE. When HSA and rCTB 
were conjugated together to the polyacryl starch microparticles and orally administered to 
the mice, both the HSA- and rCTB-specific responses were elicited quantitatively 
(elevated serum IgM/IgG and fecal s-IgA level. The results from Stertman and co-
workers indicated that only Peyer’s patches mediated particle uptake decided the immune 
responses after oral administration, and polyacryl starch was of strong adjuvant capacity 
and was able to elicit both systemic and mucosal immune responses [87]. 
1.8 Targeted Delivery to Peyer’s Patches (M Cells) 
While M cells are present at a low density along gastrointestinal tract, specific 
targeting of M cells could possibly enhance particle sampling by the M cells [88]. 
Although there is limited information available for specific markers of human M cells 
targeting, several studies have been conducted with drug delivery systems that target β1 
integrins that are overexpressed at the apical pole of human M cells [89]. Ovalbumin 
(OVA) was encapsulated into PLGA nanoparticles using W/O/W solvent evaporation 
technique by Fievez and co-workers. To further target the formulation directly to human 
M cells, four different ligands (15% w/w) [RGD oligopeptides, RGD peptidomimetic 
(RGDp), LDV derivative (LDVd) and LDV peptidomimetic (LDVp)] were grafted onto 
the PEG chain of PCL-PEG (15% w/w) co-polymer and incorporated into PLGA 
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nanoparticles (70% w/w) and tested for in vitro transport in human enterocytes (Caco-2 
cells) and human follicle-associated epithelium (Raji cells), as well as in vivo 
mucosal/cellular immunity in BALB/c mice. All ligand-grafted PLGA nanoparticles were 
sized between 220 to 260 nm and the loading efficiency (%) of OVA was between 15-
19%. Both RGD- and RGDp-nanoparticles showed significantly higher uptake across the 
mono- (Caco-2 cells) and co-culture (Caco-2 cells and Raji cells), compared to the non-
targeted nanoparticles (p < 0.05). Additionally, after 60 minutes incubation, both RGD 
and LDVd labeled PLGA nanoparticles showed doubled internalization by J774 
macrophages cells in vitro, compared to non-targeted nanoparticles. When the PLGA 
nanoparticles were administered directly to the mice duodenum via gavage, both RGDp 
and LDVd labeled nanoparticles elicited significantly (p < 0.05) higher production of 
IgG, compared to the mice administered non-targeted OVA via IM injection. Moreover, 
all the targeted-nanoparticles were able to induce a cellular immune response, as shown 
by the production of IGN-γ in the splenocytes (BALB/c mice study). Lastly, OVA 
encapsulated RGD- and RGDp-nanoparticles were able to target specifically to β1 
integrins at the surface of M cells and enhanced particle uptake of M cells, which could 
successfully lead to the induction of cellular immunity against OVA [20]. 
Aleuria aurantia lectin (AAL) has been validated as an M-cell targeting agent in a 
previous study [90]. Chablani and co-workers developed an M-cell targeting (use ALL as 
the ligand) microparticles-based oral vaccine via spray drying and used BSA as the 
model antigen. The microparticles were composed of Eudragit® FS 30D, hydroxyl propyl 
methyl cellulose acetate succinate (HPMCAS), and BSA in a ratio of 1:1:1 (by weight). 
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The obtained particles were approximately 1.5 μm in diameter with about 70% 
encapsulation efficiency. M-cell targeting/uptake of the microparticles was evaluated in-
situ on excised mice intestines. Peyer’s patches (PP) containing intestinal segments 
showed higher uptake of particles by lymphoid tissues. On the other hand, no 
fluorescence was detected in villi area indicating no particle uptake. Since follicle 
associated epithelium covering the PP is composed of M-cells, particles translocating the 
epithelium are possibly only mediated by M-cells sampling. Therefore, such enhanced M 
cell uptake can be attributed to the presence of AAL ligand as previously discussed [90]. 
BSA-loaded microparticles (with rhodamin-123 as a fluorescence dye) were also orally 
inoculated into C57BL/6 mice. These enteric polymer-based microparticles showed a 
prolonged BSA release over 8 hours. Furthermore, 8 hours after immunization, 
fluorescent-labeled microparticles were found in the Peyer’s patches of the mice intestine 
[91], which implied that an oral delivery platform composed of pH-sensitive enteric 
polymer and M-cell targeting ligand, AAL could be of potential in oral vaccination, 
however, additional immunity responses followed by vaccination must be further studies. 
The phage display technique (expression of a foreign peptide sequences by 
transfection a set of genetically recombinant bacteriophages) is a validate method to find 
interacting peptide ligands to certain targets [92]. Additionally, identification of homing 
peptide ligands targeting various organs or tissues, such as, M cells have been 
investigated in previous studies [93]. Yoo et al. developed a M-cell targeted oral vaccine 
composed of chitosan nanoparticles and M-cell homing peptide that was coded by a 
phage clone encoding CKSTHPLSC (CKS9) sequence. The manufacturing chitosan 
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nanoparticles were sized approximately 225 nm in diameter and labeled with 
fluorescence dye. Transcytotic efficiency of the nanoparticles (CKS9-CNs) to the M cells 
in vitro and Peyer’s patch targeting properties in vivo were evaluated by in vitro 
transcytosis assay and closed ileal loop assay, respectively. From the in vitro transcytosis 
assay performed in Caco-2 cells at 37 °C, the amount of translocated nanoparticles across 
M-cell layer was significantly (p < 0.05) increased, compared to the amount that was 
observed under 4 °C. In addition, the high transcytosis was regained once the incubation 
temperature was elevated back to 37 °C. Since M cells are specialized cells which are 
able to sample antigens via transcytosis, the temperature-dependent change of particle 
translocation efficiency found in Yoo’s study indicated that the translocation was 
mediated by transcytosis through the M cells, rather than by simple diffusion through 
intercellular spaces. Furthermore, both the chitosan nanoparticles, CKS9-CNs and 
chitosan nanoparticles alone (CNs), showed similar amounts of particle translocation 
across Caco-2 cell layers without any significance at the begging of the in vitro test. 
However, transcytosis CKS9-CNs increased gradually over time. After 3 hours, the 
accumulated amount of CKS9-CNs across the cell layer was about 1.5-fold higher than 
CNs, which illustrated that CKS9-CNs were taken up by M cells in a more efficient 
manner, compared to CNs. This efficient sampling by M cells was as a result from the 
incorporation of M cell-homing peptide. On the other hand, the targeting property of 
CKS9-CNs to Peyer’s patches was also monitored in vivo (closed ileal loop incubation). 
And similarly to the in vitro M cell results, CKS9 promoted the affinity of chitosan 
nanoparticles to Peyer’s patches in rat small intestine under the demonstration of confocal 
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scanning microscopy. Moreover, CKS9-CNs injected into closed ileal loop were 
specifically localized within FAE layer Peyer’s patches, where located the most abundant 
M cells, in contrast to CNs without targeting ligands [94]. These M-cell targeted 
formulations we discussed earlier were summarized in Table 1.4. 
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1.9 Mucoadhesion  
Mucus is a complex viscous adherent secretion synthesized by specialized goblet 
cells in the columnar epithelium, that line all of organs exposed to an external 
environment. Mucus serves many functions, including lubrication for the passage of 
objects, maintenance of a hydrated layer over the epithelium, acting as a barrier to 
pathogens and noxious substances, and being as a permeable gel layer for the exchange 
of gases and nutrients with the underlying epithelium. Mucus is also the first barrier by 
which nutrients and drugs must interact and diffuse through in order to be absorbed and 
gain access to the circulatory system, as well as their subsequent target organs [95]. 
Physically, mucus is composed of about 90-95% water, and 5-10% mucins. Mucins are a 
family of polydispersable molecules with high molecular mass and a high proportion of 
covalently bound oligosaccharide side chains, which afford high resistance to the effects 
of acid and digestive enzymes. In mammals, mucins typically contain fructose, galactose, 
N-acetylglucosamine, N-acetylgalactosamine, and sialic acid, together with small 
amounts of sulfate, and mannose [96].  
Mucoadhesion is a process by which mucoadhesive polymers contact and attach on 







Figure 1.3: Mechanisms of mucoadhesion process: (A) Wetting and swelling; (B) 
Entanglement; (C) Bond formation. 
 
Mucoadhesive polymers get swollen once they are soaked and wetted in the 
physiological environment. Swelling of the polymers provides an outward force and help 
the polymers approach the mucus membrane. Once the polymers get contact with the 
mucus membrane, the swelling force further act as a “pushing force” which enhances the 
following steps of mucoadhesion process. After mucoadhesive polymers and mucus 
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membrane make contact, the polymer chains and glycoprotein chains of the mucus 
membrane start to entangle. The entanglement process pulls the two substances closer 
and closer, which finally, lead to the last process of mucoadhesion, the bonds formation 
between the mucoadhesive polymers and mucus membrane. These chemical bonds can be 
hydrogen bonds, electrostatic forces or even covalent bonds. These bonds/interaction 
provide an increased residence time at the attached site. The increased residence time can 
possibly lead to higher absorption and bioavailability of a dosed drug. Therefore, 
numerous studies have been focusing on incorporating mucoadhesive polymers into 
different formulations, such as buccal, nasal and oral dosage forms to enhance the 
bioavailability by virtue of an increased residence time at the sites of absorption. Both 
natural and synthetic polymers can be utilized as a mucoadhesive agent. The most well-
known and recently investigated mucoadhesive materials are chitosan [97], alginate [98], 
carbomers [99], polycarbophil [100], pectin [101], and some thiolated derivatives of 
mucoadhesive polymers (e.g. thiolated chitosan) [102].  
1.10 In vitro mucoadhesion test 
In the past 20 years, several methods have been developed and used to determine 
the mucoadhesive properties of different dosage forms. The oligosaccharide chains of 
mucins are attached to the protein core and carry negative charges (due to the sialic acid 
and sulfates moieties). Therefore, a material that carries positive charges (such as 
chitosan) is generally considered to be of mucoadhesive property (due to the electrostatic 
interactions between the material and mucus membrane). Zeta potential is used to 
represent the electrokinetic potential in colloidal systems Zeta potential not only 
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determines the electrostatic interactions between dispersed particles, but also serves as an 
important parameter in characterizing the properties of dispersion systems affected by 
this electrical phenomenon. Whether electrostatic interactions between a mucoadhesive 
polymer and mucus membrane play a decisive role in mucoadhesion, therefore, zeta 
potential measurements of polymer dispersions can be used to predict the mucoadhesive 
properties of the polymer [103]. Alternately, other methods have been developed to 
predict bioadhesion/mucoadhesion, including tensile strength tests [104], dynamic 
techniques [105], and everted-gut sac method [106]. In a tensile strength study, one side 
of a testing sample is fixed on a stage of a tensile meter, while the other side is contacting 
with the mucus membrane or gut tissues from an animal (usually mice or rats). Briefly, a 
tensile strength test is typically used to evaluate the adhesion force of a testing 
formulation/material. The adhesion force is generally represented as maximum 
detachment force (the maximum force required to separate the testing sample and the 
mucus membrane) and work of adhesion (the total area-under-the-curve from the force 
versus time curve during the adhesion test). Everted gut is another widely used method 
for evaluating mucoadhesion property of a sample. Everted gut method is especially 
useful in testing small particles, such as microspheres and small pellets. Briefly, guts 
from a mouse (or a rat) is freshly excised, everted and cut into 5-10 cm length sacs before 
test. In one method, testing samples (in a suspension form) are filled into the sac and then 
submerged into an aqueous medium. In the other method, the samples are dispersed into 
an aqueous medium first, followed by placing the everted sac into the same medium. 
After certain period of time, the amount of samples retaining on the everted sac is 
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quantified and the mucoadhesion property of the sample can then be determined. 
Dynamic method is another technique for evaluating mucoadhesive property. In this 
method, a freshly excised gut is placed onto a tilted surface. The gut is continuously 
flushed over by an aqueous testing medium from the upper end of the tilted surface. The 
testing samples are then placed onto the gut and mucoadhesion property can be easily 
determined by observation of the movement of the particles on the gut during the whole 
process.  
However, among these testing methods, only the dynamic method can access the 
duration of adhesion. Moreover, the dynamic method reflects real-state adhesion 
performance since both adhesion strengths and zeta-potential measurements are indirect 
methods for mucoadhesion evaluation [107]. The dynamic method attempts to mimic in 
vivo conditions in terms of temperature, humidity, and liquid flow, and aims to extract 
information about the influence of a range of parameters on the mucoadhesion process. In 
addition, the dynamic method is able to evaluate the percent retention of an applied 
sample on a mucosal surface over time [105], which makes it unique from the traditional 
adhesion strength test. 
1.11 Conclusions 
Numerous multiparticulate-based drug delivery systems have been developed in 
the past two decades for oral vaccination. These formulations showed prominently 
enhanced immune responses in both systemic and mucosal pathways. Evidence from both 
in vitro cell model and in vivo mice studies suggested that olymeric (i.e. PLGA, PLA, and 
chitosans) micro- and/or nanoparticles of particle sizes less than 10 µm in diameter can 
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be taken up by M cells in Peyer’s patches via phagocytosis and pinocytosis. The particles 
were then translocated to the lumen side of the gut and elicit a series of immune 
responses afterward (i.e. secretion of sIgA in the gut and production of serum IgG). 
However, in spite of these promising in vitro and in vivo results obtained so far in various 
multiparticulate-based oral vaccines, the translation of these formulations into the real 
clinical case still has many challenges. Such as how to scale-up the batch size of the oral 
vaccines for massive administration, the stability of the formulation, the amount of 
antigens required to elicit adequate immunity in a real human body, as well as controlling 
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Chapter 2:  Research Outline 
2.1 Overall Objective 
Most currently available vaccines require intravenous (i.v.) or subcutaneous (s.c.) 
delivery of antigens. Over the past 20 years, numerous studies have assessed the potential 
of orally delivered antigens on the induction of mucosal and systemic immune responses. 
In addition, mucosal delivery is the only vaccination route to induce effective B cell class 
switching and the development of secretory IgA-producing plasma cells. Moreover, 
mucosal vaccination (delivered via oral or nasal route) has many advantages, including 
no need for sterile needles, a reduced need for trained personnel, and the ability of 
inducing both mucosal and systematic immunity. However, the major challenge of oral 
vaccination is the harsh environment of the gastrointestinal tract and the possibility of 
orally delivered soluble antigens inducing tolerance rather than immunity. Therefore, 
protection of the antigens or utilization of a carrier system is required. Our goal is to 
develop a mucoadhesive, oral delivery platform that could be targeted to the ileum. In 
order to achieve that, we started by developing a multiparticulate drug/protein delivery 
platform. Solid Lipid Nanoparticles, SLNs and Protein Coated Microcrystals, PCMCs 
were manufactured by W/O/W double emulsification solvent evaporation and direct 
precipitation, respectively. Numerous materials (i.e. lipid matrix, surfactants, protein 
carrier, and solvent) and manufacturing parameters were investigated to optimize the 
production of SLNs and PCMCs. The desired size of all these particles was below 5 
micrometer in diameter (for M cell uptake). Drug loading capacity % under varied 
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manufacturing conditions was also evaluated. After the model antigen, bovine serum 
albumin (BSA) was loaded into the SLNs or PCMCs; mucoadhesive polymers are 
incorporated and formulated the mixture into pellets. In order to target the formulated 
pellets to the ileum (where most of the Peyer’s patches located), the pellets are then 
layered with an enteric coating, which is composed of a mixture of Eudragit® FS 
30D/Eudragit® L30D-55. In addition, since an increased residence time of a given 
formulation at the targeted site tends to enhance both absorption and bioavailability of a 
drug, our second goal was to employ mucoadhesive polymers into the developed 
platform. To do so, we must first be able evaluate mucoadhesion property in vitro. 
Therefore, we developed our own in vitro mucoadhesion testing ramp as an evaluation 
tool as one of our objectives. Adhesion properties of matrix tablet and pellets (made of 
potentially mucoadhesive polymers, Methocel® K4M, Carbopol® 934, chitosan, and 
sodium alginate) were investigated using our testing device. The objective for developing 
this in vitro biorelavent mucoadhesion test ramp was to reduce the use of live animals or 
excised animal tissues, which was in concord with the 3R’s (Replacement, Refinement 
and Reduction) of animal welfare.  
Last but not least, since the main thrust of this project was to manufacture a 
mucoadhesive multiparticulate platform, which was of potential as an oral vaccination 
delivery system targeted to the Peyer’s patches at the ileum. We planned to develop a 
suitable animal model using small rodents (i.e. mice and rats). However, the gastric 
emptying cut-off size was unclear in these small rodents. Therefore, we prepared inert 
PMMA particles of varied size range (3 different ranges for ICR mice, and 3 different 
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ranges for SD rats) and labeled them with Tc-99m for scintigraphy studies. The 
scintiscans were monitored and the gastric emptying cut-off, as well as the emptying rate 
of different sized particles could be evaluated. After the gastric emptying cut-off was 
determined, a suitable platform with appropriate particle size could be designed for these 
small rodents in the future. 
2.2 Supporting Objectives 
2.2.1 Manufacturing and evaluating mucoadhesive oral vaccine delivery systems 
composed of solid lipid nanoparticles (SLNs) 
The objective of this study was to prepare a nano-sized antigen carrying system 
composed of solid lipid nanoparticles (SLNs) with bovine serum albumin (BSA) as the 
model antigen. SLNs were design to target to the ileum and uptake at Peyer’s patches. To 
further enhance the contact time of the delivery system at the epithelium (at ileum), 
mucoadhesive polymers, Methocel® K4M and Methocel® E15, were incorporated into the 
platform. The mixture was granulated and spheronized into pellets (1-1.5 mm in 
diameter). The pellets were then enteric coated to prevent from gastric damage. We 
presume these nano-structured particles would be released through diffusion from the 
lipid matric after reaching the ileum and would be taken up by M cells at the Peyer’s 
patches, which will ultimately induce both mucosal and systematic immune response. 
2.2.3 Manufacturing and evaluating mucoadhesive oral vaccine delivery systems 
composed of protein coated microcrystal (PCMC) 
In order to assure robustness and reproducibility of the multiple dose platforms, 
various mucosal immunity is stimulated by administration of antigen directly on the 
mucosal site where an infection occurs. Antigen is processed by mucosa-associated 
lymphoid tissue (MALT) in inductive sites where plasma cell precursors are induced. Gut 
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associated lymphoid tissue (GALT) is one of the major MALT. Peyer’s Patches of GALT 
are responsible for antigen uptake. Peyer’s patches are collections of lymphoid tissue 
containing B and T lymphocytes, as well as macrophages. Antigens are taken up via 
endocytosis by the Microfold cells (M cells) at the Peyer’s patches. Particles less than 5 
µm may be transferred to the draining lymph nodes and spleen to stimulate both a 
mucosal and systemic immune response after uptake by the M cells. Therefore, the aim if 
this study was to prepare two nano- and microstructured antigen carrying system 
composed protein coated microcrystals (PCMC) with bovine serum albumin (BSA) as the 
model antigen. PCMC were design to target to the ileum and uptake at Peyer’s patches. 
To further enhance the contact time of the delivery system at the epithelium (at ileum), 
mucoadhesive polymers, Methocel® K4M and Methocel® E15, were incorporated into the 
platform. The mixture was granulated and spheronized into pellets (1-1.5 mm in 
diameter). The pellets were then enteric coated to prevent from gastric damage. We 
presume these micro-structured particles would be released through erosion after 
reaching the ileum and will be taken up by M cells at the Peyer’s patches, which will 
ultimately induce both mucosal and systematic immune response. 
2.2.3 Development of a novel in vitro mucoadhesion evaluation method 
One of the main potential advantages of mucoadhesive dosage forms is to 
increase retention time and enhance bioavailability. Several feasible methods have been 
developed to evaluate mucoadhesive polymer containing formulations using in vitro 
studies. However, all the methods introduced have required freshly excised tissue or part 
of the gastrointestinal tract from live animals. Laws that mandate replacement 
alternatives, reduction alternatives, and refinement alternatives (the Three Rs) in 
scientific research have been passed in the United Kingdom, Germany, the Netherlands, 
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the United States, and the European Union over the past decade. Therefore, our major 
concern in Specific Aim 1 is to perform an easily controlled, reproducible and 
straightforward in vitro estimation for mucoadhesion study, while avoiding the need to 
sacrifice animals we developed our own method by using an agar/mucin mixture as our 
testing platform for adhesion tests, which is in concord with “Replacement alternatives” 
in the Three Rs for the animal welfare. 
2.2.4 Evaluating the gastric emptying size at the pyloric sphincter in rodent models 
(mice/rats) 
Particle size can significantly alter the gastric emptying time. As the major testing 
animals for biological and pharmaceutical studies, the gastric emptying size at the pyloric 
sphincter (the maximum size or cut-off size of the particles that can pass through the 
gastric) of mice and rats is not validated. Therefore, our goal in Specific Aim 2 is using 
gamma scinitigraphy to evaluate the cut-off size of pyloric sphincter in mice and rats via 
inert, non-swellable and non-digestible polymethyl methacrylate (PMMA) microspheres, 
which can possibly provide accurate information for future oral delivery formulation 
studies in these rodent models. 
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Chapter 3: Development of an Oral Vaccine Delivery Platform using 
Solid Lipid Nanoparticles 
Abstract 
Introduction: Recently, targeted delivery to Peyer's patches has been widely 
investigated as a possible solution for oral vaccination delivery system. The major 
advantage of oral vaccination is that it can generate both mucosal and systemic immune 
response. Moreover, oral vaccination can improve patient compliance, compared to 
traditional vaccination via injections. Methods: Bovine serum albumin (BSA) was used 
as the model antigen for the production of solid lipid nanoparticles (SLNs) via W/O/W 
double emulsification. SLNs particles were controlled at size below 500 nm. SLNs were 
then formulated into pellets using wet-granulation/spheronization techniques. Finally, the 
pellets were coated with enteric coat(s) to protect them from gastric fluid and assure drug 
release occurred at pH above 7.2 (ileum targeting). To further enhance the residence time 
of the formulation at the targeted site, mucoadhesive polymers, Methocel K4M, was 
tailed into the formulation. Results: In the present study, all SLNs were manufactured 
with particle size less than 7 micrometers. To produce SLNs less than 500 nm, Gelucire® 
50/13 was used as the lipid matrix with lecithin as the surfactant. The encapsulation 
efficiency % of BSA was slightly less than 10%, due to the high water solubility of BSA. 
BSA was entrapped in the lipid matrix and sustain released through diffusion. Only about 
60% of BSA release in 2 hours in pH 7.2 phosphate buffer. The BSA/SLNs was 
successfully tailed into 1-2 mm pellets by wet-granulation/spheronization. After coated 
with a double-layered enteric coating using a mixture of Eudragit® L 30 D-55 and 
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Eudragit® F S 30 D, no BSA released at gastric condition for at least 2 hours, followed by 
about 60% of BSA released in 2 hours after pH was adjusted to 7.2 from 1.2, which 
confirmed that the formation was proper for ileum targeted delivery. Finally, 
mucoadhesive polymer, Methocel® K4M (5%, w/w) was incorporated into the pellets to 
enhance the residence time of the pellets after they reach ileum. Conclusions: SLNs could 
be a suitable platform for oral vaccination delivery system, for that the particle size of 
SLNs could be controlled below 500 nm. With proper enteric coating, BSA/SLNs loaded 
pellets could be manufactured for ileum targeted delivery. 
3.1 Introduction 
Globally, vaccination is estimated to save approximately 3 million lives every year 
unfortunately; however, 3 million lives are still lost to vaccine-preventable diseases. One 
contributing factor to that lack of vaccine availability is due to their inherent thermal 
instability, which results in the wastage of half of all supplied vaccines worldwide [1]. 
Vaccine wastage is especially acute in developing countries; however, improper storage 
has also been reported in temperate countries and in the developed world [2, 3]. 
Most pathogenic microorganisms infect via mucosal surfaces [4]. In order to 
protect against such pathogens, induction of the mucosal immune response is required as 
the critical first-line defense mechanism [4]. An antigen itself, when orally administered, 
cannot maintain its integrity through the acidic gastric contents, and subsequently can’t 
be taken up by a suitable lumen enterocyte [5]. However, when the antigens are loaded 
into specific carriers (e.g. biodegradable polymers, such as PLG and PLGA), it has been 
demonstrated that these antigens can be uptake and transported over the barrier by M-
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cells in Peyer’s patches [6, 7]. Uptake by these cells is ideally suited to particles sized 
less than 5μm in diameter [8]. Peyer’s patches are a collection of organized lymphoid 
tissues lining the intestinal tract, which are the most important units of gut-associated 
lymphoid tissues (GALT). Peyer’s patches are the primary induction sites for mucosal 
immunity, which regulates IgA immunity against antigens that enter via the oral route 
[9]. 
Although most of the currently available vaccines are administered via injection, 
there are several drawbacks, which including patience compliance, higher cost, and the 
necessary requirement of low temperature during storage and transportation [10, 11]. 
Importantly, it has been reported that most of the antibodies induced following the 
parenteral administration of vaccines cannot reach mucosal surfaces where pathogenic 
infections take place [12]. Therefore, oral vaccination is considered an attractive 
alternative to the standard route of administration and it has generated much research 
interest [13, 14]. Oral vaccination is potentially a patient compliant and efficient way of 
inducing both mucosal and systemic immunity. In addition, a local effect of secretory 
IgA (sIgA) that are induced at the mucosal sites can further prevent attachment of 
bacteria and viruses to mucosa, and neutralize viruses and toxins than can damage the 
host cells [15]. 
Microencapsulation and nano-encapsulation techniques can involve coating and 
isolating bioactive substances in envelopes of protective materials until such time as their 
activity is needed (after reaching the specific site, e.g. ileum, or colon [16, 17]). These 
particulates carrier systems include polymeric hydrogels [18], nanoparticles/microspheres 
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[19-21], and lipid-based drug delivery systems (e.g. fat emulsions [22], liposomes [23, 
24], and solid lipid nanoparticles (SLN) [25]. Unlike most polymeric microsphere and 
nanoparticle systems, SLN production techniques do not require potentially toxic organic 
solvents, which generally, have deleterious effect on protein or peptides (e.g. deformation 
of the protein structure, degradation of the protein). Both hydrophilic and lipophilic drugs 
can be loaded into SLNs. The lipid matrix of SLNs not only protects the loaded labile 
ingredients, but also can modulate drug release [26]. In addition, the lipophilic nature of 
the lipid carrier itself may exhibit certain absorption promoting effects [27, 28]. 
In order to enhance the oral bioavailability of poor-soluble drugs and/or protein 
(peptides), a prolonged residence time is required [29]. Mucoadhesive materials are able 
to adhere onto the mucus membrane at the gastrointestinal tract, which contributes to an 
increased absorption, due to the prolonged residence time [30, 31]. Therefore, a nano- or 
microstructured, mucoadhesive multiparticulate drug delivery system could consequently 
lead to higher efficiency. In this research we describe the development of multiparticulate 
oral vaccine delivery systems consisting of suitable mucoadhesive polymers with a 
layered enteric coating that is intended to be suitable for ileum-targeted delivery. 
3.2 Materials and methods 
3.2.1 Materials 
Bovine serum albumin and soybean lecithin was purchased from Spectrum 
Chemicals Ltd. (Gardena, CA, USA). Ethyl acetate, methylene chloride, isopropyl 
acetate, and propyl acetate were obtained from Fisher Scientific International (Hampton, 
NH, USA). Gelucire® 44/14, Gelucire® 50/13, Compritol® 888 ATO, and Precirol® ATO 
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5 were kindly provided by Gattefosse Corporation (Paramus, NJ, USA). Pluronic® F68 
and Pluronic® F127 was kindly provided by BASF Corporation (Florham Park, NJ, 
USA). Eudragit® FS 30 D, Eudragit® S-100, and Eudragit® L 30 D-55 were kindly 
donated from Evonik Degussa Corporation (Parsippany, NJ, USA). Avicel® PH101 was 
kindly donated by FMC Corporation (Philadelphia, Pennsylvania, USA). A Bradford 
protein assay kit was purchased from Bio-Rad Laboratories (Hercules, CA, USA). All the 
chemicals and solvents used were of analytical grade. 
3.2.2 Methods 
3.2.2.1 Selection of solid lipids 
     Due to the hydrophilic nature of BSA, W/O/W double emulsification was 
selected to prepare solid lipid particles in the study. A number of preliminary experiments 
are conducted in order to select the most appropriate conditions for nanoparticle 
formation. Physicochemical data of the selected solvent is listed in Table 3.1.  
Table 3.1: Physicochemical and toxicity properties of solvents used in W/O/W 
preparation 
Solvent bp (°C) Water solubility (20°C) DL 50 (rat, mg/kg 
Ethyl acetate 76 150.4 5620 
Methylene chloride 40 13.4 1600 
Isopropyl acetate 88 30.9 6750 
Propyl acetate 101 18.9 9370 
Solubility of the employed lipids in different solvents will be investigated. Briefly, 
0.1 ml of milli-Q water (inner aqueous phase) are added to a 1 mL solvent containing 100 
mg of lipid and surfactant (oil phase). This mixture was dispersed with an ultrasonic 
probe to form a W/O emulsion. A double emulsion W/O/W is formed after addition of 
different volumes of the outer aqueous phase to the previous W/O emulsion followed by 
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another sonication cycle. This double emulsion was then diluted to 10 mL. The solvent 
was then evaporated with continuous stirring. The influence of variables, including the 
volume of the outer aqueous phase, types of surfactant, and surfactant concentration on 
the particle size distribution of nanoparticle suspensions was evaluated. After 
determination of the optimal manufacturing conditions, the physicochemical properties of 
nanoparticles were then characterized (Section 3.2.2.3). 
3.2.2.2 Preparation of BSA loaded solid lipid nanoparticles 
BSA-loaded SLNs were prepared by W/O/W double emulsion–solvent evaporation 
technique as previously described (Section 2.2.1). The composition and manufacturing 
conditions of SLNs were listed in Table 3.2. Briefly, 25 mg BSA was dissolved in 1 mL 
milli-Q water. The protein solution was emulsified in 5 mL solvent containing 500 mg 
dissolved lipid with an emulsifier (soy bean lecithin) using probe sonication over an ice 
bath. The resulting emulsion was further emulsified into an additional surfactant solution 
comprised of 2% Pluronic® F68, followed by further sonication using the condition 
previously described for the formation of a W/O/W double emulsion. The organic solvent 
in the double emulsion was eliminated by evaporation with continuous stirring for 3–5 
hours. The nanoparticles were collected by centrifugation at 12,000 rpm for 30 minutes at 
4  C, and washed three times with distilled water. The SLNs were suspended in 5 mL 
distilled water and lyophilized for 24 hours. The control nanoparticles were prepared in 






Table 3.2: The composition and manufacturing condition and labeling of SLNs. 
 
3.2.2.3 Physicochemical characteristics of SLNs 
3.2.2.3.1 Particle size distribution 
The size of the nanoparticles, (as well as the particle size distribution of each 
formulation) was measured using a Zetasizer Nano ZS by photon correlation 
spectroscopy (PCS) ((Malvern Instruments Ltd, Worcestershire, UK). 
3.2.2.3.2 Zeta potential 
SLNs were re-suspended in milli-Q water. Zeta potential of the nanoparticles was 
investigated using a Zetasizer Nano ZS by Laser Doppler Anemometry (Malvern 
Instruments Ltd, Worcestershire, UK). 
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3.2.2.4 BSA loading capacity of SLNs 
The content of BSA in nanoparticles was determined indirectly by measuring the 
protein that was not encapsulated. The concentration of protein in the aqueous phase was 
determined by Bradford Assay. The encapsulation efficiency was calculated by formula 
(1): 
                 (1) 
3.2.2.5 In vitro release of antigen loaded SLNs 
Loaded SLNs were isolated from non-encapsulated BSA by ultracentrifugation 
(85,000 rpm) and re-suspension in PBS. Particles were incubated for 24 hour at 37 C. At 
time intervals of 1, 2, 4, and 24 hours, a sample aliquot was collected and 
ultracentrifugated for 1 hour at 85,000 rpm. BSA content in the supernatant was 
determined by Bradford Assay. 
3.2.2.6 Pellets manufacturing 
Optimization of the pellet formulations was done using an easily detectable marker 
drug, theophylline via extrusion/spheronization technique [32]. Detailed pellet 
compositions were listed in Table 3.3. Briefly, SLNs were re-suspended with milli-Q 
water. SLN suspensions were pre-blended with MCC (Avicel® PH 101), and lactose 
(Total weight of mixture: 250 mg) for 5 minutes as the filler. A mucoadhesive polymer 
solution (Methocel® K4M and Methocel® E15) was added into the mixture and 
granulated for another 5 minutes. The mixture was then transferred into a Luwa Benchtop 
Granulator (LCI Corporation, Charlotte, NC, USA) and extruded into granules. The 
resultant granules were then transferred into a Caleva, Model 250 bench-top spheronizer 
(Caleva Process Solutions Ltd., Sturminster Newton UK) and spheronized into pellets. 
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The pellets were dried in oven overnight at 40℃and stored in a desiccator at room 
temperature prior to further testing. Pellets in the size range of 1.0-1.5 mm were used in 
subsequent studies.  
Table 3.3: Composition of pellets 
*For BSA (PCMC) loaded pellets, the compositions of pellet 1-4 are exactly the same, 
except that the API was replaced by BSA/PCMC 
 
3.2.2.7 Enteric coating of pellets 
After manufacturing, the pellets were further coated with an enteric coat (a mixture 
of Eudragit® FS 30 D/Eudragit® L 30 D-55 to affect the release profile) using fluid-bed 
coating method [32]. The composition the three different enteric coating solution 









Table 3.4: Composition of enteric coating solutions 
 
*: w/w % ratio related to polymer content.  
**: w/w % ratio related to polymer content. 
Briefly, the pellets were put in the coating chamber of Strea-1 (Aeromatic-Fielder, 
Bubendorf, Switzerland) fluidized-bed coater (bottom set-up and a Wurster column). The 
operating conditions were set as follows: atomized air pressure; 2 bar; outlet air 
temperature: 30℃. The coating dispersion was stirred continuously during spraying. 
After coating, the pellets were dried in the bed at the same temperature for 10 minutes 
and then put in an oven at 40℃ for 2 hours. The target weight gains after coating were 
5%, 10%, and 20% (w/w). After the coating conditions were optimized using 
theophylline-based pellets, BSA loaded SLNs suspension was introduced into the final 
pellet formulations to replace theophylline as the API. Briefly, BSA loaded SLNs were 
re-suspended in milli-Q water and used as the binder solution in the wet-
granulation/pelletization process as previously described. After manufacturing, 
BCA/PCMC containing pellets were enteric coated in the exactly same manner as we 
coated the theophylline pellets. 
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3.2.2.8 In vitro release of BSA loaded pellets 
BSA release from coated pellets was determined using a USP Ⅱ dissolution 
apparatus [33]. Pellets were added to 900 mL 0.1N HCl (pH 1.2) at 37 °C. The paddle 
speed was set at 100 rpm. At each time point (10, 30, 60, 90, and 120 min), a 5 mL 
sample was taken and the same volume of simulated gastric fluid was replaced. After 2 
hours, the dissolution medium was replaced with 900 mL phosphate buffers (pH 7.2). 
Additional samples were taken at 3, 4, and 5 hours. Samples were analyzed by Bradford 
assay according to Bradford [34]. Dissolution tests were repeated six times for all 
formulations and the release profile of BSA was evaluated. 
3.2.3 Statistics 
All results were shown as mean ± standard deviation (N=6). Analysis of variance 
(ANOVA), Turkey's HSD or Wilcoxon test is used to evaluate the results via JMP 7.0 
software (JMP, Cary, NC, USA). p <0.05 was considered to be a significant difference. 
3.3. Results and discussion 
3.3.1. Physicochemical characteristics of SLNs 
After manufacturing, particle size of each formulation of the SLNs was measured 
by photon correlation spectroscopy (PCS) using Malvern Zetasizer Nano ZS. Particle size 
(Z-average), polydispersity index (PSD), and zeta-potential were obtained and listed in 
Table 3.5. In order to obtain a SLN formulations with a smaller particle size (less than 
500 nm) and narrower particle size distribution, several different factors were controlled 
over the manufacturing process, including the type of lipid matrix (Gelucire® 44/14, 
Gelucire® 50/13, Compritol® 888 ATO, and Precirol® ATO 5), amount of surfactant 
(lecithin), sonication power, as well as duration of sonication. From the results, only 
Gelucire® 50/13 was suitable under our SLNs manufacturing protocol. Gelucire® 44/14 
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emulsified and solidified rapidly once in contact with the ice bath during the sonication 
process; therefore, was not able to generate SLNs in this case. On the other hand, 
Compritol® 888 ATO, and Precirol® ATO 5) dissolved well in the solvent, DCM, as 
Gelucire® 50/13 (Z-average, less than 200 nm), however, the particles created by these 
two lipid matrix were significantly larger than Gelucire® 50/13 based SLNs (p<0.05, Z-
average of Compritol® 888 ATO, Precirol® ATO 5, and Gelucire® 50/13 based SLNs was 
around 3000, 6000, and 190 nm, respectively) (Table 3.5). Therefore, Gelucire® 50/13 
was chosen as the final lipid matrix for SLN preparation in the subsequent studies.  
Table 3.5: Particle size, PSD, zeta-potential, and encapsulation efficiency % of 
manufactured SLNs. * N=6, Mean value ± Stdev 
 
 
In addition, we speculated that the intensity (power) and duration (time) of the 
sonication process would affect the formation of SLNs and alter the size and 
encapsulation efficiency % of SLN products. Under a lower sonication intensity of 20 
watt (Z-average, approx. 270 nm), SLNs were significantly larger (p<0.05), compared 
those prepared at a power of 50 watt (Z-average, approx. 185 nm). However, when the 
power was further increased to 80 watt, the particle size was not further reduced (Z-
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average, approx. 270 nm). This might due to the instability of SLNs during the 
emulsification process for that the force applied was too strong. Therefore, we set the 
sonication intensity at 50 watt and the duration of sonication at 30 seconds using ice to 
prevent damage or degradation of the BSA. While both particle size and PSD were 
altered by the intensity of sonication process, zeta-potential was only affected by the type 
and the amount of lipid matrix that was incorporated into the formulations. With the same 
amount of lipid matrix used, SLNs composed of Gelucire® 50/13 showed significantly 
lower zeta-potential (p<0.05), compared to Compritol® 888 ATO and Precirol® ATO 5 
containing SLNs. However, this was because that the particles generated by both 
Compritol® 888 ATO and Precirol® ATO 5 were significantly larger than particles 
generated by Gelucire® 50/13, therefore, more lipid matrix was presented in the 
formulation, which resulted in a higher negative charge on the surface of SLNs. Due to 
the high solubility of BSA, the encapsulation efficiency % after SLN manufacturing via 
W/O/W double emulsification was low. The majority of BSA remains in the aqueous 
phase during the sonication process, or is partitioned back into the aqueous phase during 
the solvent-evaporation process. Both of these factors can contribute to the poor 
encapsulation efficiency. Under our preparation method, the encapsulation efficiency % 
was affected largely by the size of SLNs, rather than the type lipid matrix, or sonication 
intensity. Encapsulation efficiency increased with increasing particle size, since more 
BSA was entrapped in the SLNs. However, one primary goal was to manufacture SLNs 
with particle size between less than 500 nm and with lower particle size distribution. 
Based on the results we found, the final optimized SLNs formulation was composed of 
Gelucire® 50/13 as the lipid matrix. The ratio of Gelucire® 50/13 : Lecithin : BSA was 
controlled at 20 : 1 : 1, while the sonication process was controlled at 50 watt for duration 
of 30 seconds on an ice bath. 
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3.3.2 In vitro release of antigen loaded SLNs 
After manufacturing, BSA loaded SLNs (Gelucire® 50/13) were weighed and 
placed in 20 mL vials for a modified dissolution test, in pH 7.2 phosphate buffer as 
previously described (Section 2.2.5). The BSA release profile (accumulated release %) 
was shown in Figure 3.1. Almost 50% of BSA released in the first hour of dissolution, 
while about 75% of BSA released in 2 hours. Approximately 15% of BSA was still 
entrapped in the lipid matrix up to at least 12 hours. BSA showed complete release in 48 
hours. 
Figure 3.1: Dissolution of BSA loaded SLNs with Gelucire® 50/13 as lipid matric in pH 
7.2 phosphate buffer. * N=6, Mean value ± Stdev 
 
3.3.3 Pellets production 
Granulation/pelletization is widely used in oral drug delivery systems [35, 36]. 
Compared to dry-granulation direct compression (tablets), wet-granulation is more cost-
effective, since it can be processed using much less expensive equipment. In addition, 
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wet-granulation improves free-flowing properties, homogeneity of the powder 
ingredients, provides better compressibility, and reduces dust during the processing. In a 
wet-granulation process, the pharmaceutical active ingredient can be either a dry 
substance or, be dissolved in a medium as a binder solution, which increases the 
possibility of optimizing a formulation based on the physicochemical property of its API, 
compared to direct compression. After wet-granulation, the granules can be further 
processed for direct compression, or extruded before pelletization. In general, pellets 
offer the well-known benefits of more uniform release and reproducibility of the 
formulation. This is due to the in vivo dispersion of a multiparticulate system, and the 
gastrointestinal transit in human body. While the gastric emptying transit time of a single 
solid tablet might range from 30 minutes to a couple hours, the dispersion of a 
multiparticulate system starts from the gastric and provide a more reproducible overall 
transit time. Furthermore, wet-granulation/pelletization can be easily scaled-up for 
industrial manufacturing.     In order to produce a more easily handled formation, as 
well as reducing possible damage during the manufacturing process to the acid labile 
BSA, Eudragit® S-100 coated PCMC was formulated into the pellets using wet-
granulation/pelletization techniques. Eudragit® S-100 coated PCMCs were re-suspended 
in IPA and used as a binder during the wet-granulation process. MCC (Avicel® PH 101) 
was used as the filler since it has a well-known advantage of forming an easy moist 
granulated mass, and generating strong granules on drying.. Since the objective of the 
study was to design an oral vaccination delivery platform using a multiparticulate system, 
BSA loaded SLNs were required to release promptly after reaching ileum. To achieve 
more rapid release Kollidon® CL was added during the wet-granulation/pelletization 
process to act as a as superdisintegrant. Furthermore, in order to control the release time 
of BSA loaded SLNs, and synchronize this to the regional position of the GI tract, three 
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different enteric coating mixtures were evaluated using the easily detectable drug 
theophylline.  
3.3.4 Enteric coating of pellets 
The GI tract is a very hostile environment, with regions of lower and higher pH, 
high enzymatic activity, and lipid solubilizing ability. For ileum targeted drug delivery, it 
is necessary to traverse an extended section of the lumen whilst not experiencing lost 
efficacy. A pH solubility dependent coating is effective and well described in the 
literature [37, 38]. These drug delivery systems utilize polymeric carriers that are 
insoluble in the low pH media of the upper gastrointestinal tract, but dissolve at a higher, 
near neutral pH of the distal gut. Such polymers will begin to dissolve in the ileum and as 
such are more appropriately defined as the materials for ileum targeting. The pH-
dependent approach for ileum drug delivery is based on the pH differences along the 
gastrointestinal tract with values increasing from about 1 to 2.5 in the stomach through 
6.6 in the proximal small bowel to a peak of about 7.5 in the terminal ileum [39]. The 
mean gastric residence time is considered to be 0.25–2 hours and small intestinal 
residence time between 3 and 4 hours [40]. These conditions are valid for single solid 
dosage forms and for fasting state of patients. One of the major concerns for this study 
was to make protein antigens (BSA) release rapidly after the delivery system reached 
ileum. Therefore, Kollidon® CL was included into the pellets to act as a superdisintegrant. 
Without superdisintegrant, less than 10% of drug was released at 30 minutes; and only 
about 45% of the drug was released in 1 hour at pH 7.2 (pellet 1, Figure 3.2). With 10% 
w/w Kollidon® CL, more than 95% of the drug was released at 30 minutes; and the drug 
release was completely in less than one hour in pH 7.2 (pellet 2, Figure 3.2). This is 
potentially appropriate for an ileum targeted oral vaccination delivery system, since once 
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the pellets reached ileum, all antigens could be released promptly once triggered, rather 
than passing the targeted site to release in the large bowel. We assumed that with the 
mucoadhesive polymers, the pellets would adhere onto the targeted site after wetted, 
which would prevent the pellets from emptying out ileum before drug release [41, 42]. 
Therefore, mucoadhesive polymer, Methocel® E15 or K4M was included into the fast-
disintegrating pellets. However, from the results, with 10% Methocel® E15, only less than 
25% of the drug was released in 30 minutes at pH 7.2 (pellet 3, Figure 3.2), while nearly 
60% of the drug was released in 30 minutes, when 5% Methocel® K4M was used (pellet 4, 
Figure 3.2). The release rate of drug was hindered, because of the gel formation of 
HPMC, which formed a matrix system and controlled the drug release through a 
combination of diffusion/erosion [43]. 
Figure 3.2: Dissolution of enteric coated pellets (API: theophylline): Non-coated pellets. 
* N=6, Mean value ± Stdev 
 
In order to protect the pellets from the stomach, the pellets were adequately 
coated with suitable enteric coat(s). The focus was to control drug to release at pH > 7.2 
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(in accordance with the physiological conditions found in the ileum). Eudragit® L and S 
polymers enable targeting specific areas of the intestine. Eudragit® L 30 D-55 dissolves at 
pH above 5.5, which is advantageous for drug delivery at the upper intestine [44]; while 
Eudragit® FS 30D polymer dissolves at pH above 7.0 and is suitable for drug delivery to 
colon area [45]. The objective was to both prevent drug being released/damaged at gastric 
pH and prevent drug release along the proximal intestine, followed by a rapid release at 
ileum. To achieve this, three enteric coating layers were combined in the final 
formulation. In coating solution 1, a single layer of a mixture of Eudragit® L 30 D-55 and 
Eudragit® F S 30D (w/w ratio: 2:3) was coated onto the pellets. No drug was found to 
release for up to 2 hours at pH 1.2, regardless of the amount (weight-gained, % w/w) of 
enteric coating applied. When applying only 5 % w/w (weight-gained) Eudragit® L 30 D-
55 coating to the pellets (including 10% w/w superdisintegrant, Kollidon® CL), more than 
90% of the drug released in just one hour after adjusting the pH from 1.2 to 7.2. 
Nonetheless, after the enteric coating applied increased to 10% w/w (weight-gained), 
approximately 20% of the drug released at 2 hours, and 90% at 3 hours after adjusting the 
pH from 1.2 to 7.2 (Figure 3.3). However, without the superdisintegrant, Kollidon® CL, 
no drug released for up to 2 hours after adjusting the pH from 1.2 to 7.2, while nearly 








Figure 3.3: Dissolution of enteric coated pellets (API: theophylline), Coating solution 1.  
* N=6, Mean value ± Stdev 
 
In this study, the second type of enteric coating was comprised of a double-layer 
enteric coat. The inner coat was composed of Eudragit® L 30 D-55 (neutralized with a pH 
of 5.6 in the enteric coating suspension). Neutralizing the inner coat would help the rapid 
release of coated drug, since part of the Eudragit® L 30 D-55 was dissolved during the 
preparation process of the coating solution. The outer coat was composed of Eudragit® F 
S 30D as with enteric coating solution 1. With 10% (w/w of the total weight of a pellet) 
superdisintegrant (Kollidon® CL), nearly 90% of the drug released in less than one hour 
after the pH was adjusted from 1.2 to 7.2, regardless of the coating level (Figure 3.4). 
Without Kollidon® CL, about 5% (w/w of the total weight of a pellet) of the drug released 
with either 5% or 10% (weight-gained, w/w) of the outer coat applied (with 5% w/w 
weight-gained inner coat) in 2 hours at pH 1.2, which showed non-successful enteric 
coating under gastric condition. 
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Figure 3.4: Dissolution of enteric coated pellets (API: theophylline): Coating solution 2.  
* N=6, Mean value ± Stdev 
 
     Without Kollidon® CL, about 5% (w/w of the total weight of a pellet) of the drug 
released with either 5% or 10% (weight-gained, w/w) of the outer coat applied (with 5% 
w/w weight-gained inner coat) in 2 hours at pH 1.2, which showed non-successful enteric 
coating under gastric condition. When the outer coat was increased to 20%, no drug 
released under gastric condition for up to 2 hours, however, more than 90% of the drug 
released in less than 2 hours after the pH was adjusted from 1.2 to 7.2 (Figure 3.5), which 
could not be considered as suitable for ileum targeting, as most of the drug would be 
likely to be released prior to reaching the ileum. The results demonstrated that the pre-
neutralization showed a more rapid release of the drug, once the outer enteric coating 




Figure 3.5: Dissolution of enteric coated pellets (API: theophylline, without disintegrant), 
Coating solution 2. * N=6, Mean value ± Stdev 
 
     Finally, a third enteric coating solution composed of a modified (from the second 
type of enteric coating solution) outer layer was prepared. The outer coat was replaced 
with a mixture of 1:4 w/w ratio of Eudragit® L 30 D-55 and Eudragit® F S 30D, compared 
to enteric coating solution 2. With 10% (w/w of the total weight of a pellet) 
superdisintegrant (Kollidon® CL) and 10% (w/w, weight-gained) outer enteric coating 
(5% w/w, weight-gained inner coat), no drug released for up to 2 hours at pH 1.2 (Figure 
3.6). However, more than 50% of the drug released in one hour after the pH was adjusted 
from 1.2 to 7.2. Nevertheless, after the outer coat was increased to 20% (w/w, weight-
gained), the drug was prevented from releasing for one hour after the pH was adjusted 
from 1.2 to 7.2, followed by about 90% of the drug release in the subsequent hour. This 
indicates a suitable profile for a potential ileum targeted formulation, since the drug was 
well-protected against gastric conditions, and could be further protected for about another 
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hour at pH above 7 (paralleling the transit time from duodenum to the ileum), followed 
by prompt release of the drug in less than an hour (Figure 3.6). 
Figure 3.6: Dissolution of enteric coated pellets (API: theophylline), Coating solution 3. * 
N=6, Mean value ± Stdev 
 
3.3.5 In vitro release of BSA/SLNs loaded pellets 
When loaded with BSA the results from pellets coated with enteric coating solution 
1 and 2 were similar as what we found before when theophylline was used as a marker 
drug. Pellets coated with enteric coating solution 1 were able to prevent BSA release for 
more than 2 hours after the dissolution medium was converted to pH 7.2 from pH 1.2 at a 
coating level of 20% w/w, however, this transit time was too long, and would possible 
resulted in drug release in the colon area. Additionally, pellets coated with enteric coating 
solution 2 also not fitting to the targeting goal, since almost all BSA released in less than 
one hour after the dissolution medium was converted to pH 7.2 from pH 1.2, regardless 
of the weight-gain added with the enteric coating. These results were again in accordance 
with what we found in our previous theophylline loaded pellets. BSA/SLNs loaded 
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pellets (with 5% Methocel® K4M) coated with a double-layer enteric coating (enteric 
coating 3, 5% w/w weight-gained inner coat and 20% w/w weight-gained outer coat) 
were suitable for ileum targeted delivery, since no BSA release was found at low pH for 
at least 2 hours. After the pH was adjusted from 1.2 to 7.2, less than 5% of BSA released 
after at 3 hours, but a prompt release of BSA occurred in the subsequent hour (up to 60% 
of BSA released) (Figure 3.7). This was in concordance with gastrointestinal transit from 
stomach to ileum at fasted state as previously described. 
Figure 3.7: Dissolution of enteric coated pellets (loaded with BSA/SLNs): (A) Non-
coated pellets; (B) Coating solution 3, 5% inner coat and 10% outer coat; 
(C) Coating solution 3, 5% inner coat and 20% outer coat. * N=6, Mean 
value ± Stdev 
 
3.4. Conclusions 
     Nano-particulates platforms can be appropriate for oral protein/peptide drug 
delivery. However, the acid labile pharmaceutical active ingredients must be well-
protected to avoid deactivation/damage in the gastric. In this study, BSA was successfully 
loaded into SLNs with Gelucire 50/13 as the lipid matrix using a double emulsification 
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method. The manufacturing process was optimized by screening various parameters (i.e. 
type of lipid matrix, type of surfactant, sonication speed, and sonication power). In 
summary, the particle size of SLNs manufactured was proper for oral vaccination 
delivery systems. The manufactured BSA loaded SLNs were then successfully 
incorporated into pellets as a potential platform for oral delivery. Furthermore, our study 
provided proof that with a suitable  (a double-layered enteric coating (Eudragit® L 30 D-
55 and Eudragit® F S 30D) enteric coating, the release of BSA/SLNs loaded pellets could 
be well-controlled across the pH range and time that is appropriate for targeted delivery 
to ileum. In addition, the pH sensitive, well-targeted system we developed could act as a 
potential platform for a variety of payloads related to protein/peptide or even antigen 
delivery to the ileum in the future. Nonetheless, further improvement on the enteric 
coating property is required to help stabilize the platform for long-term storage processes. 
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Chapter 4: Development of A pH Sensitive Targeted Oral Release 
Platform Containing Protein Coated Microcrystals (PCMC) 
Abstract 
Introduction: Recently, targeted delivery to Peyer's patches has been widely 
investigated for oral vaccination delivery system. The major advantage of oral 
vaccination over injection is that it can generate both mucosal and systemic immune 
response. In this study, we were focusing on developing a pH sensitive targeted oral 
release platform containing protein coated microcrystals (PCMC), which could be an 
advantageous platform for future oral vaccination delivery systems. Methods: BSA was 
used as the model protein and co-precipitated with a protein carrier, DL-valine as protein 
coated microcrystals (PCMC). PCMC particles were controlled at size between 2-5 µm 
and coated with enteric coating (Eudragit® S-100). The enteric coated PCMC were then 
formulated into pellets (wet-granulation/spheronization). Finally, the pellets were coated 
by another layer of enteric coat (Eudragit® L 30 D-55 and/or Eudragit® F S 30D) for ileum 
targeted delivery). To further enhance the residence time of the formulation at the 
targeted site, mucoadhesive polymers, Methocel® K4M, was incorporated into the 
formulation. Results: PCMC of particle size: 2-10 µm and 95-98% BSA loading: were 
manufactured. The enteric coated pellets were well protected against gastric fluid (pH 
1.2) for at least 2 hours, and started dissolving/disintegrating after 1 hour after adjusting 
the pH from 1.2 to 7.2, which made the pellets suitable for ileum targeting delivery. 
Conclusion: Enteric coated pellets with BSA loaded PCMC could be a possible candidate 
for oral vaccination delivery system, however, further coating condition or protecting 
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method must be conducted to enhance the stability and prolong the storage period of 
formulation. 
4.1 Introduction 
     Vaccine immunization is considered one of the most successful public health 
achievements of the 20th century and has prevented thousands of deaths and illnesses [1]. 
According to WHO report in 2006, about three-quarters of the world’s children received 
a standard package of childhood vaccines through the WHO/UNICEF Expanded Program 
on Immunization. These vaccines protected children against diphtheria, tetanus, pertussis, 
polio, measles and neonatal tuberculosis. The vaccination was estimated to save 
approximately 3 million lives every year in the world [2]. However, another 3 million 
lives are still lost to vaccine-preventable diseases, mainly due to the thermal instability of 
vaccines, which leads to the wastage of half of all supplied vaccines worldwide. Since 
most currently available vaccines require intravenous (i.v.) or subcutaneous (s.c.) delivery 
of antigens, storage of these vaccines at low temperature (i.e. at 4 °C or below) is 
required. Therefore, depletion is especially acute in the developing countries, but 
improper storage has also been reported in temperate countries and in the developed 
world [3, 4]. Over the past 20 years, numerous studies have assessed the potential of 
orally delivered antigens on the induction of mucosal and systemic immune responses [5, 
6]. In addition, mucosal delivery is the only vaccination route to induce effective B cell 
class switching and the development of secretory IgA-producing plasma cells [7]. 
Moreover, mucosal vaccination (delivered via oral or nasal route) has many advantages, 
including no need for sterile needles [8], a reduced need for trained personnel [9], and the 
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ability of inducing both mucosal and systematic immunity [10]. However, the major 
challenge of oral vaccination is the harsh environment of the gastrointestinal tract (GI 
tract) [11] and the possibility of orally delivered soluble antigens inducing tolerance 
rather than immunity [12]. Therefore, protection of the antigens or utilization of a carrier 
system is required.   
     Most pathogenic microorganisms actually invade through mucosal surface when 
infecting a subject. In order to protect against such pathogens, induction of the mucosal 
immune response is required as the critical first-line defense mechanism [13]. An antigen 
itself, when orally administered, cannot survive through the acidic gastric condition [14] 
However, when the antigens are bounded to (or loaded into) particular carriers (e.g. 
biodegradable polymers, such as PLG and PLGA [15, 16]) it is found and proven that the 
antigens can be uptake and transported over the barrier by M-cells in Peyer’s patches 
(typically, for particles sized less than 5μm in diameter) [17]. Peyer’s patches are a 
collection of organized lymphoid tissues lining the intestinal tract, which are the most 
important units of gut-associated lymphoid tissues (GALT). Peyer’s patches are the 
primary induction sites for mucosal immunity, which regulates IgA immunity against 
orally entered antigens [18].  
     Although most of the currently available vaccines are administered via the 
parenteral route, this is associated with several important drawbacks. These drawbacks 
including: patience compliance [19], higher cost [20], and requirement of low 
temperature during storage and transportation [21, 22]. In addition, most of the antibodies 
induced following the used of a parenteral route cannot reach mucosal surfaces where 
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pathogenic infection takes place [23]. As an alternative, oral vaccination can be a simple 
and efficient way of inducing both mucosal and systemic immunity [24, 25]. In addition, 
secretory IgA (sIgA) induced at the mucosal sites can further prevent attachment of 
bacteria and viruses to mucosa, and neutralize viruses and toxins that can damage the 
host cells [26]. 
     Other than encapsulation techniques, many other particle-engineering processes 
have been developed to manufacture micro- or nano-sized particles of poorly soluble 
drugs, such as spray drying [27, 28], spray-freeze drying [29, 30], spray-freeze-into-
liquid [31, 32], precipitation with supercritical fluid [33], ultra-rapid-freezing [34, 35], 
and controlled precipitation [36, 37]. Size reduction enhances the solubility and 
bioavailability of the active ingredients, which can contribute to a less fluctuating PK 
profile [38, 39]. In addition, micro- or nano-structured particles tend to have higher 
stability and have less storage issues [40, 41]. Multiparticulate drug delivery systems are 
generally considered to have several advantages compared to a single unit dosage form, 
including a more predictable gastric transit and a more uniform drug distribution, both 
contributing to less variance of inter- or intra-individual bioavailability [42]. A 
combination of nanostructured and multiparticulate drug delivery results in an enhanced 
dissolution and higher saturation solubility, in comparison to micronized drugs [43]. In 
addition, nanostructured particles tend to have higher affinity to the inflammatory sites 
along the gastrointestinal tract [44]. Recently, XstalBio (XstalBio Limited, GLASGOW, 
U.K.) developed a novel Protein-coated microcrystals particle engineering approach for 
the formulation of proteins, peptides, DNA/RNA and vaccines [45]. Protein-coated 
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microcrystals (PCMC) are water-soluble micron-sized particles, which are comprised of a 
core crystalline material (e.g. amino acid, sugar or salt) on which is coated the therapeutic 
biomolecule [46]. The advantage of PCMC is that they can be prepared by using a one 
step process that simultaneously dehydrates these two components and results in the 
immobilization of the protein on the surface of the carrier, which helps prevent protein 
degradation during the manufacturing process [47, 48]. The preparation of PCMC 
involves dissolution of the appropriate crystal-forming carrier together with the given 
biomolecule in aqueous solution. Rapid dehydration of the two components is facilitated 
by the addition of the aqueous solution to a water-miscible organic solvent (anti-solvent), 
resulting in the immediate formation of the PCMC with the biomolecule immobilized on 
the surface of the crystalline core carrier (via a crystal-lattice mediated self-assembly 
process). By adjusting the dehydration conditions, particle morphology, protein payload 
and particle size can be controlled [49]. Potentially a vaccine made of PCMC is of better 
thermostability, since Parker and co-workers validated that protein-coated micro-crystals 
(PCMC) are able to improve the thermostability of a model vaccine (adenylate cyclase 
toxin, CyaA) for intramuscular delivery [50]. The model vaccine, CyaA-PCMC was 
prepared by co-precipitated of CyaA with L-glutamine as the crystalline materials using 
the rapid dehydration method. It was reported in the work that following storage as dry 
powder vaccines at 37 ° C for 2 weeks, the adenylate cyclase activity recovered from the 
CyaA-PCMC was only marginally reduced.  
     In order to enhance the oral bioavailability of poor-soluble drugs and/or protein 
(peptides), a prolonged residence time is required [51]. Mucoadhesive materials are able 
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to adhere onto the mucus membrane at the gastrointestinal tract, which contributes to a 
prolonged residence time at the targeted site [52]. The goal of this study was to 
manufacture a delivery platform that would be capable of carrying a model 
protein/peptide safely through the stomach and allow it to adhere to a suitable part of the 
GI tract. Bovine serum albumin (BSA) was chosen as the model protein antigen, which is 
commonly used as an antigen to induce immune responses in different animal models. 
4.2. Materials and methods 
4.2.1 Materials 
     Bovine serum albumin was purchased from Spectrum (Spectrum, Gardena, CA, 
USA). DL-valine, L-glutamine, and L-glycine were obtained from Sigma (Sigma, St. 
Louis, MO, USA). Pluronic® F68 and Pluronic® F127 was kindly provided by BASF 
(BASF Corporation, Florham Park, NJ, USA). Eudragit® FS 30 D, Eudragit® S-100, and 
Eudragit® L 30 D-55 were kindly donated from Evonik (Evonik Degussa Corporation, 
Parsippany, NJ, USA). Avicel® PH101 was kindly donated by FMC (FMC Corporation, 
Philadelphia, Pennsylvania, USA). A Bradford protein assay kit was purchased from Bio-
Rad (Bio-Rad Laboratories, Hercules, CA, USA). All the chemicals and solvents used 
were of analytical grade. 
4.2.2 Methods 
4.2.2.1 Preparation of PCMC 
Protein coated microcrystals in this study were prepared by a simple co-precipitation 
process. Briefly, a saturated solution of amino acid was prepared at 25 °C (DL-valine: 60 
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mg/mL; L-glutamine: 40 mg/mL, and L-glycine: 250 mg/mL) as a protein carrier during 
the co-precipitation process. 25 mg/mL of stock BSA solution was prepared by 
dissolving lyophilized BSA powders in pH 6.8 phosphate buffer at 25 °C. Both solutions 
were stored at 4 °C before PCMCs manufacturing or further analysis. In order to 
optimized the particle size of the PCMC products, BSA stock solution was added into 
saturated aqueous amino acid solution at the ratio of 1 to 1, 1 to 2, 1 to 3 or 2 to 3 (v/v) to 
prepare amino acid solution at different % saturation level (Table 4.1) to optimize the 
precipitation of PCMCs. The mixture solution was mixed for 30 seconds right before the 
precipitation process. The aqueous mixture solution was then added dropwise to an 
amino acid saturated anti-solvent (ethanol, propanol, or isopropyl alcohol) through a 
syringe pump under suitable feeding rate (1, 2, or 5 mL/min) under sonication (Branson 
Sonifier® S-250A, Branson Ultrasonics, Danbury, CT, USA). The whole mixture was 
sonicated for 10 minutes at a pulse mode (50% cycle). The precipitated crystals were then 
obtained by filtration and then dried in the fume hood until a constant weight was 
obtained. The dry powders were then transferred into HDPE bottles and conducting seal 










Table 4.1: Manufacturing condition of PCMC 
 
4.2.2.2 Physicochemical characteristics of PCMC 
4.2.2.2.1 Particle size distribution 
A Malvern Zetasizer Nano ZS was used to determine the size distribution of the 
PCMC by photon correlation spectroscopy (PCS) (, Malvern Instruments Ltd, Worcester, 
UK). 
4.2.2.2.2 Morphology of PCMC 
     PCMC were fixed onto the SEM specimen stem by carbon tapes and then coated 
with Pt/Pd using a Cressington 208HR sputter Coater (Cressington Scientific Instruments 
Ltd, Watford, UK) at 12 mV. The coating thickness was set at 12 nm (estimated coating 
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thickness). The morphology of PCMCs was then observed using a Zeiss Gemini 1530 
scanning electron microscope (Carl Zeiss NTS, LLC, Peabody, MA, USA).  
4.2.2.2.3 Loading capacity of bovine serum albumin 
The content of BSA in PCMC was determined directly by measuring the protein 
that was co-precipitated onto the surface of amino acid carriers. The concentration of 
BSA was determined using Bradford Assay [53]. The loading capacity (LC%) was 
calculated by using Equation 1: 
 
                                     (1) 
4.2.2.3 Enteric coating of PCMC 
     After drying, PCMC were then coated with Eudragit® S-100 at two different 
coating level. Briefly, PCMC were re-suspended with isopropyl alcohol; Eudragit® S-100 
was then added to the mixture at 1:2 or 1:5 w/w polymer to BSA/DL-valine ratio to 
optimize the enteric coat. Eudragit® S-100 was dissolved with constant magnetic stirring 
at 150 rpm for 30 minutes. The final mixture was then dropped into excess liquid paraffin 
under continuous agitation at 400 rpm using a RW-16 basic mechanic stirrer (IKA® 
Works, Inc., Wilmington, NC, USA) overnight to let the solvent (isopropyl alcohol) to 
completely evaporate. The whole mixture (coated PCMC and liquid paraffin) was left 
still on benchtop for 1 hour to let the coated PCMC settle down at the bottom of the 
beaker. The excess amount of liquid paraffin was poured out and dumped. The coated 
PCMC (with residual liquid paraffin) were then washed with de-ionized water for three 
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times to get rid off the liquid paraffin. The final particles were harvested by using a 
Marathon 21K/R centrifuge at 3,000g for 10 minutes (Fisher Scientific, Pittsburgh, PA, 
USA). 
4.2.2.4 Dissolution transit of enteric coated PCMCs 
The transit and size change of Eudragit® S-100 coated PCMC was determined using 
a modified dissolution method. Briefly, 20 mg dried Eudragit® S-100 coated PCMC were 
weighted and transferred into a glass vial containing 20 mL of heated (37 °C) 0.1N HCl 
(mimic gastric pH, pH 1.0) or phosphate buffers (mimic pH at lower intestine, pH 7.2). 
The vial was then placed in an Orbit Environ Shaker shaking incubator (LABLINE, 
Tripunithura, Kochi, India) and agitated at a constant rate of 150 rpm at 37 °C. At time 
intervals of 10, 30, 60, 120, and 180 minutes, 0.5 mL aliquots were withdrawn from the 
sample suspension. The withdrawn sample was then placed (stub via a transfer pipit) and 
let dry on an SEM specimen prior to SEM imaging. 
4.2.2.5 Pellets production 
The model API theophylline was used to optimize the pellet manufacturing using 
an extrusion/spheronisation technique [54]. Briefly, suspensions of PCMC were pre-
blended with MCC (Avicel® PH 101), and lactose to a total mixture weight of 250 mg 
(Table 4.2), for 5 min.  Methocel® K4M or Methocel® E15 was added into the mixture 
and granulated for a further 5 minutes. The mixture was then introduced into a Luwa 
benchtop granulator (LCI Corporation, Charlotte, NC, USA) and extruded into granules. 
The granules were then transferred into a Caleva, Model 250 bench-top spheronizer 
(Caleva Process Solutions LTD, Sturminster Newton, UK) and spheronized into pellets. 
The pellets were dried in oven overnight at 40 °C. Pellets in the size fraction 1.0-1.5 mm 
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were separated by U.S. standard sieves (Fisher Scientific, Pittsburgh, PA, USA) and 
stored in desiccators at room temperature prior to further testing. 
Table 4.2: Composition of pellets 
*For BSA (PCMC) loaded pellets, the compositions of pellet 1-4 are exactly the same, 
except that the API was replaced by BSA/PCMC 
     Using this method, 250 grams of pellets (as the core) were coated using a Strea-1 
(Aeromatic-Fielder, Bubendorf, Switzerland) fluidized-bed coater (bottom set-up and a 
Wurster column) with an atomized air pressure of 2 bar and an inlet temperature of 45 
°C; outlet air temperature of 30 °C. The coating dispersion was stirred continuously 
during the coating process. The coated weight gain (% w/w, Eudragit® to core pellets 
ratio) was monitor every 10 minutes, till the final desired weight gain was reached. After 
coating, the pellets were dried continuously within the fluidized bed at 30 °C for another 
10 minutes before transferring to an oven set at 40 °C for 2 hours. The target coating 
weight gain was set at 5, 10, 15, or 20 %w/w. After the coating conditions were 
optimized using theophylline-based pellets, BSA/PCMC was introduced into the final 
pellet formulations to replace theophylline as the API. Briefly, BSA loaded PCMC were 
re-suspended in IPA and used as the binder solution in the wet-granulation/pelletization 
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process as previously described. After manufacturing, BCA/PCMC containing pellets 
were enteric coated in the exactly same manner as we coated the theophylline pellets. 
4.2.2.6 Enteric coating of pellets 
In order to reduce the waste of BSA, the enteric coating process/condition was first 
tested with placebo pellets with Theophylline as the active ingredients (in replacement of 
BSA, while the rest ingredients remained the same as previously described in Section 
2.2.6). After manufacturing, the pellets were further coated with an enteric coat (a 
mixture of Eudragit® FS 30 D/Eudragit® L 30 D-55 to control the release profile) using a 
previously described fluid-bed coating method [54], and the three different coating 
solution compositions shown in Table 4.3. 
Table 4.3: Composition of enteric coating solutions 
 
*: w/w % ratio related to polymer content. 
**: w/w % ratio related to polymer content. 
4.2.2.7 In vitro release of BSA loaded pellets 
BSA release from coated pellets was determined using a USP paddle dissolution 
apparatus [55]. Pellets were added to 900 mL pH 1.2, 0.1N HCl and maintained at 37 °C, 
with the paddle speed set at 100 rpm. At intervals of 10, 30, 60, 90, and 120 minutes, a 5 
mL sample was taken from each dissolution vessel and was replaced with the same 
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volume of pH 1.2, 0.1N. After 2 hours, the testing medium was replaced with 900 mL pH 
7.2, phosphate buffer. Additional 5 mL samples were taken at time intervals of 3, 4 and 5 
hours. Samples were analyzed using the Bradford assay as previously described in 
Section 2.2.3. Dissolution tests were repeated six times for all formulations and the mean 
% BSA released was evaluated. 
4.2.2.8. Stability of antigen loaded pellets 
After enteric coating, the pellets were stored and protected from light at controlled 
room temperature for 3 months (25 °C, 60% RH and 40 °C, 75% RH). The formulations 
were observed for change in physical appearance, color, BSA content and release 
characteristics monthly. 
4.2.3 Statistics 
     All results were shown as mean ± standard deviation (N=6). Analysis of variance 
(ANOVA), Turkey's HSD or Wilcoxon test is used to evaluate the results via JMP 7.0 
software (JMP, Cary, NC, USA). p <0.05 was considered of significant difference. 
4.3 Results and discussion 
4.3.1 Particle size, particle size distribution and BSA loading of PCMC 
After manufacturing, particle size of each batch of the PCMC formulation was 
measured using a Mastersizer 2000 to determine D10 , D50, D90 the respective cut-off 
size of 10, 50%, and 90% by volume, as well as the particle span (span = D50/(D90-
D10)) as shown in Table 4.4. In order to obtain a formulation of PCMC with a smaller 
average particle size (2-5 μm) and lower particle size distribution, several different 
factors were controlled during the manufacturing process. These factors included: the 
type of protein carrier (DL-valine, L-glutamine, and L-glycine), the feeding rate of the 
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BSA/amino acid carrier solution, the type of anti-solvent used (ethanol, n-propanol, and 
IPA), and % saturation of carrier amino acid solution (80, 66, and 50% saturation). From 
our results, only DL-valine and L-glutamine were suitable for PCMC manufacturing 
PCMC made of L-glutamine tended to aggregate together and turned into brittle flakes, 
instead of fine crystal powders as PCMC made of DL-valine and L-glutamine. PCMC 
made of L-glycine showed varied particle distribution (particle span >1.7), with particle 
size larger than 25 μm (D50), which was not fit for oral vaccination delivery system. 
Particle size of the microparticles is an important parameter in vaccine delivery. In 
general, particulate systems with a particle size smaller than 10_μm have been shown to 
improve the immune response significantly, allowing the antigen taken up by the mucosal 
associated lymphoid tissues (MALTs) [56]. PCMC made of L-glutamine or DL-valine 
showed a more suitable particle size range for oral vaccination (<10 μm) delivery system. 
However, PCMC made of DL-valine showed significantly higher % BSA loading 












Table 4.4: Particle size distribution and BSA loading % of PCMC formulations 
 
Therefore, DL-valine was chosen as the final amino acid carrier for preparation of 
PCMC in the following studies. In addition, we speculated that the type of anti-solvent, 
the feeding rate (the rate of adding BSA solution into the anti-solvent) and % saturation 
of the amino acid carrier containing anti-solvent would affect the precipitation process 
and alter the size and loading % of PCMC products. Under the same manufacturing 
conditions, particle size of PCMC obtained from different anti-solvents were significantly 
varied (p<0.05.) The rank order of particle size of the three different PCMC products 
from the smallest to the largest was: PCMC made using IPA as anti-solvent < PCMC 
made of n-propanol < PCMC made of ethanol. In order to prepare PCMC of proper 
characteristic for the oral delivery, we used IPA as the antisolvent throughout the 
following studies. Three feeding rate were used for PCMC preparation, 1, 5, and 10 
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mL/min. However, both particle size (D50) and particle span showed no significant 
difference at different feeding rate (particle size: p=0.45; particle span: p=0.11). The 
concentration level of protein carrier (the amino acids) in the aqueous phase before 
contacting the antisolvent was critical, since the starting concentration was seen to greatly 
affect the particle size of PCMC during the precipitation process. The solubility of DL-
valine in water at room temperature is 60 mg/mL. Therefore, through out our study, a 60 
mg/mL DL-valine aqueous solution represented 100% saturation, while 18 mg/mL and 
48 mg/mL DL-valine aqueous solutions represented 30% and 80% saturation, 
respectively. At 30% (D50, 3.76 μm) and 80% (D50, 2.90 μm) DL-valine saturation, 
PCMC had a significantly smaller particle size (p <0.05), compared to PCMC prepared at 
60% DL-valine saturation (D50, 4.78 μm). At lower DL-valine concentrations (i.e. 30% 
saturation), less amount of DL-valine was in contact with the antisolvent under a given 
time and resulted in the formation of smaller precipitated DL-valine (the protein carrier). 
Therefore, less BSA could be physically precipitated onto the surface, which resulted in 
the production of smaller PCMC. However, at a much higher saturation level (i.e. 80%), 
once the carrier (DL-valine) solution was in contact with the antisolvent, a rapid 
precipitation occurred, resulting in PCMC with even smaller particle size. However, rapid 
precipitation was a double-edged knife, while particle size of PCMC could be greatly 
reduced; the amount of BSA that was able to load/precipitate onto the carrier was also 
hindered. BSA loading (% w/v) was significantly reduced at 80% DL-valine saturation, 
(79.89% BSA loading), compared to 30% and 60% DL-valine saturation (97.72% and 
96.44% BSA loading, respectively) (p=0.024). However, the goal of this study was to 
manufacture a suitable platform for possible oral vaccination delivery system. In order to 
achieve this, the particle size of the PCMC should be limited to less than 5 μm. 
Therefore, the final PCMC manufacturing procedure was set at a BSA feeding rate of 1 
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mL/min, with 80% saturation DL-valine as the protein carrier and IPA as the anti-solvent 
in the precipitation process. 
4.3.2 Enteric coating of PCMCs 
PCMC made by using a combination of BSA and DL-valine was highly water 
soluble. However, it should be noted that oral vaccination requires antigen containing 
micro (or nano) particles to be taken up by the M cells at Peyer’s patches, followed by the 
induction of mucosal immune responses [57]. Therefore, the PCMC described in this 
study were modified by coating with Eudragit® S-100. The main goal of enteric coating 
was to protect the PCMC from dissolving before they reach the distal small intestine (pH 
7.0-7.8), where most of the Peyer’s patches are located in man [57]. In order to achieve 
this, the PCMC must remain intact throughout the stomach (pH 1-2) and the upper 
intestine (pH 6.0-7.2). PCMC were coated with Eudragit S-100 at varied polymer to 
BSA/DL-valine ratio (1:2 and 1:5 w/w). After coating, the size of PCMC increased from 
about 4 μm to approximately 20-25 μm (1:2 w/w coating) and 30-40 μm (1:5 w/w 
coating). When testing in acidic media to simulate the pH of the stomach (0.1N HCl at 
pH 1.0), the coated PCMC were observed to remain intact for up to 2 hours in pH 1.0 
acidic media (Figure 4.1), which indicated that both coating layers (1:2 or 1:5 w/w, 
BSA/DL valine: Eudragit® S-100) were able to protect the PCMC in vitro acidic 
condition. We then evaluated the suitability of the Eudragit® S-100 coating in pH 7.2 
phosphate buffers to simulate the pH of the small intestine. PCMC coated with a 1:2 w/w 
(BSA/DL valine: Eudragit® S-100) enteric coat dissolved rapidly with no PCMC particles 




Figure 4.1: SEM images of Eudragit® S-100 coated PCMC after testing in SGF: (A) 0 
min, 1:2 w/w coating; (B)1 hr, 1:2 w/w coating; (C) 2 hr, 1:2 w/w coating; 





For PCMC coated with a 1:5 w/w (BSA/DL valine: Eudragit® S-100) enteric coat, 
although the coated layer was gradually eroded at pH 7.2, PCMC particles were still 
observed, as shown on the isolated SEM images (Figure 4.2) for up to 2 hours. Intestinal 
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transit from the upper intestine (duodenum) to the lower intestine (ileum) is 
approximately 1-2 hours (under fasted conditions) with a transit time through the ileum 
of approximately 1-2 hours [58]. Therefore, in order to design a suitable for targeting the 
mucosal immunization response at Peyer’s patches in the ileum (pH 7-8), the ideal 
particles type should be eroded/dissolved gradually until the size is less than 5 μm. As 
indicated above, the 1:5 w/w Eudragit® S-100 coated PCMC were able to remain intact 
below pH 6.8. In addition, the enteric coating layer of these Eudragit® S-100 coated 
PCMC was eroded gradually once they were in contact with pH 7.2. The size of these 
PCMC particles were reduced to a suitable 2 μm size for M cell uptake [24] after 1 
hour. Therefore, the transit time and size reduction of these PCMC demonstrated a 














Figure 4.2: SEM images of Eudragit® S-100 coated PCMC after testing in simulated 
intestinal fluid: (A)SIF, 30 min, 1:5 w/w coating; (B) SIF, 1 hr, 1:5 w/w 





4.3.7 Pellets production 
Granulation/pelletization is widely used in oral drug delivery system [59, 60]. 
Compared to dry-granulation direct compression (tablets), wet-granulation is more cost-
effective and can improve free-flowing properties, homogeneity of the powder 
ingredients, provides better compressibility, and reduces dust during the processing. In a 
wet-granulation process, the pharmaceutical active ingredient can be either a dry 
substance or, be dissolved in a medium as a binder solution, which increases the 
possibility of optimizing a formulation based on the physicochemical property of its API, 
compared to direct compression. After wet-granulation, the granules can be further 
processed for direct compression, or extruded before pelletization. In general, pellets 
offer the well-known benefits of more uniform release and reproducibility of the 
formulation. This is due to the in vivo dispersion of a multiparticulates system, and the 
gastrointestinal transit in human body. While the gastric emptying transit time of a single 
solid tablet might range from 30 minutes to a couple hours, the dispersion of a 
multiparticulates system starts from the gastric and provide a more reproducible overall 
transit time. Therefore, in order to produce a more easily to handle pharmaceutical 
formation, as well as reducing possible damage during the manufacturing process to 
labile peptides/proteins/antigens (e.g. the model BSA used in these studies) wet-
granulation/pelletization techniques were adopted. Eudragit® S-100 coated PCMC were 
re-suspended in IPA as the API, as well as the binder during the wet-granulation process. 
MCC (Avicel® PH 101) was used as the filler since it has a well-known advantage of 
forming an easy moist granulated mass, and generating strong granules on drying [61]. 
One of the objectives of the present study was to design a pellet based platform that could 
be capable of targeting the ileum due to a controlled release effect of the Eudragit® S-100 
coated PCMC.  
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4.3.8. Enteric coating of pellets 
For ileum targeted drug delivery, it is necessary to overcome relatively long part of 
GI tract without any drug activity and its stability changes. pH-dependent coating is 
effective and well known in GI tract targeted drug delivery systems [62, 63]. These 
systems utilize polymeric carriers that are insoluble in the low pH media of the upper 
gastrointestinal tract, but dissolve at a higher, near neutral pH of the distal gut. Such 
polymers will begin to dissolve in the ileum and as such are more appropriately defined 
as the materials for ileum targeted delivery systems. The pH-dependent approach for 
ileum drug delivery is based on the pH differences along the gastrointestinal tract with 
values increasing from about 1 to 2.5 in the stomach through 6.6 in the proximal small 
bowel to a peak of about 7.5 in the terminal ileum [64]. The mean gastric residence time 
is considered to be 0.25–2 hours and small intestinal residence time between 3 and 4 
hours [65]. These conditions are valid for single solid dosage forms and for fasting state 
of patients.  To provide a rapid disintegration at a desirable time, Kollidon® CL was 
added during the wet-granulation/pelletization process as an incorporated 
superdisintegrant. Furthermore, in order to control the releasing time of Eudragit® S-100 
coated PCMC and synchronize the releasing time to gastrointestinal transit, three 
different enteric coating mixtures were evaluated using the model theophylline. . Without 
superdisintegrant, less than 10% of theophylline was released in 30 minutes; and only 
about 45% of the drug was released in 1 hour in pH 7.2 phosphate buffers (pellet 1, 
Figure 4.3A). With 10% w/w Kollidon® CL, more than 95% of the drug was released in 
30 minutes; and the drug release was complete in less than one hour in pH 7.2 phosphate 
buffers (pellet 2, Figure 4.3A). This was appropriate for ileum targeted oral vaccination 
delivery system, since once the pellets reached ileum, all antigens would be released 
promptly, rather than miss the target site and be released the lower intestine. In addition, 
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the Methocel® E15 or Methocel® K4M where incorporated into the fast-disintegrating 
pellets, to potentially acts as mucoadhesive polymer carriers. By incorporating a 
mucoadhesive polymer, the pellets (the material following disintegration) have the 
potential to slow transit at targeted site of the ileum after wetting and prolong the uptake 
window. However, with 10% w/w Methocel® E15, only less than 25% of the drug was 
release in 30 minutes in pH 7.2 phosphate buffer (pellet 3, Figure 4.3 A), while nearly 
60% of the drug was released in 30 minutes, when 5% w/w Methocel® K4M was used 
(pellet 4, Figure 4.3 A). The release rate of drug was hindered, because of the gel 
formation of Methocel®, which formed a matrix system and controlled the drug release 
through a combination of diffusion/erosion [66].  
In order to protect the pellets from the gastric environment, the pellets were coated 
with proper enteric coat(s). Here we were focusing on controlling the drug release at pH 
> 7.2 (according to the physiological condition in the ileum). Eudragit® L and S polymers 
enable targeting specific areas of the intestine. Eudragit® L 30 D-55 dissolves at pH above 
5.5, which is excellent for drug delivery at the upper intestine [67]; while Eudragit® FS 
30D polymer dissolves at pH above 7.0 and is suitable for drug delivery to colon area 
[68]. In this study, it was necessary to both prevent drug release at gastric pH, and control 
drug release gradually in a way that corresponds to drug delivery along the proximal 
intestine, followed by a rapid release at ileum. To achieve this, three different enteric 
coating conditions were tested. In coating solution 1, a single layer of a mixture of 
Eudragit® L 30 D-55 and Eudragit® F S 30D (w/w ratio: 2:3) was coated onto the pellets. 
No drug was release for up to 2 hours at pH 1.2 (gastric condition), regardless of the type 
of enteric coating. When applying only 5% w/w (weight gained) Eudragit® L 30 D-55 
coating to the pellets, with 10% w/w superdisintegrant, Kollidon® CL, more than 90% of 
the drug released in just one hour after adjusting the pH from 1.2 to 7.2 (pellet 4, 5% 
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coating, Figure 3B). When the enteric coating was increased to 10% w/w (weight 
gained), only about 20% of the drug released in 2 hours after adjusting the pH from 1.2 to 
7.2, and nearly 90% of the drug released in 3 hours after adjusting the pH from 1.2 to 7.2 
after the (pellet 4, 10% coating, Figure 4.3B). Nevertheless, without superdisintegrant 
(Kollidon® CL), no drug released for up to 2 hours after adjusting the pH from 1.2 to 7.2, 
while nearly 90% of the drug released within another hour, regardless enteric coating of 
5% or 10% (pellet 1, 5% and 10% coating, Figure 4.3B).  
In enteric coating 2, a double-layer coating was applied. The inner coat was 
composed of Eudragit® L 30 D-55 (while the coating solution was neutralized to pH 5.6). 
Neutralizing the inner coat would help the rapid release of coated drug, since part of the 
Eudragit® L 30 D-55 was dissolved during the preparation process of the coating solution. 
The outer coat was composed of Eudragit® L 30 D-55 and with exactly the same 
composition as enteric coating 1. With 10% superdisintegrant, Kollidon® CL, nearly 90% 
of the drug released in less than one hour after the pH was adjusted from 1.2 to 7.2, 
regardless of the coating level (pellet 4, Figure 4.3D). Without superdisintegrant, 
Kollidon® CL, about 5% of the drug released while 5% or 10% w/w (weight gained) of 
the outer coat was applied (with 5% w/w inner coat) in 2 hours at pH 1.2 (pellet 1, 5% 
inner coat, 5% and 10% outer coat, Figure 4.3C), which showed non-successful enteric 
coating under gastric condition. When the outer coat was increased to 20% w/w (weight 
gained), no drug released under gastric condition for up to 2 hours, however, more than 
90% of the drug release in less than 2 hours after the pH was adjusted from 1.2 to 7.2 
(pellet 1, 5% inner coat, 20% outer coat, Figure 4.3C), which did not fit properly for our 
ileum targeting delivery system, for that most of the drug would release before it reach 
ileum. Therefore, neutralization indeed, created a more rapid release of the drug; 
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however, the drug released too early and would not be suitable for ileum targeting 
delivery system.  
     Finally, a third enteric coating composed of a modified outer layer was 
prepared (enteric coating 3). The inner enteric coat of enteric coating 3 was the same as 
the inner enteric coat of enteric coating 2. Nevertheless, the outer coat was replaced with 
a mixture of 1:4 w/w ratio of Eudragit® L 30 D-55 and Eudragit® F S 30D, compared to 
enteric coating 2. With 10% w/w superdisintegrant, Kollidon® CL and 10% w/w (weight 
gained) outer enteric coating (5% w/w inner coat), no drug released for up to 2 hours at 
pH 1.2 (pellet 4, 5% inner coat, 10% outer coat, Figure 4.3E). However, more than 50% 
of the drug released in just one hour after the pH was adjusted from 1.2 to 7.2. After the 
outer coat was increased to 20% w/w (weight gained), the drug was protected from 
releasing for one hour after the pH was adjusted from 1.2 to 7.2, followed by about 90% 
of the drug released within the following one hour (pellet 4, 5% inner coat, 20% outer 
coat, Figure 4.3E). This would be advantageous for our ileum targeted formulation, for 
that the drug was well-protected against gastric condition, and could be further protected 
for about another hour at pH above 7 (this is parallel to the transit time from duodenum to 
ileum), followed by prompt release of the drug in less than an hour. 
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Figure 4.3: Dissolution of enteric coated pellets (API: theophylline): (A) Non-coated 
pellets; (B) Coating solution 1; (C) and (D) Coating solution 2; (E) Coating 









4.3.9 In vitro release of BSA loaded pellets 
After the pellet manufacturing process and enteric coating conditions were 
optimized with theophylline as API, theophylline was replaced with BSA loaded PCMC 
was as the model protein. The release profile of BSA loaded PCMC containing pellets 
was similar to the release profile of theophylline as previously described. The major 
difference was that the release rate of BSA/PCMC was significantly reduced, compared 
to corresponding theophylline composition using the same coating conditions (p<0.05). 
Following the dissolution pH adjustment 1.2 to 7.2 only about 80% of BSA released in 
two hours compared to more than 90% of theophylline release under the same conditions 
(pellets coated with enteric coating 3, Figure 4.4). This was due to the enteric coating of 
BSA loaded PCMC as previously described. The release of BSA loaded PCMC hindered 
by the enteric coat (Eudragit® S-100) at intestinal pH, which made the whole delivery 
system (BSA loaded PCMC in enteric coated pellets) release slower than the theophylline 
pellets. With this design, we could possibly restricted BSA/PCMC particles release from 












Figure 4.4: Dissolution of enteric coated pellets (API: BSA loaded PCMC). * N=6, Mean 
value ± Stdev 
 
4.3.10 Stability of antigen loaded pellets 
BSA/PCMC loaded pellets were stored at 25℃, 60% RH and 40℃, 75% RH for 
stability test for 3 months. After 3 months, about 45% of BSA released at pH 1.2 under 
both stability test conditions (Figure 4.5). This might resulted from the burst release of 
BSA that was diffused from the core to the surface of the enteric coat. In addition, nearly 
all drug released in one hour after the pH was adjusted from 1.2 to 7.2, which failed our 
objective of preventing the release of drug for another 1 to 2 hours after the pH was 
adjusted from 1.2 to 7.2 as previously described. Therefore, our formulation was not 
successful in the three-month stability tests, and further adjustments must be taken into 







Figure 4.5: Dissolution of enteric coated pellets (API: BSA loaded PCMC) after 3 month 





     In this study, BSA loaded PCMC with high drug loading (95-98%) were 
manufactured using a simple direct precipitation method. In order to produce PCMC with 
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specific particle size (less than 2 μm), the manufacturing process was optimized by 
screening various parameters (i.e. feeding rate of BSA/DL-valine solution and % 
saturation of DL-valine). Enteric coated pellets with BSA loaded PCMC could be a 
possible candidate for oral vaccination delivery system, since a protection layer can 
prevent the drug delivery platform from damage in the gastric pH. A double-layered 
enteric coating (Eudragit® L 30 D-55 and Eudragit® F S 30D) showed a successful drug 
releasing profile for ileum-targeted delivery system in our results.  
In summary, our study provides proof of successfully manufacturing BSA loading 
PCMC with particle size fit in the range that is suitable for oral vaccination (< 5 μm). 
Moreover, we developed a potentially pH sensitive, well-targeted system that could act as 
a platform for a variety of payloads related to protein/peptide or even antigen delivery to 
the ileum. Nonetheless, further improvement on the enteric coating property is required to 
help stabilize the platform for long-term storage processes. 
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Chapter 5: In Vitro Evaluation of Mucoadhesive Formulations 
Abstract 
Purpose. To evaluate the mucoadhesive properties of different formulations using an 
adjustable ramp and an artificial biorelavent gel layer. Methods. Various formulation 
types (i.e. lyophilized powders, films, pellets, and tablets) were manufactured to include 
the known mucoadhesive polymers: chitosan, alginate, HPMC (Methocel® K4M), or 
Carbopol® 974P (CP974P). Biorelevant gels comprised of agar and porcine mucin were 
prepared, and placed in a specially made holder on top of a constant temperature water-
circulating system. Each mucoadhesive polymer containing formulation was applied onto 
the gel to adhere in a horizontal position for 1 minute. The test apparatus could be 
adjusted to any selected preset angle perpendicular to the horizontal plane, and a 
biorelavent wash medium was allowed to flow down the face of the experimental ramp at 
a preset rate (1, 2 or 5 mL/min). Visual progression of the test samples was observed and 
the quantity of test article remaining on the biorelevant ramp was assessed to quantify the 
relative in vitro mucoadhesiveness. The results were compared to an equivalent test using 
excised porcine intestine that replaced the synthetic biorelevant gel layer. Additionally, 
the data was compared to that of a previously reported rotating cylinder test method using 
the excised porcine tissues. To further compare the relative mucoadhesiveness of the 
biorelevant gel and the excised porcine intestine a texture analyzer was used to determine 
a force of adhesion profile with both materials. Results. The retention time of different 
mucoadhesive polymer containing formulations on the biorelevant gel ramp varied 
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significantly (p<0.05) in all cases.  For all formulation types, HPMC (Methocel® K4M) 
showed the most promising mucoadhesion property (the longest retention time on the 
biorelevant gel ramp or excised porcine intestine), followed by Carbopol® 974P 
(CP974P), alginate, and chitosan. In addition, results from our biorelevant gel and from 
porcine intestine were comparable when using both the flowing ramp method and the 
tensile strength method (p<0.05). In addition, although the retention time of the test 
formulation (mucoadhesive tablets, 7mm in diameter) increased significantly on the 
porcine intestine, compared to the biorelevant gel (p<0.05), the adhesive rank order 
among the mucoadhesive polymers remained the same (HPMC (Methocel® K4M) > 
Carbopol® 974P (CP974P) > alginate). Conclusions. The in vitro ramp with biorelevant 
gel was able to evaluate the mucoadhesiveness of various polymer-containing 
formulations. Parameters under the control of the operator include the composition and 
inclination of the biorelevant gel layer, and the rate of biorelevant media washing over 
the test area. With this flexibility of operating conditions, the apparatus could be adjusted 
to parallel the varying physiological conditions along the gastrointestinal tract, as well as 
other potentially mucoadhesive sites in man. Furthermore, the in vitro test described in 
these studies works to reduce the burden on animal testing for high throughput screening 
purposes. 
5.1 Introduction 
“Bioadhesion” refers to the interactions between bioadhesive material (either 
natural or synthetic polymers) and the substrates (surface of biological cell membrane). 
Theories of bioadhesion have been well documented, including the wetting theory, the 
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diffusion theory, the electronic theory and the absorption theory [1]. Briefly, bioadhesive 
polymers are first wetted and absorb water, which allows the polymers to swell and 
further approach the biological cell membrane (Wetting theory). Once the polymers are 
in contact with the substrate, the polymer chains start to diffuse into the biological cell 
membrane. These diffused polymer chains entangle with the glycoprotein chains in the 
biological cell membrane (Diffusion theory), where numerous interactions between the 
two materials are then built-up (e.g. hydrogen bonding, electrostatic interactions, van Der 
Waals force, and covalent binding) (Electronic and absorption theory). These interactions 
provide the adhesive property of the polymers and enable a prolonged retention time of 
the polymers on the adhered substrates.  
Bioadhesive drug delivery systems are designed to adhere onto different biological 
cell membranes, such as the buccal membrane [2], nasal cavity [3], vaginal membrane 
[4], and the mucus membrane lining along gastrointestinal tract (GI tract) [5, 6]. 
Satishbabu and co-worked prepared a bilaminated buccoadhesive film comprised of 
sodium alginate and atenolol with or without Carbopol® 974P. In an in vitro 
mucoadhesion study, both of the bilaminated films were able to remain staying on 
porcine buccal tissues for up to 48 hours. In addition, bilaminated films with Carbopol® 
974P showed a higher hydration rate (better swelling property and higher viscosity due to 
the physicochemical property of the polymer), which contributed to a well-controlled and 
delayed release pattern of the drug [7]. Mohammadi-Samanni et al. demonstrated the use 
of hydroxypropylmethyl cellulose (HMPC, or Hypromellose), sodium carboxy methyl 
cellulose (NaCMC), and Carbopol® 974P (CP974P) for buccal adhesive tablets. The 
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composition of these polymers controls not only the period of adhesion, but also the 
release profile of the active ingredients used in the study. For the buccal adhesive tablets 
comprised of HPMC 500 mPas, the increase in the ratio of CP974P/HPMC or 
CP974P/NaCMC reduces the release rate of prednisolone, which is suitable for a 
controlled prednisolone release in 4-6 hours. However the increase in the ration of 
CP974P/NaCMC reduces the adhesiveness of the buccoadhesive tablets. Therefore, 
tablets made of HOMC 500 mPas and Cp974P are more suitable for controlled 
mucoadhesive prednisolone delivery in the buccal cavity [8].  
The term “mucoadhesion” is used when adhesion is associated with the mucous 
membrane surfaces lining certain regions of the gastrointestinal tract including the 
stomach [6], intestine [9], and colon [5]. There has been increasing interest in the study of 
mucoadhesive drug delivery system. One of the main potential advantages of 
mucoadhesive formulations is the prolonged retention time and enhanced bioavailability. 
[10, 11]. It has been well proposed that a mucoadhesive formulation can minimize first-
pass effect and provide long-term drug delivery [12]. A suitable mucoadhesive polymer 
should be inert, non-toxic, biodegradable and biocompatible. In addition, these polymers 
are generally hydrophilic, being able to absorb water and able to form a gel-like network 
easily after water absorption. After hydration, the macromolecular chains of 
mucoadhesive polymer diffused into the mucus membrane and entangled with the mucus 
glycoproteins (mucins). Such associated network then contributed to numerous 
interactions between the mucoadhesive polymer and mucins, including hydrogen 
bonding, van Del Waal’s interactions, even covalent bonding, which provide firm 
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adhesion forces that allow the polymers retain on the substrate [1]. Mucoadhesive 
polymers can be either naturally originated, (e.g. sodium alginate [13], pectin [14], and 
chitosan [15] or synthetic / semi-synthetic, (e.g. HPMC [16], CP 974P [17], NaCMC [18] 
and some thiolated polymers. 
Several feasible methods have been proposed to evaluate the mucoadhesiveness 
of different dosage forms in vitro. These include tensile test [19], everted-gut method 
[20], rotating cylinder method [21], and flowing test method [22]. Investigating 
mucoadhesive property through modified tensile tests was well documented. A rheometer 
is a good apparatus for evaluating mucoadhesive strength by measuring the maximum 
detachment force between the adhering analytes (mucoadhesive polymer containing 
formulation in a tablet or a disc form) and mucin films (or excised gastrointestinal 
membrane from animal models) [23]. The use of a rheometer in mucoadhesive strength 
monitoring is easy, feasible, and straightforward. Other similar methods include modified 
tensile strength test, [24] shear stress test [25], or studies using modified texture analyzer 
[26] have also been brought out. 
     “Everted intestine sacs” method [27-30] was also wildly used for mucoadhesion 
studies. Briefly, test animal intestine (e.g. rats or pigs) were harvested fresh and cut into 
smaller sections. Each section was everted to expose the mucus membrane and filled up 
with test medium. The everted sacs were then immersed into a medium containing 
mucoadhesion formulations (e.g. nano- or microparticles). Over a period of time, the 
amount of particles attached onto the everted sac was quantified and thus a relative 
mucoadhesiveness could be obtained. In a variation on this method, the rotating cylinder 
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method requires that the everted intestines be fixed onto a USP dissolution cylinder (or 
paddle). Here the test formulation (e.g. tablets or multiparticles) is affixed onto the 
everted intestinal tissue before immersion into a test medium. During the emersion period 
the basket/paddle is rotated at a set speed (usually 50 to 100 rpm) for a controlled period 
of time. Finally, the relative mucoadhesiveness of the test formulation can be obtained by 
evaluating the amount of material remaining on the everted intestinal tissues. 
     “Flowing test” is another approach for mucoadhesive strength measuring came up 
in the late 90’s [31, 32]. In short, “Flowing test” is done by the creation of an apparatus 
mimicking the in vivo condition, in which a piece of mucus membrane or fresh excited 
gastrointestinal membrane lining tissue is prepared and placed on a thermal-controlled 
(regarding to the body temperature) slant (set at certain angle), gastric simulated fluid is 
flushing down the slant continuously at constant rate, while the mucoadhesive polymer 
containing analytes are applied and adhere on to the membrane film. Therefore, the 
retention time of the analytes and the amount of analytes on the film can be measured and 
quantified easily [33]. In addition, different in vivo mucus turnover rates at different 
region of GI tract might be paralleled by adjusting the flow rate of the specific simulated 
GI test medium, which is a useful variable when compared to other published in vitro 
methods. 
     However, all the methods introduced above need freshly excised tissue or part of 
the gastrointestinal tract from life animals. In recent year, laws that mandate replacement 
alternatives, reduction alternatives, and refinement alternatives (the Three Rs) in 
scientific research have been passed in the United Kingdom, Germany, the Netherlands, 
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the United States, and the European Union over the past decade. Therefore, our objective 
of this work is to perform an easily controlled, reproducible and straightforward in vitro 
estimation for evaluating mucoadhesive property of different formulations, while 
avoiding the need to sacrifice animals at the same time. We developed our own in vitro 
method by using a biorelevant gel (an agar/mucin mixture) as our test platform for 
mucoadhesion tests, which is in concord with “Replacement alternatives” in the Three 
Rs for the animal welfare. In this current study, various formulation types (powders, 
films, pellets, and tablets) were applied onto this platform and their retention time (transit 
on the test platform), as well as drug release profile could be monitored. Additionally, in 
order to investigate the correlation between using our biorelevant gel and using porcine 
intestinal mucus membrane as the mucoadhesion test material, the relative 
mucoadhesiveness of tablets on a biorelevant gel and excised porcine intestine was 
compared using both a modified in vitro mucoadhesion test with a texture analyzer and a 
modified in vitro rotating cylinder method. 
5.2 Materials and methods 
5.2.1 Materials 
We purchased theophylline, Carbopol® 974P (CP974P) and porcine mucins from 
Spectrum (Spectrum, Gardena, CA, USA). Hypromellose (HPMC, Methocel® K4M) was 
obtained from Dow Chemical (Dow Chemical, Midland, Michigan, USA). Sodium 
Alginate and chitosan (medium molecular grade) was purchased from Sigma (Sigma, St. 
Louis, MO, USA). Avicel® PH101 was kindly provided by Asahi (Asahi, Tokyo, Japan). 
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5.2.2 Methods 
5.2.2.1 Preparation of lyophilized powder 
Theophylline and selected polymers (HPMC, Methocel® K4M, CP974P, sodium 
alginate, or chitosan) were dissolved in deionized water (dH2O) overnight in 1:2 ratios 
(final concentration, 0.5% w/w theophylline and 1% w/w polymer). The final solution 
was frozen at -70 °C and then lyophilized for 2 days using a benchtop freeze dryer 
(Virtis, Gardiner, New York USA). After lyophilization, the samples were transferred 
into glass vials, sealed, and stored in desiccators at room temperature until needed. 
5.2.2.2 Preparation of mucoadhesive polymer containing films 
     Alginate or HPMC containing films were prepared by dissolving 2% w/w (1: 1 
ratio) polymer and theophylline 2% w/w in dH2O overnight. The solution was then 
poured into a 15 x 15 cm2 polytetrafluroethylene (PTFE) mold and dried at 60 °C for 5 
hours. Following the casting and drying steps the films were carefully peeled off from the 
PTFE molds and cut into 2 x 1 cm2 rectangular pieces for the in vitro mucoadhesion test.  
5.2.2.3 Preparation of pellets 
Polymer containing pellets were prepared via wet granulation and spheronization 
(Table 5.1). Before mixing, all ingredients were sieved through a US standard sieve 
(mesh No. 30). Each blend was dry mixed for 2 minutes using a two-blade impeller. 
Deionized water (15 mL) was added into the mixture and granulated for 5 minutes. The 
mixture was then transferred to a bench-top granulator (Luwa Benchtop Granulator, LCI 
Corporation, Charlotte, NC, USA) for extrusion as granules. The granules were then 
transferred into a bench-top spheronizer (Caleva, Model 250, Caleva Process Solution 
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LTD, UK) and spheronized into pellets. The pellets were dried in oven overnight at 60 °C 
and stored in desiccators at room temperature until needed. 
Table 5.1: Composition of mucoadhesive tablets (w/w %) 
 
5.2.2.4 Preparation of tablets 
The composition of varies tablets with mucoadhesive polymers were listed in Table 
5.2.  
Table 5.2: Composition of mucoadhesive polymer containing pellets (w/w %) 
 
Before mixing, all ingredients were sieved through an US standard sieve (mesh No. 
30). Methocel® K4M, sodium alginate, and Carbopol® 974P (Spectrum, Gardena, CA) 
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were selected as polymers for matrix tablet preparation. Avicel® PH101, each polymer, 
talc, and theophylline were mixed for 20 minutes in a V-shape blender. Magnesium 
stearate was then added before a further mixing for 5 minutes. The tablet mixture was 
compressed into either 7 mm or 10 mm diameter tablets by direct compression using a 
rotary tablet press (Stokes, Dual Pressure Press Model 2, PA, USA). All tablets were 
controlled at the same hardness of 5kp. 
5.2.2.5 Preparation of artificial gel for the in vitro mucoadhesion test: 
     Biorelavent gels for in vitro mucoadhesion test were prepared fresh before each 
test. Agar (2 g) was dissolved into deionized water (100 mL) and heated up in a 
microwave for 2 minutes, at 700-Watt power. The agar gel solution (2% w/v) was then 
poured into a PTFE mold (15 cm in length and 3 cm in width, Figure 5.1). The gels were 
left on a benchtop at room temperature for cooling (30 minutes). Another biorelevant gel 
was prepared by the same method as previous described, but comprised of 1or 2% (w/v) 








Figure 5.1: Preparation of artificial gels. (A) A 4% w/v mucin suspension was first mixed 
with a heated solution of 4% w/v agar to make a final mixture of 2% mucin 
and 2% agar. (B) The mixture was then cooled down and poured into the 
Teflon mold to form the final gel for mucoadhesion test. 
 
5.2.2.6 In vitro mucoadhesion test: Flowing ramp 
5.2.2.6.1 Powders and films 
A biorelevant gel was first attached onto a 500 mL incubation flask using double-
sided tape and then placed at an angular elevation of 40 degree (adjustable). The 
incubation flask was filled with circulating water at 45 °C by a water bath and a sink 
water pump to maintain the surface temperature of the biorelevant gel at 37 °C. A plastic 
cover was then put onto the flask (covering the whole biorelevant gel) to keep the system 
at 37°C (all temperature was verified using an infrared thermometer (Fisher Scientific, 
Pittsburgh, PA, USA). Simulated gastric fluid (SGF) or simulated intestinal fluid (SIF) 
was allowed to flow down from the top of the biorelevant gel using a reservoir that was 
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powered by a peristaltic pump (Q-400, Watson Marlow, Wilmington, MA, USA) at a 
constant rate (adjustable). At the beginning of each mucoadhesion test, a sample (250 mg 
of prepared powders or 250 mg of prepared films) was applied directly onto the 
biorelevant gel at a specific starting point (shown in Figure 5.2) and set for 5 minutes to 
equilibrium the temperature to 37°C. All samples were hydrated before the test. 
Deionized water at37 °C (200 µL) was immediately applied onto each sample using a 
transfer pipette, for a 30 second hydrated period. In each test, SGF (or SIF) was set to 
flow at a starting point (0.5 cm above the sample position). Photos of the test samples 
were taken by digital camera (Casio EX-Z40, Casio, Shibuya, Tokyo, Japan); also, 1 mL 











Figure 5.2: In vitro mucoadhesion test ramp. The prepared gel was attached onto a plastic 
flask by double-sided tape. The flask was filled with water and circulated 
with a water bath to maintain the system temperature at 37◦C. The whole gel 
area was covered by a plastic thermal cover to avoid moisture lost and 













An aliquot (200 µL) of the collected eluent samples was placed into a 96-well 
culture plate (BD Falcon Microplate, Germany) and analyzed by a UV detector at 270 
nm. All measurements were carried out in triplicate and drug release was calculated 
retrospectively following completion of drug release (drug loading and the total drug 
released from a tablet after complete dissolution were measured and found the same). 
5.2.2.6.2 Tablets 
The inclined mucoadhesion platform was set-up as previously described. A tablet 
was put on the biorelevant gel and a force of 20 N was applied onto the tablet for 30 
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seconds to hold the tablet at the starting position. 200 µL deionized water (37 °C) was 
immediately applied onto the each sample using a transfer pipette. The tablet was then 
allowed to be hydrated for 30 seconds. In each test, SGF (or SIF) was set to flow at a 
starting point (0.5 cm above the sample position). All sample collecting and analyzing 
methods were the same as described in the methods description for powders or films. The 
flow rate of SGF (or SIF) was controlled at 1, 2, or 5 ml/min. 
5.2.2.6.3 Pellets 
     For each test, 50 pellets were applied onto the gel with 200 µL deionized water at 
37 °C for hydration, and allowed to remain at a horizontal position for 1 minute. All 
sample collecting and analyzing methods were the same as described in the methods 
description for powders or films. 
5.2.2.7 In vitro mucoadhesion test: Tablet and porcine intestinal mucus membrane 
     Pig intestines were obtained from freshly excised animals at a local slaughterhouse 
(Taylor Meat, Taylor, TX, USA) and stored in 37 °C normal saline during transportation. 
Before each mucoadhesion test, the pig intestines were cut into sections of 15 cm in 
length, and remaining intestinal content residues were flushed out using pH 6.8 phosphate 
buffer. The intestine tissue was then cut open and attached onto a 500 mL culture flask, 
with the surface of the porcine intestine being maintained as smooth as possible. A 10 
mm diameter tablet was applied onto the porcine intestinal mucus membrane, and a force 
of 20N was applied onto the tablet for 30 seconds before the mucoadhesion test started. 
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Photos were taken at 0.5, 1, 2, 3, and 4 hours. . All sample collecting and analyzing 
methods were the same as described in the methods description for powders or films. 
5.2.2.8 In vitro mucoadhesion test: Rotating cylinder method 
     In order to validate our objective of using artificial get as a replacement of animal 
tissue for in vitro mucoadhesion test, the differences of mucoadhesion property of various 
mucoadhesive tablets between the biorelevant gel and pig intestine were conducted via a 
modified rotating cylinder method. Polymer containing or control tablets (10 mm in 
diameter, manufactured as previously described) were attached onto freshly excised 
intestinal porcine mucosa (or 2% mucin, 2% agar biorelevant gel), which was been 
adhered onto a stainless-steel cylinder (diameter 4 cm; height 5. cm; apparatus 4-cylinder, 
USP) by cyanoacrylate glue. Thereafter, the cylinder was placed in the dissolution 
apparatus according to the USP, entirely immersed with 900 mL of pH 6.8 phosphate 
buffer at 37 °C and agitated with 100 rpm (Figure 5.3). The detachment of the test tablets 










Figure 5.3: In vitro mucoadhesion test: Rotating cylinder method. Two different test 
substrates were used to compare the mucoadhesion property between the 
test material and mucoadhesive polymer containing tablets: (A) Pig 
intestinal mucus membrane (a layer of everted porcine intestine was 
adhered/wrapped a disc of artificial gel (2% mucin, 2% agar, 7mm in 
diameter), (B) Artificial gel. 
 
 
5.2.2.9 In vitro mucoadhesion test: Texture Analyzer 
     To further quantify the adhesive property of the mucoadhesive tablets and validate 
that whether it is feasible to use our biorelevant gel as a replacement for life animal tissue 
(from GI tract). A modified in vitro mucoadhesion test using TA.XTPlus Texture 
Analyzer (Texture Technology, Scarsdale, NY, USA) was conducted [10, 26]. Briefly, 
mucoadhesion was evaluated by means of a tensile test, where the measurement of 
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maximum detachment force (Fmd) or work of adhesion (Wad) required for detach the 
test tablet from a piece of biorelevant gel or pig intestinal mucus membrane, after an 
initial period of intimate contact, is indicative of the mucoadhesion property. The force 
involved in the detachment process was measured by a TA-XT2 texture analyzer under 
the adhesive mode. Immediately before the mucoadhesive measurements, biorelevant gel 
or freshly excised porcine intestinal mucus membrane were rinsed with deionized water 
(37 °C), and mounted onto the instrument clamp and immersed into 600 mL pH 6.8 
phosphate buffer (37 °C) for 10 minutes. A test tablet was attached onto a plastic probe 
(cylindrical, 15 mm diameter) by means of double-sided carbon tape. The contact region 
of either the artificial get or pig intestinal mucus membrane was kept as smooth as 
possible and the contact area was larger than the diameter of the test tablet to avoid test 
errors. Each group of test tablets (attached on the probe) was then immersed in the test 
fluid for a hydration period of 10, 30 or 60 seconds. The probe was then lowered at a 
speed of 1 cm per minute until it touched the biorelevant gel surface or porcine mucus 
membrane surface. A contact force of 0.05N was applied for 30 seconds. Subsequently, 
probe was brought to its initial position at a speed of 0.5 mm/min. and Fmd and Wad were 
measured automatically by the software provided with the texture analyzer. 
5.2.3 Statistics 
     All biorelevant gel related tests where repeated (n=6), and tests using pig intestine 
were repeated less (n=3) due to the limited access to animal tissues. All results were 
analyzed by statistic software, SAS JMP 7.0 (Student’s t Test, Tukey HSD, and /or 
ANCOVA). 
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5.3 Results and discussion 
5.3.1 Biorelavent Gel 
Before setting up the in vitro mucoadhesion test device, several different gelling 
materials were tested and screened for the most appropriate material for our study. 1, 2, 
or 5% (w/v) of porcine mucin suspension was prepared and the viscosity of each 
suspension was measured using a rheometer (AR2000ex rheometer, TA Instrument, New 
Castle, DE, USA). As the mucins content in each suspension increased, the viscosity also 
increased (Table 5.3). However, when the mucins content reached 5% w/v, the final 
product of the biorelevant gel became soft and was not able to form a stable gel 
subsequent mucoadhesion testing. Therefore, a 2% mucins (w/v) solution was selected as 
the final biorelevant gel throughout the study. Alginate, Carbopol® 974P, Methocel® 
K4M, and agar were tested as the gel forming material after the final mucins content was 
decided (2% w/v). Several biorelevant gel forming mixtures were prepared and their 
viscosity was measured using a rheometer (Table 5.3). Although a mixture composed of 
2% Methocel® K4M (w/v) and 2% mucins (w/v) showed the highest viscosity 
(766.32±12.12 cp), the mixture was not able to form a stable gel after cooling down to 
room temperature; therefore, agar was selected as the gel forming material in this study, 
and the final biorelevant gel prepared for the in vitro mucoadhesion test was made of 2% 







Table 5.3: Summary of the viscosity test of screening the artificial gel forming material 
 
5.3.2 In vitro mucoadhesion test: Biorelevant gel inclined mucoadhesion platform 
5.3.2.1. Lyophilized powder 
     As a preliminary study, we used a biorelevant gel composed of only 2% w/w 
agar as our prototype test gel for our in vitro mucoadhesion test ramp. In the test with 
either simulated intestinal fluid or simulated gastric fluid, HPMC (Methocel® K4M) and 
Carbopol® 974P showed promising mucoadhesion properties by displaying an increased 
retention time on our test gel slant (p<0.05, Student’s t Test). However, sodium alginate 
containing sample showed similar increased retention time when tested with simulated 
gastric fluid (Figure 5.4A), but this lasted less than 30 minutes when simulated intestinal 
fluid was used (Figure 5.4B). Chitosan containing samples were surprisingly found top 
have no adhesive properties when using agar as a substrate, this is in contrast to previous 
study with other experimental designs [6, 9]. This lack of adhesion could be due to the 
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fact that the lyophilized powders dissolve more rapidly in both simulated gastric fluid and 
simulated intestinal fluid, a consequence of the large surface area and overall porosity of 
the samples which was evidenced by SEM imaging, compare to alginate, HPMC 
(Methocel® K4M) and Carbopol® 974P (data not shown). Previous studies have indicated 
that microcrystalline chitosan does not demonstrate an in vitro in vivo correlation in terms 
of mucoadhesive properties [5], demonstrating that further investigation is required for 
this material. Modified chitosans, such as thiolated chitosan have been shown to have 
good mucoadhesion of therapeutic ingredients in many in vitro studies [34]. 
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Figure 5.4: % Retention of lyophilized mucoadhesive polymer containing powders (A): 
Test media: SGF; flow rate: 1mL/min; artificial gel: 2% mucin; angle: 30 
degree; (B):Test media: SIF; flow rate: 1mL/min; artificial gel: 2% mucin; 


















































To further investigate the modified test apparatus, different composition of the test 
gels were compared. The 2% w/v agar gel was replaced with a 2% w/v agar and 2% w/v 
mucins gel mixture for our test device. Lyophilized samples containing selected polymers 
had a statistically significant longer retention time on the biorelevant gel with both agar 
and mucin compared to the agar alone (p < 0.05) (Figure 5.4 and 5.5), implying that the 
interaction between agar and mucin might be a more suitable tool for a future in vitro 
mucoadhesion test by allowing for a greater formulation discrimination time. Therefore, a 
biorelevant gel composed of 2% mucin and 2% agar might be able to parallel current in 
vitro mucoadhesion tests, where animal tissues are required. 
Figure 5.5: % Retention of lyophilized mucoadhesive polymer containing samples (Test 
medium: SIF, flow rate: 1mL/min; artificial gel: 2% w/w agar and 2% 


























5.3.3.2 Mucoadhesive polymer containing films 
     Similar trends were found when test polymer containing films under the same 
condition (2% w/v mucin: 2% w/v agar biorelevant gel, flow rate: 1 mL/min). No 
significant difference was found between two test mediums, SGF and SIF (p>0.05, 
Student’s t Test). Films made of HPMC or sodium alginate showed significant longer 
retention time on the test gel ramp (p<0.0001, Student’s t Test), compared to the control 
film. And after 180 minutes the HPMC containing film showed an increased retention 
time on the test gel ramp compared to the film containing sodium alginate (p<0.05, 
Student’s t Test). However, contrary to the lyophilized sample, the retention time of films 
composed of sodium alginate showed no significant difference, compared to the HPMC 
containing film (p>0.05), regardless of whether SGF or SIF was used as the flowing 
media (Figure 5.6). Each film itself was seen to dissolve much slower than was observed 
with the corresponding lyophilized powders. For each film during the testing phase, 
thorough wetting followed by adhesion enabled each film to stick on the gel ramp for a 
longer period of time, compared to the corresponding lyophilized powders.  
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Figure 5.6: % Retention of mucoadhesive polymer containing films: (A): Test medium: 
SGF, flow rate: 2mL/min; artificial gel: 2% mucin, 2% agar; angle: 30 
degree; (B): Test medium: SIF; flow rate: 2mL/min; artificial gel: 2% 


















































5.3.3.3 Polymer containing pellets 
At a flow rate of 1 mL/min all pellets stayed on the gel throughout the 4-hour test 
period. As the flow rate doubled up to 2 mL/min, pellets containing HPMC or Carbopol 
absorbed water quickly to cause swelling in the first 10-30 minutes. This enabled the 
pellets to attach more firmly onto the gel, supporting the same observations obtained for 
the polymer containing powders or films, described above. At a constant flow rate of 2 
mL/min, pellets containing sodium alginate or chitosan remained on the gel ramp for 2 
hours and 3 hours, respectively. Control pellets were flushed down from the gel ramp in 
less than 1.5 hours (Figure 5.7 and 5.8).   
Figure 5.7: In vitro mucoadhesion test of mucoadhesive polymer containing pellets (Test 




When the flow rate was increased to 5 mL/min, only HPMC and Carbopol 
containing pellets were able to remain attached to the gel ramp for up to 2 hours, with all 
the other pellets being washed down the test ramp in less than 1.5 hours (control pellets: 
5 minutes; chitosan pellets: 30 minutes; alginate pellets: 1.5 hours) (Figure 5.8). 
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Figure 5.8: % Retention of pellets; (A): Test medium: SIF; flow rate: 2mL/min; artificial 
gel: 2% mucin, 2% agar; angle: 40 degree; (B): Test medium: SIF; flow 
rate: 5mL/min; artificial gel: 2% mucin, 2% agar; angle: 40 degree. * N=6, 







The adhesiveness of each polymer formulation was greatly affected by the flow 
rate of the simulated GI tract medium. It is well documented that the he thickness of the 
mucus gel and its turnover rate varies along the GI tract [35, 36]. For example previous 
studies have shown that in a rat model, mucus secretion rate was significantly higher in 
the jejunum (1.1 ±0.5 μg glucose equivalent/min*cm2) than in the colon (0.5±0.2 μg 
glucose equivalent/min*cm2 [37]. It is highly likely that the adhesiveness of a given 
mucoadhesive formulation would be influenced differently at particular regions of the GI 
tract. Using the test method described in this study for the in vitro biorelevant gel ramp, 
different in vivo mucus turnover rates at different region of GI tract might be paralleled 
by adjusting the flow rate of the specific simulated GI test medium, a useful variable 
when compared to other published in vitro methods. 
5.3.3.4 Polymer containing tablets 
     Similar trends to those found with the lyophilized samples and films were found 
seen with the polymer containing matrix tablets. HPMC, sodium alginate, and Carbopol 
enhanced the retention time of tablets for more than 4 hours at a continuous flow SIF of 1 
mL/min. However, significant differences were seen after 120 minutes, for each tablet 
with a SIF flow rate set at 2 mL/min. Both HPMC and Carbopol displayed better 
retention than sodium alginate (p<0.05, Tukey HSD). When comparing the control tablet 
with the HPMC containing tablets, a significant difference (p<0.05) was observed at 120 
minutes (flow rate: 2 mL/min). At 2 hours, the control tablet was completely 
disintegrated and was not able to attach onto the gel ramp; while a tablet containing 40% 
HPMC maintained its initial starting position on the artificial mucous ramp for at least 4 
hours. Even with a change in ramp elevation, from 20 to 40 degrees adjacent to the 
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horizontal plane, no significant change in movement was seen (p>0.05, Student’s t Test) 
(Figure 5.9).  
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Figure 5.9: % Retention of mucoadhesive polymer containing tablets; (A): Test medium: 
SIF; flow rate: 1mL/min; artificial gel: 2% mucin, 2% agar; angle: 20 
degree; (B): Test medium: SIF; flow rate: 1mL/min; artificial gel: 2% 


















































The flow rate (1 ml/min and 2 ml/min) can significantly affect the retention of our 
test tablets, except for tablets composed of HPMC (p<0.05, Student’s t Test) (Figure 
5.9A and 5.10), which can be further applied to the study that needs to be carried out at 
different flowing speed to mimic different sections of the GI tract of living animals.  
Figure 5.10: % Retention of mucoadhesive polymer containing tablets (Test medium: 
SIF; flow rate: 2mL/min; artificial gel: 2% mucin, 2% agar; angle: 40 

























     In addition, when the flowing rate of test medium was further increased to 5 
mL/min, only tablets made of HPMC (Methocel® K4M) (Figure 5.11) and Carbopol® 
974P could still hold on to the gel ramp for more than 4 hours, while tablet with sodium 
alginate can only stay on the gel for about 45 minutes (data not shown). 
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Figure 5.11: Pictures taken at specific time points during the in vitro mucoadhesion test. 
Sample: 10mm, 40% w/w Methocel®, K4M tablet; test media: SIF; flow 
rate: 5mL/min (A. 0 minute; B. 30 minutes; C. 2 hours; D. 3 hours). 
 
(A)                (B)                (C)               (D) 
 
     In summary, the rank order for tablet mucoadhesion was found to be HPMC > 
Carbopol > sodium alginate. Both HPMC and Carbopol containing tablets showed a 
prolonged retention time that could potentially be exploited to enhance local absorption 
of a drug at a particular region of the GI tract.  
     The increased retention time of all the tablet formulation compared with the other 
studied formulation types is a direct result of the more rapid wetting and water absorption 
properties, whereby tablets were observed to wet and absorb the simulated GI fluids 
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within the first 1-2 minutes, enabling the tablets to adhere firmly onto the artificial 
mucous gel layer. 
     The different retention times of polymer containing tablets at various flow rates is 
shown in Figure 5.12. Since physiological conditions vary in different sections of the GI 
tract, a given orally administered formulation encounters changing conditions during GI 
transit (e.g. varied propagating rate from the stomach to the lower small intestine or 
colon) This varying propagation rate may be due to different flow rates of the 
physiological fluid or even varying gravitational influences related to patient/gut 
orientation. Using the adjustable components of by our in vitro biorelevant gel flowing 
ramp, it is possible to monitor mucoadhesive property of a given formulation at 
conditions to parallel different sections of the GI tract in vitro (i.e. media flow rate of the 
testing medium and/or testing angle). 
Figure 5.12: Retention time of different mucoadhesive polymer containing tablets under 
varied flow rate. * N=6, Mean value ± Stdev 
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Furthermore, when using porcine intestine as test material, a slight increase, but 
not significant (p>0.05) retention time was found with the HPMC and Carbopol 
containing tablets, compared to using the biorelevant gel (2% mucin, 2% agar) as test 
material. However, chitosan containing tablets showed an increased retention time on the 
porcine intestine, compared to that on the biorelevant gel (p<0.05). This is likely that the 
polymer chains of chitosan were able to diffuse and entangle with the glycoprotein chains 
of the porcine intestinal mucus membrane, which provide the adhesion force between 
each other. However, although the biorelevant gel was made of 2% mucin content, after 
the gelling process, the accessibility of glycoprotein chains from mucin was highly 
hindered; which limited the diffusion and entanglement of polymer chains between 
mucin glycoprotein; therefore, greatly reduced the adhesion force. Unlike chitosan, 
HPMC and Carbopol have a greater propensity to uptake substantial quantities of water 
[38]. It is well documented that both HPMC and Carbopol swell and form gel network 
after hydration [39, 40], while chitosan swells rapidly, but requires ionic or covalent 
cross-linking with basic salts to generate a gel network after hydration [41]. Therefore, in 
our study, tablets made of only 40% chitosan disintegrated rapidly and then spread along 
the biorelevant gel during the mucoadhesion test; while tablets made with 40% HPMC or 
Carbopol swelled and formed a gel network at the surface of the biorelevant gel to enable 
an increased retention time on the gel ramp. 
5.3.3.5 Polymer containing tablet test using excised porcine intestine 
     To validate our results using biorelevant gel as a potential replacement of animal 
tissues for in vitro mucoadhesion test, freshly excised porcine intestines were obtained 
and tested with mucoadhesive polymer containing tablets as comparison. The % retention 
of test tablet is shown in Figure 5.13. The results from porcine intestine were in 
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agreement with the results from the biorelevant gel (2% mucin, 2% agar). Both HPMC 
and Carbopol containing tablets were able to stay onto the porcine intestine ramp for 
more than 4 hours. Alginate containing tablets were able to stay adhered to the ramp for 
up to 3 hours.  
Figure 5.13: % Retention of mucoadhesive polymer containing tablets (Test medium: 
SIF; flow rate: 2mL/min; test angle: 30 degree), (A) Artificial gel, 2% 






Furthermore, when using porcine intestine as test material, a slight increase, but 
not significant (p>0.05) retention time was found with the HPMC and Carbopol 
containing tablets, compared to using the biorelevant gel (2% mucin, 2% agar) as test 
material. However, chitosan containing tablets showed an increased retention time on the 
porcine intestine, compared to that on the biorelevant gel (p<0.05). This is likely that the 
polymer chains of chitosan were able to diffuse and entangle with the glycoprotein chains 
of the porcine intestinal mucus membrane, which provide the adhesion force between 
each other. However, although the biorelevant gel was made of 2% mucin content, after 
the gelling process, the accessibility of glycoprotein chains from mucin was highly 
hindered; which limited the diffusion and entanglement of polymer chains between 
mucin glycoprotein; therefore, greatly reduced the adhesion force. Unlike chitosan, 
HPMC and Carbopol have a greater propensity to uptake substantial quantities of water 
[38]. It is well documented that both HPMC and Carbopol swell and form gel network 
after hydration [39, 40], while chitosan swells rapidly, but requires ionic or covalent 
cross-linking with basic salts to generate a gel network after hydration [41]. Therefore, in 
our study, tablets made of only 40% chitosan disintegrated rapidly and then spread along 
the biorelevant gel during the mucoadhesion test; while tablets made with 40% HPMC or 
Carbopol swelled and formed a gel network at the surface of the biorelevant gel to enable 
an increased retention time on the gel ramp. 
5.3.4 In vitro mucoadhesion test: Rotating cylinder 
     Mucoadhesion is a complex phenomenon that can be influenced by numerous 
physicochemical circumstances. Clearly one of these is the electrostatic force. The 
chemical nature of the cell surface and mucin causes negative charges at physiological 
pH, and so positively charged molecules interact with them. The mucoadhesive 
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properties of neutral HPMC polymers and anionic Carbomers are based on other 
physicochemical processes, such as hydrogen bonding and van der Waal’s interactions 
[42]. A USP dissolution apparatus modified rotating cylinder method is well documented 
to evaluate and compare mucoadhesive properties among different mucoadhesive 
polymers, such as, PAA, pectin, thiolated-chitosan and thiolated-PAA. Of the polymer 
tablets tested, both HPMC and Carbopol containing tablets showed significant prolonged 
adhesion times on the biorelevant gel made of 2% mucin and 2% agar, when compared to 
the gel made of only 2% agar (p<0.05). This was in agreement with the previous 
observations determined using the in vitro ramp test. Chitosan tablets disintegrated 
rapidly when immersed in the dissolution medium, therefore, its mucoadhesive property 
could not be evaluated using this method. In addition, the adhesion time of HPMC 
(Methocel® K4M), Carbopol® 974P and alginate tablet on the everted porcine intestine 
mucus membrane was more than 8-, 5-, and 4-fold increased, respectively, in comparison 









Figure 5.14: In vitro mucoadhesion test: Rotating cylinder, (A) 2% agar; (B) 2% mucin, 





5.3.5 In vitro mucoadhesion test: Texture Analyzer 
     Orally delivered dosage forms reach the GI tract in a wetted state [26], and so each 
of the test tablets were pre-hydrated before starting the tensile test. The pre-hydration 
time was set at 10, 30, or 60 seconds. However, it was determined that 10 seconds was 
too short to allow a tablet to fully wet, and 60 seconds was deemed to cause certain 
tablets to disintegrate before adhesion could take place (i.e. the control and alginate 
tablets). Therefore, the final pre-hydration time selected was a compromise of 30 
seconds.  
     Data from tensile test showed a significant difference (p<0.05) in the behavior 
(both Force of Detachment and Work of Adhesion) of either the HPMC or Carbopol 
containing tablets with respect to the control tablets. The analysis of mucoadhesive power 
by the detachment force and the adhesion work allowed for a better characterization of 
the interactions between mucoadhesive polymers and substrate material (i.e. the mucus 
membrane) according to findings from other studies on the bioadhesive drug delivery 
systems. The maximum force of detachment (Fmd) for either HPMC or Carbopol 
mucoadhesion was significantly higher (Figure 5.15) than for either the alginate or the 
control groups (p<0.05), regardless whether the 2% w/w mucin: 2% w/w agar biorelevant 
gel or porcine intestine was used as the tablet attachment substrate. This was in 
concordance with both the results from the in vitro ramp and rotating cylinder methods. 
The work of adhesion (Wad), using the experimental conditions described above showed 
that adhesion values of HPMC and Carbopol were always greater than those for the 
alginate or the control groups (Figure 5.15) (p<0.05). Additionally it was observed that 
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both Fmd and Wad showed an increase, but not statistically significant, when the 
biorelevant gel was replaced by porcine intestine as the test substrate material, which is in 
accordance to what we found from the in vitro ramp study. 
 169 
Figure 5.15: Tensile test of mucoadhesive polymer containing tablets, (A) on 2% mucin, 
2% agar artificial gel; (B) porcine intestinal mucus membrane. * N=6, Mean 





     The in vitro biorelevant gel flowing ramp developed in this study may be used to 
investigate the mucoadhesive properties of polymers and provide an in vitro rank order 
for study. It is anticipated that this may reduce the burden of testing animals future 
proposed mucoadhesive studies. Among the mucoadhesive polymers tested in the study, 
HPMC (Methocel® K4M) showed best mucoadhesive property, followed by Carbopol® 
974P, and sodium alginate. This is anticipated that this may reduce the burden of test 
animals future proposed mucoadhesive studies. Moreover, we proved that, the in vitro 
biorelevant gel flowing ramp we developed is capable of investigating the mucoadhesive 
properties of different dosage forms, including powders, pellets, and tablets. The device 
could further be adapted to mimic physiological conditions at different sections of the 
gastrointestinal tract by adjusting the flow rate, device angle, and the testing medium 
applied. Most important of all, it is anticipated that the biorelevant gel is able to replace 
animal tissues in in vitro mucoadhesion and reduces the burden of test animals in in vitro 
mucoadhesion test, which is in concord with the 3R’s of animal welfare. 
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Chapter 6: Size Discrimination in Rat and Mouse Gastric Emptying 
Abstract 
Objectives: To investigate the relationship between particle size and gastric 
emptying in rodents using radiolabeled insoluble polymethyl methacrylate (PMMA) 
microcapsules/beads. Methods: PMMA microcapsules (50–500 µm) and beads (0.5–3 
mm) loaded with technetium-99m diethylene triamine pentaacetic acid (99mTc-DTPA) 
were administered to ICR mice or Sprague Dawley (SD) rats by oral gavage (n=6 in each 
testing group). Gamma scintiscans were acquired initially following administration and 
then at hourly intervals to 4 hours. Results: Scintiscans revealed that the smallest PMMA 
microcapsules (50-100 µm) or beads (0.5-1 mm) were impeded in the stomach and 
emptied slower in both rodent species. In mice, no significant difference in gastric 
emptying was found with microcapsules between 100 to 300 μm in diameter (p=0.25). In 
rats, beads with diameters of 2-3 mm stayed in the stomach for up to 4 hours. 
Conclusions: Gastric emptying in both ICR mice and SD rats was remarkably influenced 
by particle size. However, the cut-off emptying size in ICR mice could not be 
determined, due to the limitation of current available dosing method (the largest particle 
that could be administered via oral gavage was 300 µm)The cut-off emptying size in SD 
rats was between 1.5 to 2 mm. Therefore, particles with a diameter greater than 2 mm 
should not be used for gastric emptying studies of intact particles in SD rats, as their 
emptying is retarded in the stomach. 
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6.1 Introduction 
     The rate of gastric emptying is a key concern for oral drug administration and its 
potential impact on drug bioavailability and/or localized therapies in the gastrointestinal 
(GI) tract [1-3]. The gastric emptying rate is dependent on both physiological variables 
[4] and pharmaceutical factors [5]. Physiological variables include the fed or fasted state 
of a testing subject, health/disease status [6], and the dosing time in relation to the 
interdigestive migrating myoelectric current (IMMC) [5]. Pharmaceutical factors include 
size, shape and the density of oral solid dosage forms. In a monogastric species, the 
gastric emptying rate of an oral dosage form can be altered by its size, shape, as well as 
density, and the varied gastric emptying rate, which is related to the sieving property of 
the pylorus [5]. Martinez et al. further indicated that particles larger than 2-3 mm in 
diameter were not able to pass freely to the duodenum, inferring that particles larger than 
this range are retained in the stomach for continued attrition and size reduction due to 
gastric motility [5]. Additionally, in a canine model under fasted state, particles less than 
1 mm in diameter take approximately 0.5 hours to empty the stomach, while particles of 
5-10 mm in diameter empty following 1.5 hours [7]. In humans, particle of diameters 
between 3-7 mm can pass through the pylorus freely, although particles larger than this 
range and up to 16 mm have been shown to pass through the stomach and reach the small 
intestine when administered with water. [5]. In addition to size and density of the given 
formulation, the composition of food can also alter the gastric emptying rate. In general, 
foods with high fat or high carbohydrate content display a longer gastrointestinal 
emptying time [8]. The gastric emptying rate was prolonged in the fed state of beagle 
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dogs when compared to a fasted state, irrespective of the administered particle sizes in 
the study [7]. 
     The relationship between particle size and the rodent stomach pylorus are currently 
not fully understood in vivo. It is widely accepted that the pylorus of monogastric animals 
performs a sieving function during the postprandial state, allowing passage of liquid 
chyme and small particles into the duodenum but retaining larger particles, during each 
contraction [5, 8]. The larger particles are propelled to the back of the stomach (at which 
point their size may be reduced) until they can pass into the small intestine [5]. Therefore, 
the gastric emptying time of larger particles would be delayed until suitable attrition has 
occurred; compared to smaller particles. Thus, it may be assumed that different particle 
sizes would have differing gastric emptying rates. In the case of a rodent, orally 
administered insoluble matter is generally masticated to a smaller size, and can pass 
through the pyloric sphincter to the intestine. However, when considering intact particles 
and their passage through the stomach it is potentially very useful to understand to what 
extent size exclusion may be present in the applicable rodent models.  
Gamma scintigraphy is one of the most useful techniques for mapping 
gastrointestinal transit [9, 10]. A solid oral dosage form can be mixed with a gamma 
emitting radionuclide to monitor gastrointestinal transit in animal or human subjects [11, 
12]. After the administration of a radionuclide such as technetium-99m (99mTc), the test 
subject is monitored via a gamma camera. In addition, gastric emptying rate and/or 
gastrointestinal transit can be further investigated by biodistribution analysis, which was 
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based on subsequent analysis of the obtained images (region of interest ROI) from the 
test animals [13].  
     The length, volume and diameter of the stomach and intestine of several laboratory 
animals (e.g. beagle dog, pig, and rabbit) as well as that of the human were previously 
investigated [14]. The cut-off size at the pyloric sphincter of some larger laboratory 
animals and humans was also validated, but this had not been determined for the smaller 
rodent models. As part of this investigation, the maximum particle size that could 
potentially pass through the pyloric sphincter intact for mice and rats was initially 
estimated according to their relative body mass by extrapolating from other larger 
laboratory animals. In this study, it was hypothesized that by administering inert, non-
disintegrable PMMA microcapsules/beads with an incorporated radiopharmaceutical, 
99mTc-diethylene triamine pentaacetic acid (99mTc-DTPA) to rodents (mice and rats), the 
gastric emptying rate and size discriminating ability of the pyloric sphincter in these 
rodent species could be evaluated using gamma scintigraphy.  
6.2 Materials and Methods  
6.2.1 Materials 
Poly(vinyl alcohol) (PVA) 80%, poly(methyl methacrylate) (PMMA) (MW 
120,000), benzoyl peroxide (reagent grade, >98%), 4, N,N-trimethylaniline, and sodium 
acetate were obtained from Sigma (Sigma Aldrich, St. Louis, MO, USA). Methyl 
methacrylate (MMA), ferrous ammonium sulfate, dichloromethane, and 1,10-
phenanthroline was purchased from Spectrum (Spectrum Chemical, Brunswick, NJ, 
USA). Hydroxylamine hydrochloride, 97% was obtained from Acros (Acros Organics, 
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New Jersey, NJ, USA). 99mTc-DTPA was obtained from GE Healthcare Radiopharmacy 
(GE Healthcare Radiopharmacy, San Antonio, TX, USA). All the other reagents used 
were analytical grade (Sigma Aldrich, St. Louis, MO, USA).  
6.2.2. Preliminary PMMA Microcapsule/Bead Size Selection 
To avoid using an excessive amount of the radioactive isotope, ferrous ammonium 
sulfate (ferrous ammonium complex) was used as a model compound instead of 99mTc-
DTPA to estimate loading efficiency of the microcapsules/beads. The loading efficiency 
value was used to estimate the amount of radionuclide needed for encapsulation in the 
subsequent animal study. 
Based on the validated body mass and pylorus diameter of rabbits and beagle dogs 
from literature [14], the pylorus cut-off size for mice and rats was estimated to be 250 µm 
and 2 mm, respectively (Table 6.1). Following this estimation, three particle size ranges 
were selected for each animal model (Table 6.2). Sizes were selected ad hoc with the 
assumption that the largest particles in both animal models would stay in the stomach 
throughout the test period, and that the mid-sized range would be approximately at the 







Table 6.1: Body mass and pylorus diameter of common laboratory animals and human 
Animal Body mass Pylorus diameter  
Human 70 kg 5 cm  
Pig 25-35 kg 2.5-3.5 cm  
Beagle dog 10-12 kg 1 cm  
Rhesus Monkey 5-10 kg 1.2-2 cm  
Animal Body mass Pylorus diameter Estimated pylorus diameter 
Mouse 20-30 g Not determined 250 μm 
Rat 250-350 g Not determined 2 mm 
Table 6.2: Particle sizes of PMMA microcapsules/beads received by 36 rodents of the 
study 
Group Formulation Number of 
Animals 
1. Mice-Small 50-100 μm microcapsules with model material 6 mice 
2. Mice-Medium 100-250 μm microcapsules with model material 6 mice 
3. Mice-Large 250-500 μm microcapsules with model material 6 mice 
   
4. Rat-Small 0.5-1 mm beads with model material 6 rats 
5. Rat-Medium 1-2 mm beads with model material 6 rats 
6. Rat-Large 2-3 mm beads with model material 6 rats 
6.2.3 Manufacture of PMMA Microcapsules/Beads 
To prepare beads of different size ranges, two manufacturing methods were used. 
Solvent evaporation microencapsulation was used to prepare microcapsules ranging from 
50 to 500 µm. For mice study, three size ranges were prepared: 50-100 μm, 100-250 μm, 
and 250-500 μm. Microencapsulation functioned well to prepare PMMA particles below 
500 μm; however, PMMA particles larger than this size range could not be manufactured 
using this method. Attempts at microencapsulation at sizes >500 µm resulted in either 
ruptured particles, or particles with irregular shapes. Therefore, surface polymerization 
using methyl methacrylate monomer was chosen to prepare PMMA beads above 500 μm 
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in the study (ranging from 0.5 to 3 mm). PMMA bead sizes prepared for the rat study 
were: 0.5-1 mm, 1-2 mm, and 2-3 mm in diameter. 
6.2.3.1. Preparation of Microcapsules: Solvent Evaporation Microencapsulation 
Microcapsules with diameters <500 μm were prepared using a solvent 
evaporation method, as previously described in the literature [15]. Briefly, an inner 
aqueous phase was made by dissolving an appropriate amount of PVA, dependent on the 
required particle size (2% w/v for microcapsules size of 50-100 µm and 100-250 μm, and 
6% w/v for microcapsules size of 250-500 μm) in de-ionized water. After the PVA was 
fully dissolved, ferrous ammonium sulfate was dissolved to make a 0.07 M ferrous 
ammonium solution (as the inner aqueous phase). The oil phase was obtained by 
dissolving 5% w/w PMMA in dichloromethane (DCM). To initiate encapsulation, the 
aqueous phase was added into the organic phase, followed by 2 minutes with gentle 
shaking by hand to make a W/O emulsion. Each W/O emulsion was then poured into 2% 
w/w PVA solution (outer aqueous phase), with continuous agitation by an RW-16 basic 
overhead mechanical stirrer (IKA® Works, Inc., Wilmington, NC, USA) at speeds 
ranging from 100 rpm to 600 rpm (dependent on the desired particle size; 200 rpm for 
microcapsules between 250-500 μm; 600 rpm for microcapsules between 50-100 μm) to 
form the final W/O/W emulsions. After 30 minutes, an additional 100 mL of 0.5% w/w 
PVA solution was added to further stabilize and solidify the microcapsules. After 
microencapsulation, each mixture was centrifuged at 5,000 rpm for 5 minutes. The 
microcapsules were then washed with de-ionized water 3 times to remove the non-
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encapsulated ferrous ammonium complex and residual PVA. All microcapsules were 
oven dried (60°C) and weighed before measuring the % encapsulation efficiency (%EE). 
6.2.3.2. Bead Preparation: Surface Polymerization 
Briefly, 0.5 g of benzoyl peroxide (as the initiator) was added to 10 mL methyl 
methacrylate (MMA, liquid) and stirred till fully dissolved (as the organic phase). 
Simultaneously, 0.07 M ferrous ammonium aqueous phase was prepared with 6% w/w 
PVA. The two phases were combined with gentle agitation using a plastic rod (1:10, 
aqueous:organic). The catalyst, 0.2 mL 4, N, N-trimethylaniline was then added using a 
transfer pipette, with continued gentle agitation, to make a W/O emulsion [16]. A low 
agitation speed (< 150 rpm) was maintained to ensure that the W/O droplets stayed at the 
surface of the solution for the polymerization procedure to occur (no higher than 150 
rpm). After the beads were formed, the whole mixture was agitated at 200 rpm for 
another 30 minutes to further stabilize and solidify the PMMA beads. Unlike solvent 
evaporation microencapsulation, a wide range (250 μm – 4 mm in diameter) of PMMA 
beads can be obtained from a single batch using the surface polymerization process. All 
PMMA beads were then dried in an oven overnight at 60°C. After drying, the PMMA 
beads were sieved and separated using US standard sieves (three size ranges: 0.5-1, 1-2, 
and 2-3 mm) and weighted before measuring %EE. 
6.2.4 Loading Efficiency of Ferrous Ammonium Sulfate 
The ferrous content was detected using 1, 10-phenanthroline (orthophenanthroline) 
as previously described in the literature [17]. To measure the encapsulation efficiency of 
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ferrous ammonium sulfate loaded PMMA microcapsules/beads, 10 mL of DCM was first 
added to dissolve 500 mg of microcapsules/beads. The mixture was then transferred into 
a 50 mL tube and the aqueous reagents were added (the ferrous ammonium sulfate 
partitioned into the aqueous phase). The total ferrous content was determined using 
spectrophotometry at a wavelength of 508 nm as previously described. 
6.2.5 99mTc-DTPA PMMA Loading  
On each day of the animal dosing, a fresh batch of 99mTc-DTPA was received from 
the radiopharmacy. The activity of each batch of 99mTc-DTPA (1 mL solution in syringe) 
was measured using a dose calibrator (Atomlab 100, Biodex, Shirley, NY, USA) and 
recorded both immediately upon receipt to the facility, and directly following PMMA 
bead/microcapsule manufacture just prior to dosing (Table 6.3). Microcapsules for the 
mice studies were obtained by solvent evaporation microencapsulation as previously 
described, while beads for the rat studies were manufactured by surface polymerization. 
Both methods were performed exactly in the same way as previously described, except 









Table 6.3: Radioactivity of 99mTc-DTPA sample received and dosed to animals 












   
50-100 μm 194  2.03  90  
100-250 μm 192  72  280  
250-500 μm 195  9.9  170  
99mTc-DTPA 
solution 
53  53  260  
    
Beads, Rat    
0.5-1 mm 35  60.4 10 
1-2 mm 48   11  
2-3 mm 40  3.6  12  
99mTc-DTPA 
solution 
48  48  250  
6.2.6 Particle Size Analysis 
Particle sizes for the microcapsules used in the mouse study (50-100 μm, 100-250 
μm, and 250-500 μm) were determined using a Malvern Mastersizer 2000 (Malvern 
Instruments Ltd, Worcestershire, UK). D(50) values (median particle size) and particle 
span was measured to evaluate the size and uniformity of the microcapsules. For the rat 
study, the diameter of large beads was evaluated using a micrometer (Starrett, Athol, 
MA, USA). For each batch of the PMMA beads, all beads were separated using a series 
of laboratory test sieves (500 μm, 1 mm, and 2 mm) (VWR International, LLC, Batavia, 
IL, USA). The beads were then oven-dried and weighted to calculate the percentage size 
distribution of beads in each batch. 
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6.2.7 SEM Morphology of PMMA Microcapsules 
Dried microcapsules (for the mice study) were fixed on to stainless steel SEM pin 
stub specimen mounts via double-sided carbon tape. Samples were then coated with gold 
particles before SEM imaging. Morphology and size of the microcapsules were evaluated 
using SEM imaging (LEO 1530 Scanning electron microscope, Carl Zeiss SMT Ltd, 
Germany). 
6.2.8 Percentage Encapsulation Efficiency (%EE)   
The encapsulation efficiency (%) was calculated by the following equation: 
 
- Eq. (1)                                            
6.2.9 Oral Administration 
All animal-handling procedures followed the guidance/regulation of Institutional 
Animal Care and use Committee Review (IACUC) at the University of Texas Health 
Science Center in San Antonio (UTHSCSA). Male ICR mice (25-30 g) and male 
Sprague-Dawley rats (250-300 g) were housed and maintained on a normal rodent chow 
diet with free access to water at the UTHSCSA facility. Male animals were selected, as 
growth curves for each species are less variable than that of the female animals. A total of 
24 mice and 24 rats were used in this study. Each rodent species was randomly divided 
into 4 groups (each species had 3 different groups corresponding to 3 different 
microcapsule/bead size ranges, and an additional group dosed with a 99mTc-DTPA 
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solution as a positive control) (Table 2). All animals were fasted overnight prior to 
administration of microcapsules/beads, to avoid any possible food effects of gastric 
emptying in the study. After the microcapsules were obtained, aqueous suspensions were 
prepared for mice administration (activities for each particle dose were measured for all 
test animals). Compositions were administered to mice as a suspension via oral gavage 
(approximately 40 μCi per animal), followed by oral gavage with 0.3 mL of water (to aid 
passage of each formulation in the stomach). All animals were left to rest for 10 minutes 
prior to imaging. 
For the rat study, individual beads were dry-blotted using Kimwipes® and filled 
into size 9 mini capsules (Torpac Inc., Fairfield, NY, USA) before dosing (30-40 beads, 4 
beads and 3 beads per capsule, for 0.5-1 mm, 1-2 mm and 2-3 mm bead size ranges 
respectively). A single capsule was administered to each animal (approximately 10 μCi) 
using a Torpac® mini capsule dosing syringe (Torpac Inc., Fairfield, NY, USA), followed 
by administration of 0.3 mL water via oral gavage. All animals were left to rest for 10 
minutes prior to scintigraphic imaging.  
6.2.10 Gamma Scintigraphy 
Scintigraphic images were used for determining the effect that the pylorus may 
have on size cut-off and gastrointestinal transit time. Additionally, biodistribution of 
99mTc-DTPA in different sections of the gastrointestinal tract was also evaluated as 
confirmation of the scintigraphy results. 
     The animals were anesthetized by continuous inhalation of 1-3% isoflurane 
(Vedco, St. Joseph, MO, USA) in pure oxygen using an anesthesia inhalation unit 
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(Bickford, Wales Center, NY, USA) at intervals of 10 minutes, 1, 2, 3, and 4 hours. {A 4-
hour scintiscan period was determined based on the finding from literature reviews. The 
gastric emptying time of rats and mice under fasted state is between 30-60 minutes and 
60-90 minutes, respectively [18, 19]}. The mice and rats were placed in the prone 
position on the scanner bed. All limbs of the rodents were affixed lightly to the side of a 
suitably sized rodent cradle, using surgical tape to keep the animals motionless during the 
scanning process. A standard amount of 99mTc in an Eppendorf® tube was placed beside 
the animal in the camera field of view, acting as an anatomical marker. The 140 
keV±20% window gamma rays emitted by 99mTc were imaged using dual head gamma 
cameras equipped with high-resolution parallel hole collimators (FLEX® Pre-Clinical 
Platform, Gamma Media Ideas, Northridge, CA, USA). At the predetermined time 
intervals, anterior and posterior images were acquired for 5 minutes. Radioactivity at 
esophagus, stomach and intestines of the testing animal were obtained from the 
scintiscans. 
6.2.11 Biodistribution Study 
After acquisition of the 4-hour images, the animals were euthanized using deep 
isoflurane followed by cervical dislocation. Following euthanasia, blood was withdrawn 
by performing a cardiac puncture procedure. Esophagus, stomach, intestine and cecum 
were collected, weighed and counted in automated gamma counter (Wallac Wizard 1470 
Gamma Counter, PerkinElmer, Waltham, MA, USA) for biodistribution analysis.   
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6.2.12 Data processing 
The scintigraphic images of the animals were displayed and quantified by ASIPro 
VM (Siemens Medical Systems, Knoxville, TN). A region of interest (ROI) was overlaid 
on the images for the esophagus, stomach, and intestines to obtain the quantified ROI 
(qROI) from the images. Counts were recorded in each region and the percentage of 
counts in the region compared with whole body counts was determined.  
6.2.13 Statistics 
All results are shown as mean ± standard deviation (n = 6). Analysis of variance 
(ANOVA) and Turkey-Kramer HSD was used to evaluate all the results via JMP 7.0 
software (JMP, Cary, NC, USA). A significant difference was considered when p <0.05.   
6.3. Results 
6.3.1 Preliminary PMMA Microcapsule/Bead Size Selection 
Solvent evaporation microencapsulation was used to prepare PMMA 
microcapsules for all the mouse study size ranges. Particle size, span and encapsulation 
efficiency of each microcapsule group are shown in Table 6.4. To prepare larger beads 
for the rat study, surface polymerization was used. Since monomer polymerization 
occurred in an aqueous environment, we were able to control particle size by adjusting 
the applied agitation. Here PMMA beads of various sizes were produced in a single 
batch. Following preparation and drying, the beads were separated and their size 
distributions were evaluated. Encapsulation efficiencies were evaluated. Both methods 
produced uniform and spherical particles (the approximate particle size span of the 
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microcapsules was between 1-1.3). The results of each batch were consistent and 
reproducible. 
Table 6.4: Characteristics of PMMA microcapsules/beads used for animal study 












   
50-100 μm 194  2.03  90  
100-250 μm 192  72  280  
250-500 μm 195  9.9  170  
99mTc-DTPA 
solution 
53  53  260  
    
Beads, Rat    
0.5-1 mm 35  60.4 10 
1-2 mm 48   11  
2-3 mm 40  3.6  12  
99mTc-DTPA 
solution 
48  48  250  
6.3.2 Particle Size Analysis 
Particle size and span of ferrous ammonium sulfate loaded PMMA microcapsules 
(from the preliminary test) were investigated using a Malvern Mastersizer 2000 (Malvern 
Instruments Ltd, Worcestershire, UK). The mean ± SD of D(50) values (referred to 
median particle size) for small, medium, and large microcapsules were 81.27±10.43, 
194.75±12.76, and 375.96±39.9 µm, respectively. The mean particle size spans were 
0.86, 1.14, and 1.23, respectively for the small, medium, and large microcapsules. After a 
3-day decay period, particle size and particle span of 99mTc-DTPA loaded PMMA 
microcapsules were investigated as previously described. Particle size range and span 
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were measured and compared to the desired particle size ranges designed at the beginning 
of the study (Table 4). The mean ± SD of D(50) values (median particle size) of the 
small, medium, and large radionucleoids loaded PMMA microcapsules were 88.91±9.89, 
144.75±12.76 and 405.95±39.92 µm, respectively. The mean particle size spans were 
1.09, 1.33, and 1.12, for particle sizes of 50-100 μm, 100-250 μm, and 250-500 μm, 
respectively. In addition, for both ferrous ammonium sulfate and 99mTc-DTPA loaded 
PMMA microcapsules, particle size distributions of all three sized microcapsules 
matched the intended study design. 
For the rat study, individual beads were dry-blotted using Kimwipes®. PMMA 
beads were first sieved using US standard sieves with appropriate size opening and 
separated. The actual size of the PMMA beads was measured by a micrometer and 
recorded in Table 4 (N=20). The actual size of the beads was in the same particle ranges 
as required.   
6.3.3 99mTc-DTPA PMMA Loading 
After confirming that the particle size, shape, and uniformity of the particles loaded 
with ferrous ammonium sulfate were reproducible, solvent evaporation 
microencapsulation was used to prepare microcapsules for the mouse study and surface 
polymerization was selected to obtain beads for the rat study. After allowing 99mTc decay 
for 3 days due to radioactive handling safety concerns (The half-life of 99mTc is 6 
hours.10 half-lives are required for the material to return to background radioactivity 
levels.), particle size of the microcapsules/beads was measured. No significant difference 
in size was found compared to the preliminary ferrous PMMA loading (student’s t test, p 
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>0.05). The encapsulation efficiency was 8%, 5%, and 6% for small (50-100 μm), 
medium (100-250 μm), and large (250-500 μm) microcapsules, respectively (Table 6.4). 
Encapsulation efficiencies of the PMMA beads for the rats were between 2-11% (Table 
6.4).  
99mTc-DTPA loaded microcapsules were further investigated using SEM. The small 
and medium particles displayed a spherical shape, while some of the large particles 
displayed a slightly irregular shape (Figure 6.1B-6.1C). However, all particles were 
within the required size ranges as preliminary ammonium ferrous sulfate loading test 
(Figure 6.1). 
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Figure 6.1: SEM images of 99mTc-DTPA loaded microcapsules for the mice study. (A) 
Small microcapsules, 50-100 μm; (B) Medium microcapsules, 100-250 μm; 





6.3.4 Gamma Scintigraphy 
Gamma scintigraphy for different sized microcapsules/beads was performed in 
mice and rats in order to determine the potential influence of the particle size cut-off 
imparted by the pyloric sphincter of the stomach. When the mice were dosed with a 
99mTc-DTPA solution (as the positive control), the scintigraphic images immediately 
showed localized 99mTc-activity in the stomach (Figure 6.2A). 99mTc-DTPA solutions 
emptied from the stomach quickly (less than 10 minutes post-administration). Scintiscan 
images showed 99mTc-activity in the intestine in less than 2 hours (Figure 6.2B-6.2C). 
From the images obtained, it was observed that the majority of 99mTc-DTPA solutions 
reached the lower intestine as rapidly as 2 hours (Figure 6.2D). After dosing with the 
small microcapsules (50-100 μm), scintiscans showed maximum 99mTc-activity in the 
stomach after 10 minutes (Figure 6.2E), which was identical to the control group. 
However, high 99mTc-activity was found in the stomach even up to 4 hours after dosing 
(Figure 6.2F-6.2G), which suggested that the 50-100 μm microcapsules were trapped in 
the stomach for a longer period of time, compared to the positive control. In addition, for 
the mice dosed with medium (100-250 μm) and large (250-500 μm) sized microcapsules, 
particles started emptying the stomach in less than 1 hour (Figure 6.2J and 6.2N) and 
most of the particles reached the intestine in less than 4 hours (Figure 6.2L and 6.2P) as 
shown in the scintiscans.  
Similar results were shown in the rats dosed with 99mTc-DTPA solution (positive 
control), indicated that all 99mTc-labeled beads reached the stomach after administration 
(Figure 6.3). Since a size 9 gelatin mini capsule was used as a carrier to deliver the beads 
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into the rats, the rapidly dissolved gelatin capsule was sometimes observed to stick onto 
the esophagus shortly after dosing, as shown in the appropriate scintiscans (Figure 6.3E, 
6.3I, and 6.3M). From the scintiscans, both small (0.5-1 mm) and medium (1-2 mm) 
beads were able to empty the stomach intact; however, although not significantly 
different, the gastric emptying time of the small beads trended longer than the medium 
beads (Figure 6.3G and 6.3K). In addition, more small beads remained in the stomach 
throughout the 4 hours study period, compared to the medium beads (Figure 6.3H and 
6.3L). The scintigraphy images indicated that 1 or 2 (out of the total of 3 beads loaded 
per capsule) of the large beads (2-3 mm) remained in the stomach throughout the 4 hour 
scanning period (Figure 6.3P), which was further validated by CPM quantification at 
each section along the GI tract. For those rats dosed with beads sized 2-3 mm, CPM at 
the stomach was significantly higher, compared to those rats dosed with the other two 
larger sized PMMA beads (p <0.05). This indicated that beads sized 2-3mm stayed in the 
stomach significantly longer than beads <2 mm, and were not able to pass through the rat 
pylorus intact for at least 4 hours.  
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Figure 6.2: Scintiscans of the mice dosed with 99mTc-DTPA solution or 99mTc-DTPA 
containing PMMA microcapsules up to 4 h. Yellow arrow: Standard marker. 
Radioactivity is represented in rainbow scale, red: highest intensity, purple: 
lowest intensity. Image 2(A)-3(D): 99mTc-DTPA solution, 0, 1, 2, and 4 h; 
image 2(E)-3(H): small PMMA microcapsules, 0, 1, 2, and 4 h; image 2(I)-
3(L): medium PMMA microcapsules, 0, 1, 2, and 4 h; and image 2(M)-2(P): 
Large PMMA microcapsules, 0, 1, 2, and 4 h. 
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Similar results were shown in the rats dosed with 99mTc-DTPA solution (positive control), 
indicated that all 99mTc-labeled beads reached the stomach after administration (Figure 
6.3). Since a size 9 gelatin mini capsule was used as a carrier to deliver the beads into the 
rats, the rapidly dissolved gelatin capsule was sometimes observed to stick onto the 
esophagus shortly after dosing, as shown in the appropriate scintiscans (Figure 6.3E, 6.3I, 
and 6.3M). From the scintiscans, both small (0.5-1 mm) and medium (1-2 mm) beads 
were able to empty the stomach intact; however, although not significantly different, the 
gastric emptying time of the small beads trended longer than the medium beads (Figure 
6.3G and 6.3K). In addition, more small beads remained in the stomach throughout the 4 
hours study period, compared to the medium beads (Figure 6.3H and 6.3L). The 
scintigraphy images indicated that 1 or 2 (out of the total of 3 beads loaded per capsule) 
of the large beads (2-3 mm) remained in the stomach throughout the 4 hour scanning 
period (Figure 6.3P), which was further validated by CPM quantification at each section 
along the GI tract. For those rats dosed with beads sized 2-3 mm, CPM at the stomach 
was significantly higher, compared to those rats dosed with the other two larger sized 
PMMA beads (p <0.05). This indicated that beads sized 2-3mm stayed in the stomach 
significantly longer than beads <2 mm, and were not able to pass through the rat pylorus 
intact for at least 4 hours.  
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Figure 6.3: Scintiscans of the rat dosed with 99mTc-DTPA solution or 99mTc-DTPA 
containing PMMA beads up to 4 h. Yellow arrow: Standard marker. 
Radioactivity is represented in rainbow scale, red: highest intensity, purple: 
lowest intensity. Image 3(A)-3(D): 99mTc-DTPA solution, 0, 1, 2, and 4 h; 
image 3(E)-3(H): small PMMA beads, 0, 1, 2, and 4 h; image 3(I)-3(L): 
medium PMMA beads, 0, 1, 2, and 4 h; and image 3(M)-3(P): Large PMMA 
beads, 0, 1, 2, and 4 h. 
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6.3.5 Quantified ROI Images  
To further confirm the ROI collected from scintigraphy, quantitative ROI (qROI) 
data was investigated. The qROI was used to back up the images and provided a pattern 
of the movement of the particles. The total body Tc-99m radioactivity of each test animal 
was obtained and represented as “Whole Body Radioactivity”. Tc-99m radioactivity at 
each part of the gastrointestinal tract (esophagus, stomach, or intestines) was also 
obtained and converted to a ratio of Tc-99m radioactivity at each part to total body 
radioactivity (e.g. % Esophagus/Whole Body). Figure 6.4 represents the Tc-99m 
radioactivity along the mouse gastrointestinal tract at 0, 1, 2, and 4 hours, respectively 
(Mean ± SD). Tc-99m radioactivity showed no significant difference at the mouse 
esophagus at all time points, regardless of the administered microcapsules size. In the 
mouse stomach at 4 hours (last time point), the smallest microcapsules (50-100 μm) 
showed significantly higher Tc-99m radioactivity, compared to the medium and large 
microcapsules (p=0.0023 and 0.0007, respectively). Moreover, at the mouse intestines at 
2 and 4 hours, the smallest microcapsules (50-100 μm) showed significantly lower Tc-
99m radioactivity, compared to the medium and large microcapsules (p=0.0389). Figure 
6.5 represents the Tc-99m radioactivity along the rat gastrointestinal tract at 0, 1, 2, and 4 
hours, respectively (Mean ± SD). At the earlier test time points (0 and 1 hour), the 
largest beads (2-3 mm) showed significantly higher Tc-99m radioactivity at the rat 
esophagus, compared to the small and medium size beads (p=0.0155 and 0.0043, 
respectively). At the rat stomach at 1 hour, the smallest and largest beads showed 
significantly higher Tc-99m radioactivity, compared to the medium size beads 
(p=0.0023). However, from the qROI, at 2 and 4 hours, the small beads showed 
significantly lower Tc-99m radioactivity, compared to medium and large beads (p=0.021 
and 0.003, respectively). At the rat intestines, medium size beads (1-2 mm) showed 
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significantly higher Tc-99m radioactivity at 1 hour, compared to the small and large size 
beads (p=0.0027). In addition, at 2 and 4 hours, both small and medium beads showed 
significantly higher Tc-99m radioactivity at the rat intestines, compared to the large size 
beads (p=0.001 and 0.0478, respectively). The qROI results were therefore consistent 
with the scintigraphy images obtained from both the mice and the rats. 
Figure 6.4: Quantified ROIs in mouse esophagus, stomach, and intestine at: (A) 10 min, 
(B) 1 h, (C) 2 h, and (D) 4 h. The Tc-99m radioactivity was represented as 
% at each area related to the whole body radioactivity, 1 means a total of 
100% Tc-99m activity. *: With statistically significant difference (p<0.05). 













Figure 6.5 represents the Tc-99m radioactivity along the rat gastrointestinal tract 
at 0, 1, 2, and 4 hours, respectively (Mean ± SD). At the earlier test time points (0 and 1 
hour), the largest beads (2-3 mm) showed significantly higher Tc-99m radioactivity at the 
rat esophagus, compared to the small and medium size beads (p=0.0155 and 0.0043, 
respectively). At the rat stomach at 1 hour, the smallest and largest beads showed 
significantly higher Tc-99m radioactivity, compared to the medium size beads 
(p=0.0023). However, from the qROI, at 2 and 4 hours, the small beads showed 
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significantly lower Tc-99m radioactivity, compared to medium and large beads (p=0.021 
and 0.003, respectively). At the rat intestines, medium size beads (1-2 mm) showed 
significantly higher Tc-99m radioactivity at 1 hour, compared to the small and large size 
beads (p=0.0027). In addition, at 2 and 4 hours, both small and medium beads showed 
significantly higher Tc-99m radioactivity at the rat intestines, compared to the large size 
beads (p=0.001 and 0.0478, respectively). The qROI results were therefore consistent 
with the scintigraphy images obtained from both the mice and the rats. 
Figure 6.5: Quantified ROI in rat esophagus, stomach, and intestine at: (A) 10 min, (B) 1 
h, (C) 2 h, and (D) 4 h. The Tc-99m radioactivity was represented as % at 
each area related to the whole body radioactivity, 1 means a total of 100% 
Tc-99m activity. *: With statistically significant difference (p<0.05). * N=6, 















Following the imaging portion of the study, the radioactivity in different sections 
along the gastrointestinal tract of the test animals was evaluated. Blood, esophagus, 
stomach, intestine, and cecum from the test animals were harvested and collected 
separately into scintillation vials. The activity of each of the tissues was measured using a 
gamma counter to determine the biodistribution of the 99mTc-DTPA-loaded formulations. 
The radioactivity was quantified and represented in terms of “Count per Minute” (CPM), 
higher CPM represented higher radioactivity in a specific organ (which indicated that 
more 99mTc-DTPA labeled substances were remained in that area). The counts obtained 
from the blood and esophagus samples were below the limit of detection (compared to 
the 99mTc-DTPA standard marker used during the scintiscan) and were subsequently 
rejected for use in the biodistribution analysis. The counting results were converted into 
“count-per-minute in different organs” (CPM/Organ) and “percentage of 99mTc-DTPA 
dosed remaining in different organs” (% 99mTc-DTPA/Organ).  
When comparing the mice dosed with medium microcapsules (sized 100-250 μm) 
to the mice dosed with large microcapsules (sized 250-500 μm ), no significant difference 
was found in the stomach (CPM/stomach: p=0.0617, % 99mTc-DTPA/stomach: p=0.1597) 
or in the cecum (CPM/cecum: p=0.1953, % 99mTc-DTPA/cecum: p=0.0661) (Figure 6.6). 
In addition, no significant difference was observed in the mouse intestine throughout the 
4-hour study period among the three different microcapsule size groups (p=0.3083, 
0.1615, 0.1407, 0.4848, and 0.303, at 10 minutes, 1, 2, 3, and 4 hours after 
administration, respectively). From the intestinal results, CPM of the mice dosed with 
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small microcapsules (50-100 μm) was significantly lower compared with the other two 
sized microcapsules (p=0.0052), which suggested that the gastric emptying of particles at 
sizes between 50-100 μm was impeded, compared to the other two microcapsule sizes. 
However, from the scintigraphy images, it was clear that all three sized microcapsules 
were ultimately able to pass through the pyloric sphincter, in spite of differences 
observed in the emptying rate in the mice. 
Figure 6.6: Biodistribution of 99mTc-DTPA loaded microcapsules in mice (Mean ± SD). 
Percentage of 99mTc-DTPA dosed in each specific organ. *: With statistically 
significant difference (p<0.05). * N=6, Mean value ± Stdev 
 
     When the rat was dosed with medium sized beads (1-2 mm), CPM/intestine and % 
99mTc-DTPA/intestine were significantly higher (p=0.0469 and 0.0112, respectively), 
compared to the animal dosed with the other two sized beads. This implied that particles 
sized 1-2 mm passed through the rat pylorus faster than particles either <1 mm or >2 mm. 
On the other hand, CPM/stomach and % 99mTc-DTPA/stomach were significantly higher 
(p<0.05) in the rats dosed with either small (0.5-1 mm) or large (2-3 mm) beads, 
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compared to the animals dosed with medium beads (1-2 mm) (Figure 6.7). In addition, 
when the rats were dosed with small and large beads, CPM/Cecum and % 99mTc-
DTPA/Cecum were significantly lower (p=0.0396 and 0.02, respectively), compared to 
the animals that were administered with medium beads. These observations indicated that 
particles <1 mm were delayed in the rat stomach and would be emptied out slower 
(compared to particles between 1-2 mm), while beads >2 mm are unlikely to be able to 
pass through the rat pyloric sphincter intact. 
Figure 6.7: Biodistribution of 99mTc-DTPA loaded beads in rats (Mean ± SD). 
Percentage of 99mTc-DTPA dosed in each specific organ. *: With 
statistically significant difference (p<0.05). * N=6, Mean value ± Stdev 
  
6.4 Discussion 
     Our objective was to evaluate the relationship between particle size and gastric 
emptying in small rodents using gamma scintigraphy. Particles at the size ranges tested 
were either prepared by solvent evaporation or surface polymerization. Integrity of the 
particles was confirmed prior to the study no rupturing was found in particles prepared by 
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solvent evaporation microencapsulation, as a result of the manufacturing process. Particle 
shape, size, span, and encapsulation efficiency were reproducible; therefore, both solvent 
evaporation emulsification and surface polymerization were both demonstrated to be 
appropriate methods for preparing uniform PMMA microcapsules/beads. SEM evaluation 
of preliminary ferrous loaded and 99mTc-DTPA loaded particles indicated that respective 
microcapsule/beads were of identical size and shape, indicating the effectiveness of 
substitution with the ferrous sulfate to allow for processing/formulation optimization 
without using a radioactivity during the development process. Microcapsule and bead 
sizes could be well controlled by altering the surfactant content (%PVA) and/or agitation 
speed. Furthermore, microparticles/beads were effectively prepared to be the exact size 
ranges as were purposed in the estimation of pylorus cut-off size in mice and rats as 
extrapolated from the existing literature (Section 2.2 above). (Table 6.1) 
     The estimated cut-off size at the pyloric sphincter of mice and rats was determined 
to be 250 µm and 2 mm, respectively. Therefore, it was assumed that particles above 
those specific sizes would remain in the stomach during the scintigraphy study. However, 
in the mice all sizes of microcapsules emptied over the course of the study. One limiting 
factor when dosing the mice with an oral gavage is an upper limit of using 18-gauge 
gavage needle (which is the largest size recommended for mice dosing due to physical 
concerns). Subsequently a concern was realized in that microcapsules at the upper size 
range were found to stick in the gavage tube. As a consequence, we confirmed 
retrospectively that only particles less than approximately 300 µm were actually 
delivered to the animals during oral gavage. It should be considered that it is not even 
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practically possible or ethical for mice to be dosed using conventional methods with 
particles greater than about 300 µm, due to practical constraints imposed by the use of an 
18-gauge gavage tube.  
     Previous work has shown that smaller particles (or dosage forms) empty from the 
stomach faster than larger particles [20, 21]. We also investigated the effect of particle 
size on gastric emptying rate in this study. However, compared to the medium and large 
microcapsules, the gastric emptying rate of the small microcapsules was remarkably 
delayed. From the scintiscans, we found that many of the small microcapsules remained 
in the stomach even after 3 hours, while most of the medium and large microcapsules 
passed through the pyloric sphincter in approximately 2 hours. 
     All PMMA microcapsules reached the lower intestine after 4 hours (Figure. 6.3), 
regardless of the size of the particles. It was anticipated that the largest size 
microcapsules/beads would not empty from stomach as quickly as the smallest size 
microcapsules, before the study in both rodent models. However, it was found that in the 
mouse study, all medium and large microcapsules reached intestine and cecum after 
approximately the same transit time. Since the maximum particles dosed to the mice were 
approximately 300 μm, it can be concluded that in the mouse model used, the PMMA 
microcapsule size has no effect on the gastric emptying rate, when the particle size was 
between 100 and 300 μm. 
     A similar trend of gastric emptying was observed in the rat study. The medium size 
beads (1-2 mm) passed through the pyloric sphincter to the intestine and then reached the 
cecum significantly faster than the other two size groups (from the results shown in both 
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the biodistribution and scintiscan images). From the scintiscans, gastrointestinal transit of 
the smallest beads (0.5-1 mm) was found to be similar to that of the largest beads (2-3 
mm), except in fact that the smallest beads were able to empty the stomach, while the 
largest beads were trapped in the stomach. Therefore, above a certain particle size range 
(1 mm in the SD rats and 100 μm in the ICR mice), gastric emptying time of intact 
particles increases with increasing particle size, provided that the particles are able to 
pass through the pyric sphincter. On the other side, gastric emptying was prolonged if the 
particles were below this size range. This may due to the rough surface or the mucosal 
folds in the stomach of these two rodent species [22, 23] impeded the smallest particles 
from passing through the stomach, which was found similarly in healthy human subjects 
by Podczeck and co-workers [24]. Moreover, after the small beads emptied from the 
stomach, no significant differences in CPM were observed when comparing the intestine 
to the cecum, suggesting that the particles were only hindered in the stomach, rather than 
the other regions along the lower GI tract.  
     Mucoadhesion is a process by which mucoadhesive polymers contact and attach on 
to the mucus membrane, which can attribute to a prolonged residence time in the nasal, 
buccal, vaginal, and gastrointestinal tract [25, 26]. PMMA is inert, non-dissolvable, well 
known and is therefore, an ideal carrier polymer for a drug delivery system. In this study, 
PMMA carriers were prepared using microencapsulation/surface polymerization. 
Although the mucoadhesive property of PMMA is not fully confirmed or conducted, it is 
possible that the these PMMA microcapsules/beads were able to adhere onto the mucous 
membrane lining the GI tract via hydrogen bonding [27], which led to an extended 
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residence time, especially considering what was observed for the scintiscans in the gastric 
region of the mouse model. However, it may be assumed that the retention of small 
microcapsules (50-100μm) in the gastric region (mouse) was more likely due to 
microcapsule impedance in the mucosal folds in the stomach, rather than mucoadhesive 
property of PMMA microcapsules. This is because the prolonged residence time that 
occurred at the gastric region when the smallest microcapsules were administered to the 
mouse only, but not in the small intestine or lower intestine area. Further studies must be 
conducted to confirm whether PMMA is mucoadhesive. 
     By observing the scintiscans, it can be clearly seen that 1 or 2 out of the total 3 
administrated beads in the largest bead size group (2-3 mm) stayed in the rat stomach 
throughout the 4 hours study (Figure. 6.4). Although about 30% radioactivity (from the 
biodistribution data) was found in the esophagus of 2-3 mm PMMA beads dosed SD rats, 
as we stated earlier, the “hot spot” at the esophagus we found on the scintiscans at 1 hour 
was from the residues of the dissolving gelatin capsule, not the PMMA beads. These 
radioactive residues of the gelatin capsules contributed to the high radioactivity reading at 
esophagus, even at 4hour. However, from the scintiscans, we could not find the “hot-
spot” at esophagus, which in concords with our arguments. Therefore, we did not 
consider the delayed gastric emptying was resulted from the stuck of beads at esophagus 
in our study. Moreover, CPM/Organ is remarkably lower in intestine and cecum in the 
rats dosed with large beads, compared to the animals dosed with the other two smaller 
size beads. These results are consistent with our hypothesis that inert particles ranging 
from 2-3 mm in diameters fitted well for evaluating the cut-off size at the pyloric 
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sphincter of the rats. In rats, non-disintegrating, non-dissoluble particles larger than 2-3 
mm in diameter are retained in the stomach. Therefore, we conclude that PMMA beads 
larger than approximately 3 mm could not pass through the pyloric sphincter intact in a 
rat, which is close to the initial estimation of the pylorus cut-off size in this animal model.  
     Since oral gavage is commonly used to administer solid dosage forms to the 
laboratory animal [28], it could be of critical importance to understand whether the 
formulation could reach the proximal or distal intestine intact, especially if it contains 
acid labile components. In other words, when evaluating an enteric-coated solid oral 
dosage form in rodent models, there exists the possibility that the given formulation could 
be retarded (with prolonged transit time) in the gastric area, with no possibility of leaving 
the stomach in a timely fashion. This scenario of prolonged gastric retention could make 
the formulation fail to elicit the desired effect at the target site(s) in the GI tract. To avoid 
this issue, we have successfully defined the particle cut-off size and gastric sieving 
property in the Sprague Dawley rats investigated. In summary, for oral dosage forms 
designed for the Sprague Dawley rat model using oral gavage, it is not advisable to 
administer particles above 3 mm, as it is unlikely that these particles could pass through 
the stomach. 
     It should be noted that although we confirmed that gastric emptying rate is 
dependent on the particle size of the administered dosage forms in mice, we were not able 
to define the specific pyloric cut-off size for the ICR mice investigated. However, we 
have determined that the maximum particle size that can be feasibly administered in ICR 
mice is limited to the upper limit of gavage feeding tube gauge. Moreover, the larger 
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particles (250-300 μm in diameter) administered could be emptied from the gastric by 
ICR mice.  
6.5 Conclusions 
    In this study, we conclude that the cut-off size at the pyloric sphincter in Sprague 
Dawley rats (body weight 250-300 g) is approximately 3 mm, and the cut-off size for 
stomach emptying in ICR mice is limited only by the upper limit of feasible dosing (300 
µm) method. Additionally, particle size was found to significantly alter gastric emptying 
rates in both rodent species investigated. This information is valuable for designing 
preclinical rodent testing studies, especially for oral drug delivery systems designed for 
lower intestine targeting, or when investigating acid labile compounds for oral drug 
delivery systems.  
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Chapter 7: Dissertation Conclusion 
Most currently available vaccines require intravenous (i.v.) or subcutaneous (s.c.) 
delivery of antigens. Over the past 20 years, numerous studies have assessed the potential 
of orally delivered antigens on the induction of mucosal and systemic immune responses. 
In addition, mucosal delivery is the only vaccination route to induce effective B cell class 
switching and the development of secretory IgA-producing plasma cells. Moreover, 
mucosal vaccination (delivered via oral or nasal route) has many advantages, including 
no need for sterile needles, a reduced need for trained personnel, and the ability of 
inducing both mucosal and systematic immunity. However, the major challenge of oral 
vaccination is the harsh environment of the gastrointestinal tract and the possibility of 
orally delivered soluble antigens inducing tolerance rather than immunity. Therefore, 
protection of the antigens or utilization of a carrier system is required. Our goal was to 
develop a mucoadhesive, oral vaccination delivery system designed to target Peyer’s 
patches in the ileum. In order to achieve that, we started by investigating the possibility 
of preparing particles of various sizes using W/O/W solvent evaporation method. The 
particle size (uniformity and particle span), loading efficiency, and drug releasing profile 
are evaluated. From the animal study, we conclude that the cut-off size at the pyloric 
sphincter in Sprague Dawley rats (body weight 250-300 g) was approximately 3 mm, and 
the cut-off size for stomach emptying in ICR mice was limited only by the upper limit of 
feasible dosing (300 µm) method. Additionally, particle size was found to significantly 
alter gastric emptying rates in both rodent species investigated. This information is 
valuable for designing preclinical rodent testing studies, especially for oral drug delivery 
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systems designed for lower intestine targeting, or when investigating acid labile 
compounds for oral drug delivery systems. 
In addition, since an increased residence time of a given formulation at the targeted 
site tends to enhance both absorption and bioavailability of a drug, our second goal was 
to coat or employ mucoadhesive polymers into the carrier system. To do so, we first 
developed our own in vitro mucoadhesion testing device as an evaluation tool. Adhesion 
properties of matrix tablet and pellets (made of potentially mucoadhesive polymers. 
Methocel® K4M, Carbopol® 934, chitosan, and sodium alginate were investigated using 
our testing device. The mucoadhesive property of several polymers, HPMC (Methocel® 
K4M), Carbopol® 974P and sodium alginate were studied using a novel in vitro test ramp. 
Both HPMC (Methocel® K4M) and Carbopol® 974P containing formulation showed 
significantly prolonged retention time. The increased retention time could potentially 
enhance local absorption of the drug in the GI tract. 
The in vitro test ramp developed in this study may be used to investigate the 
mucoadhesive properties of polymers and provide a rank order for study. Among the 
mucoadhesive polymers tested in the study, HPMC (Methocel® K4M) showed best 
mucoadhesive property, followed by Carbopol® 974P, and sodium alginate. We proved 
that, the in vitro flowing test ramp we developed was capable of investigating the 
mucoadhesive properties of different dosage forms, including powders, pellets, and 
tablets, providing a rank order of mucoadhesion property. The device could further be 
adapted to mimic physiological conditions at different sections of the gastrointestinal 
tract by adjusting the flow rate, device angle, and the testing medium applied. Most 
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important of all, it is anticipated that the biorelevant gel is able to replace animal tissues 
in in vitro mucoadhesion and reduces the burden of test animals in in vitro mucoadhesion 
test, which is in concord with the 3R’s of animal welfare. 
Mucosal immunity is stimulated by administration of antigen directly on the 
mucosal site where an infection occurs. Antigen is processed by mucosa-associated 
lymphoid tissue (MALT) in inductive sites where plasma cell precursors are induced. Gut 
associated lymphoid tissue (GALT) is one of the major MALT. Peyer’s Patches of GALT 
are responsible for antigen uptake. Peyer’s patches are collections of lymphoid tissue 
containing B and T lymphocytes, as well as macrophages. Antigens are taken up via 
endocytosis by the Microfold cells (M cells) at the Peyer’s patches. Particles less than 5 
μm could be transferred to the draining lymph nodes and spleen to stimulate both a 
mucosal and systemic immune response after uptake by the M cells. Therefore, we 
prepared two nano- and microstructured antigen carrying system composed of solid lipid 
nanoparticles (SLNs) or protein coated microcrystals (PCMC) with bovine serum 
albumin (BSA) as the model antigen. The two delivery systems were design to target to 
the ileum and uptake at Peyer’s patches. To further enhance the contact time of the 
delivery system at the epithelium (at ileum), mucoadhesive polymers (Methocel® K4M 
and Methocel® E15) were incorporated into the two delivery systems. The mixture was 
granulated and spheronized into pellets (1-1.5 mm in diameter). The pellets were then 
enteric coated with a mixture of Eudragit® F S 30 D/Eudragit® L 30 D-55 to prevent from 
gastric damage and control the release of BSA at pH above 7.2. 
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Enteric coated pellets with BSA loaded PCMC could be a possible candidate for 
oral vaccination delivery system, however, further coating condition or protecting method 
must be conducted to enhance the stability and prolong the storage period of formulation. 
BSA was successfully loaded into SLNs with Gelucire® 50/13 as the lipid matrix. The 
particle size of SLNs we manufactured was in the proper range for oral vaccine delivery 
systems. With proper enteric coating, the release of BSA/SLNs loaded pellets could be 
well-controlled for targeted delivery to ileum. However, further studies must be 
conducted to enhance the encapsulation efficiency % of BSA and assure the stability of 
the formulation for long-term storage. 
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